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Abstract 
Ahmad Khundakar September 2004 
The Effect of Antidepressant Treatment on Brain-Derived 
Neurotrophic Factor Expression in the Rat Hippocampus 
Enhanced BDNF expression has been implicated in the mechanisms of 
action of antidepressant treatment. Previous findings have shown 
that chronic antidepressant drug treatment produces a 'bi-phasic 
effect' on total BDNF gene expression, i.e. down-regulation at 4h 
and up-regulation at 24h. The earlier effect is common to acute 
administration, while the latter is unique to chronic treatment. 
To clarify the involvement of differential BDNF transcripts in 
the bi-phasic effect, this thesis aims to investigate this effect 
by examining the effect of a range antidepressant drugs on 
individual BDNF exon transcripts. For comparison, the effect of 
electroconvulsive shock application on BDNF exon transcripts was 
also studied. In addition, the thesis investigated the mechanisms 
behind the reduction in BDNF expression at 4h. It was 
hypothesised that GABA plays an inhibitory role on BDNF mRNA, 
thus various GABA enhancing drugs were examined. Finally, to 
investigate if BDNF mRNA changes correlated with changes the 
corresponding protein, BDNF protein expression was studied after 
. 
chronic antidepressant treatment. The main findings were as 
follows: 
• Acute antidepressant drug treatment inhibited total BDNF 
expression and exon IV, but not exon I mRNA in the dentate 
gyrus (DG) at 4h. 
• Acute GABAB, but not GAB~ receptor stimulation inhibited 
total BDNF mRNA in the DG at 4h 
• Chronic antidepressant treatment increased total BDNF and 
ex on I, but not exon IV mRNA in the DG at 24h 
III 
• Acute ECS increased total BDNF, exon I and exon IV rnRNA; 
chronic ECS increased total BDNF and exon If but not exon 
IV mRNA 
• Chronic ECS increased BDNF immunoreactivity in the parietal 
cortex and mossy fibre zone, CA3 and CAl of hippocampus. 
This thesis has thus shown a differential effect of acute and 
chronic antidepressant treatment on total BDNF rnRNA, an effect 
mediated by differential use of the variable exons that 
comprise the gene. 
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Chapter One 
General Introduction 
1 
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1.1. Scope of the thesis 
Depression is among the most prevalent forms of mental 
illness and a major cause of morbidity worldwide. Despite 
limited understanding into the pathophysiology of the 
disorder many treatments with varying degrees of 
effectiveness are available. 
The serendipitous discovery of two classes of 
antidepressant drugs: tricyclics and monoamine oxidase 
inhibitors indicated the facilitation of 5-HT and/or 
noradrenaline neurotransmission in the mechanism of action 
of antidepressant drugs and this has led to the development 
of numerous second-generation antidepressants designed 
specifically to augment 5-HT (SSRIs) or noradrenaline 
(NARIs). However, despite rapid augmentation in 
extracellular 5-HT and/or noradrenaline levels by 
antidepressant drug application, several weeks of chronic 
treatment are required in order for full therapeutic 
efficacy to occur. This has led to ongoing research 
focusing on events beyond the monoamine receptor. Various 
5-HT and noradrenaline receptor subtypes are known to 
selectively regulate several intracellular pathways which 
activate numerous target genes, prolonged activation of 
2 
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which may be instrumental in eventual therapeutic efficacy. 
One such downstream target gene implicated is the 
neurotrophin brain-derived neurotrophic factor (BDNF). 
Chronic antidepressant drug treatment has been shown to 
increase BDNF mRNA expression in the (Nibuya et aI, 1995) 
and human (Chen et aI, 2001) brain. In addition, direct 
infusion of BDNF protein has been shown to produce 
significant antidepressant effects in animal models of 
depression (Siuciak et aI, 1997). Contrary to this, acute 
(single) antidepressant administration has been shown to 
inhibit BDNF mRNA acutely (Coppell et aI, 2003). An 
explanation to this phenomenon may lie in the existence of 
multiple BDNF transcripts, which may respond differentially 
following short- and long-term antidepressant drug 
administration, and thus contribute to an overall change in 
the full BDNF gene. 
BDNF gene transcripts are comprised of either of four 
variable 5' exons (exons I to IV) each induced with 
individual promoters by alternative splicing of the total 
gene sequence, and an invariable 3' exon (exon V), which 
codes for the corresponding BDNF protein (Timmusk et aI, 
1993). These transcripts are expressed differentially 
3 
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across brain areas and are regulated by different 
manipulations. As the BDNF gene is variably manipulated by 
acute and chronic antidepressant drug treatment and BDNF 
facilitation is associated with the mechanism of action of 
antidepressants, investigating the effect on the variable 
BDNF exon transcripts could further elaborate on the role 
of BDNF in antidepressant drug treatment. This may be 
particularly useful in understanding the reasons and 
mechanisms behind the acute inhibition in BDNF mRNA after 
acute antidepressant administration. Thus, by using 
oligonucleotide probes specific to total BDNF mRNA, as well 
as two variable exon-specific probes, a series of in-situ 
hybridisation (ISH) experiments were conducted. This was to 
assess the effect of acute administration of numerous 
antidepressant drugs on two variable BDNF exon transcripts 
(exons I and IV), as well as total BDNF mRNA (exon V). The 
drugs were chosen for their varying effect on 5-HT or 
noradrenaline reuptake sites or metabolism in order to 
determine whether 5-HT or noradrenaline facilitation played 
a prominent role in the acute inhibitory response. For 
comparison, the effect of acute administration of two drugs 
with little effect on 5-HT transmission: the mixed 
noradrenaline/dopamine reuptake inhibitor methylphenidate 
and the selective dopamine reuptake inhibitor GBR 12909 on 
4 
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BDNF exon transcripts was also investigated. The results 
from this series of experiments are presented in Chapter 3. 
It was further hypothesised that the acute inhibitory 
effect of antidepressants on hippocampal BDNF mRNA occur as 
a result of the activation of stimulatory 5-HT receptors 
localised on GABAergic interneurones in the hippocampus. In 
order to test this series of ISH experiments, the effect of 
agonists selective to GAB~ or GABAB receptor complexes on 
BDNF mRNA was assessed. In addition, the effect of 
selective GABA receptor antagonists administered prior to 
antidepressant drugs was assessed to clarify GABAB receptor 
involvement in the acute inhibition of BDNF mRNA in the 
hippocampus (See Chapter 4). 
The up-regulatory BDNF response to chronic antidepressant 
treatment was then investigated. By employing 
oligonucleotide probes specific to two variable exons 
(exons I and IV), as well as total BDNF mRNA (exon V), a 
series of ISH experiments were performed to assess the 
effect of chronic antidepressant administration in the 
hippocampus (See Chapter 5). 
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Electroconvulsive therapy (ECT) is one of the most 
effective antidepressant treatments for severe or resistant 
forms of depression. Repeated administration of 
electroconvulsive shock (ECS) in rats has been shown to 
elicit profound increases in BDNF mRNA in the hippocampus. 
A series of ISH experiments were conducted to assess the 
effect of acute and chronic ECS on two variable exon 
transcripts as well as total BDNF mRNA (See Chapter 6). 
Though many studies have examined the effect of 
antidepressant treatment on BDNF mRNA, few have studied the 
corresponding protein product. The effect on BDNF protein 
is vital as the protein represents the functional correlate 
of BDNF signalling. Thus, Chapter 7 studied the effect of 
ECS and monoamine oxidase inhibitor antidepressant 
tranylcypromine on BDNF protein levels in the hippocampus 
using immunocytochemistry techniques. 
The aim of this work is to examine the effect of 
antidepressant drug treatment and ECS on the BDNF gene and 
its protein product within the hippocampus of the adult 
rat, with the overall objective of improving understanding 
of the mechanisms of action of antidepressant treatment. 
6 
Ahmad Adam Khundakar Chapter One 
1.2. Depression 
Depression is a common, debilitating, at times life-
threatening psychiatric illness. The term encompasses many 
symptoms and varies in severity. Many people will at some 
point experience a transient state of depressed mood 
(anhedonia), especially in times of adversity. This feeling 
usually passes with new experiences and emotions and will 
not require any form of psychiatric intervention. However, 
if the depressed mood is prolonged and begins to greatly 
impede a person's ability to lead a normal life, 
intervention may be necessary. The core symptom of 
depression is anhedonia. An individual may also experience 
'subsidiary symptoms', such as feelings of worthlessness or 
guilt, suicidal tendencies, disturbed bodily functions such 
as weight loss, psychomotor retardation and reduced 
cognitive function, fatigue, loss of sexual appetite and 
disturbed diurnal patterns (Arbabzadeh-Bouchez et aI, 
2002). In addition the persons appearance may deteriorate, 
dressing and grooming for example may be neglected. 
Generally, diagnosis of depression will occur in a person 
experiencing one core symptom as well as four subsidiary 
symptoms every day over a two-week period impairing social 
7 
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and occupational functioning in the absence of psychotropic 
drugs or bereavement (DSM-r~, 1994). 
1.3. Antidepressant Treatment 
1.3.1. Antidepressant drug treatment 
Antidepressant treatment by pharmacological means began in 
the 1950s with the serendipitous discovery of two main 
classes of antidepressant drugs: tricylic antidepressants 
(TCAs) and monoamine oxidase inhibitors (MAOls). TCA 
antidepressants were derived from phenothaizides, which 
were originally intended for use as antihistamines and 
sedatives (Zeller et aI, 1952), whereas the MAor isoniazid 
was initially intended for the treatment of tuberculosis 
(Loomer et aI, 1957. Both drugs showed antidepressant 
qualities and both had the ability to enhance or prolong 
the actions of the monoamines 5-hydroxytrytamine (5-HT; 
serotonin) and noradrenaline (NA). The recognition of 
depression as a biochemical disorder led to the monoamine 
theory of depression, which hypothesised that depression 
was due to a deficiency of brain monoaminergic activity and 
thus may be treated by pharmacological means accordingly 
(Schildkraut, 1965). 
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Among the monoamines, 5-HT has been suggested to be the 
primary target of antidepressant drugs. Thus, the last 20 
years has seen the introduction of a class of 
antidepressant aimed directly at selectively enhancing the 
transmission of 5-HT. Selective serotonin reuptake 
inhibitors (SSRIs) achieve this by potently inhibiting 5-HT 
uptake. These drugs were widely accepted as safer and 
better tolerated, though no more efficacious than TCAs and 
MAOIs (Anderson et aI, 2000), thereby questioning the role 
of 5-HT as the primary target for antidepressant drugs. 
1.3.1.1. Monoamine oxidase inhibitors 
Monoamine oxidase (MAO) was first described by Hare (1928). 
The enzyme deaminates monoamine neurotransmitters and 
exogenous amines to form aldehydes, which are then 
converted to acids or alcohols (Yu, 1994). Deamination 
terminates the action of the neurotransmitter, as well as 
detoxifying the exogenous amines. MAO exists as two 
isoenzymes: MAO-A and MAO-B. Under physiological conditions 
MAO-A is primarily found in the brain, gut and liver (but 
not platelets), and deaminates NA and 5-HT (Sandler and 
Youdim, 1972). Whereas MAO-B predominates in the brain and 
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platelets , and deaminates dopamine (Murphy et ai , 1987) . 
MAOIs are often classed by their relative selectivity for 
sub-forms of MAO (type A, type B or mixed ; Mann et aI , 
1984 : Yamada and Yasuhara , 2004) . 
The acute effects of MAOIs are to decrease the degradation 
of monoamines stored in pre- synaptic neurones , thus causing 
increased availability of monoamines at the synapse 
(Schildkraut , 1965 ; Klein and Davis , 1970) . 
Tranylcypromine Phenelzine Isocarboxazid 
Figure 1.1. Chemical structures of the monoamine oxidase 
inhibitors tranylcypromine , phenelzine and isocarboxazid 
1 . 3 . 1 . 2 . Tricyclic antidepressants 
Unlike MAOIs , TCAs have no effect on monoamine metabolism . 
Their primary mode of action is via the inhibition of pre -
synaptic reuptake of monoamines by the blockade of neuronal 
transporters (Sigg , 1959 ; Axelrod , 1962) . TCAs act with 
varying degrees of potency and selectivity towards NA and 
10 
Ahmad Adam Khundakar Chapter One 
5-HT , for example clomipramine is the most 5-HT selective 
and desipramine the most noradrenaline selective , with 
amitriptyline being relatively non-selective (Tatsumi et 
al , 1997 ; Frazer , 1997 ; See Figure 1 . 2) . 
Amitriptyline Imipramine Nortriptyline Desipramine 
Figure 1.2. Chemical structures of tricyclic 
antidepressants , amitriptyline and imipramine and their 
respective metabolites nortriptyline and desipramine 
1 . 3 . 1 . 3 . Selective serotonin reuptake inhibitors 
Reuptake inhibitors can be divided into categories based on 
their relative potency to block serotonergic or 
noradrenergic reuptake sites . Selective serotonin reuptake 
inhibitors (SSRls) are potent to the 5- HT reuptake pump 
(See Figure 1 . 3). 
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5 - HT SELECTIVITY --------+--------NA SELECTIVITf 
10000 1000 100 10 10 100 1000 10000 
Figure 1.3. Selectivity ratios for a series of uptake 
inhibitors measured in - vitro . To the left 5- HT selective 
drugs are shown by the ICso NA uptake/ICso 5- HT uptake ratio , 
whereas to the right NA selective drugs are shown by the 
1Cso 5-HT uptake/ICso NA uptake ratio . The higher the value , 
the more selective for 5-HT respective NA uptake . (Adapted 
from Hytel , 1994). 
SSRIs were the first class of antidepressant to confirm the 
inhibition of neurotransmitter uptake as an important 
therapeutic principle (Vaswani et aI , 2003) . Reuptake is 
the major inactivating mechanism for monoamines after their 
release into the synaptic cleft (Lane et al , 1995 ) . The 
mode of action of SSRIs therefore is to prolong monoamine 
activation by blocking 5- HT reuptake . Negative allosteric 
modulation of the 5- HT transporter (SERT) results in 
increased concentration of 5- HT in the extracellular space 
(Fuller and Wong , 1987 ). Inhibitory pre - synaptic auto-
receptors are activated in response , thus decreasing the 
turnover of 5- HT . However when given chronically , the 
persistent increase in synaptic concentration has been 
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shown to desensitise 5-HT1A auto- receptors after various 
SSRI treatment , thereby reducing auto-inhibition of 5-HT 
release (Chaput et ai , 1986 ; Blier et ai , 1987 ; Rutter et 
ai , 1994 ; Invernizzi et ai , 1996) . 
Fluoxetine Paroxetine 
F 
NC 
F 
Citalopram 
Figure 1.4. Chemical structures of SSRI antidepressants 
fluoxetine , paroxetine and citalopram 
1 . 3 . 1 . 4 . Serotonin/noradrenergic reuptake inhibitors 
Following the emergence of SSRls , the past few years has 
seen a renewed interest in the development of dual action 
antidepressants designed specifically to block both 5-HT 
and NA reuptake . Serotonin/Noradrenaline reuptake 
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inhibitors (SNRIs) have shown successful levels of efficacy 
and tolerability (Thase et al, 2001; Smith et al, 2002). 
The pharmacology of SNRIs depends on their relative 
affinities for 5-HT and NA reuptake blockade. 
1.3.1.5. Selective noradrenergic reuptake inhibitors 
The lack of distinction between the efficacy of SSRIs and 
TCAs has led to a re-examination of the role of NA in 
depression and an evaluation of the clinical use of 
selective NA reuptake inhibition in its treatment (Brunello 
et aI, 2002). A new generation of drugs offering specific 
NA reuptake inhibition have been developed which aim to 
offer equivalent efficacy as TCAs affecting NA reuptake 
(e.g. desipramine), whilst offering an improved side-effect 
profile. Selective NA reuptake inhibitors (NARIs) include 
the tetracyclic compound maprotiline and reboxetine. 
Maprotiline has been shown to exhibit an antidepressant 
action. It strongly inhibits the uptake of NA in the brain 
and peripheral tissues, though it is notable in its lack of 
inhibition of serotonergic uptake. Maprotiline has also 
been shown to produce effects at histaminergic and 
cholinergic receptors (Ruhdorfer and Potter, 1987). 
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Reboxetine selectively inhibits NA uptake without 
inhibition of 5-HT , DA or MAO isoforms (Kent , 2000 ). 
9 
C°'r(CH, N.) H LOC2H 5 
~ U 
Maprotiline Reboxetine 
Figure 1.5. Chemical structures of NARI antidepressants 
maprotiline and reboxetine . 
1.3.2. Electroconvulsive therapy 
The antidepressant properties of convulsive therapy were 
first demonstrated by the application of a seizure- inducing 
dose of camphor , which produced a rapid improvement in 
depressive symptoms in a number of patients (Meduna, 1935 ; 
1936) . Subsequently , chronic electroconvulsive therapy 
(ECT) has been shown to be one the most effective treatment 
of severe depression and bipolar disorder (Greenberg et al , 
1988 ; Fink , 1990 ; Mann , 1998) . Despite its major 
limitations such as high relapse rate and possible profound 
effects on memory (Weeks et al , 1980) , it is still a 
popular option for drug resistant patients. However , the 
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mechanisms that underlie the therapeutic actions of chronic 
ECT remain unclear (Fink, 1990). The application of the 
animal model of ECT, referred to as electroconvulsive shock 
(ECS), has been shown to elicit widespread effect of 
numerous neurotransmitters and signalling components within 
the brain (Nomikos et aI, 1991; Ozawa and Rasenick, 1991). 
1.4. The pathophysiology of depression 
1.4.1. Involvement of stress and the HPA axis in depression 
Chronic exposure to stress and the body's stress response 
has long been implicated for a role in the pathophysiology 
of depression (Board et aI, 1956). The prominent mechanism 
by which the brain counteracts stressors is the activation 
of the hypothalamic-pituitary-adrenal (HPA) axis (McEwen, 
2000; Nestler et aI, 2002), which receives and integrates 
inputs indicative of stress (Dunn and Berridge, 1990; 
Chrousos and Gold, 1992). Corticotrophin releasing factor 
(CRF) is released from neurones in the paraventricular 
nucleus (PVN) of the hypothalamus, which acts on anterior 
pituitary CRF receptors. This consequently stimulates the 
release of adrenocorticotrophin (ACTH), which causes the 
secretion of glucocorticoids (cortisol in humans; 
16 
Ahmad Adam Khundakar Chapter One 
corticosterone in rodents) from the adrenal cortex (Dinan, 
2001). Glucocorticoids have a profound effect on 
metabolism, such as increasing the availability of glucose 
(Holsboer, 2001), as well as behavioural effects via direct 
actions in other brain areas (Nestler et al, 2002). The 
hippocampus projects forward to the PVN of the 
hypothalamus, where it plays an inhibitory role on HPA 
activity (Herman et al, 1989; McEwen and Brinton, 1987; 
Smelik, 1987). Glucocorticoids regulate hippocampal and PVN 
neurones and therefore exert feedback effects on the HPA 
axis activity (Nestler et al, 2002). Glucocorticoids also 
act as inhibitory transcription factors, by 
antagonistically occupying a promoter site that could 
otherwise be bound by a positive regulator (Drouin et al, 
1989) • 
Hypercortisolaemia is often a key feature of depression 
(Gibbons and McHugh, 1962; Carpenter and Bunney, 1971;). 
This manifests as enhanced serum cortisol, non suppression 
of dexamethasone and adrenal gland hyperplasia (Rubin et 
al, 1995) and a blunted ACTH response to CRF challenge 
(Gold et al, 1986; Holsboer et al, 1986). Cushing's 
syndrome patients (who exhibit abnormal cortisol levels) 
have a higher prevalence of depression, however depressive 
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symptoms can often be reversed following reductions in 
cortisol levels (Holsboer, 2003). Centrally administered 
CRF also produces behavioural effects in rats, which 
closely resemble many key features of depression, including 
increased arousal and vigilance, decreased appetite, 
decreased sexual behaviour and increased heart rate 
(Arborelius et al, 1999; Holsboer, 2001). post-mortem 
studies on depressed patients have revealed increased CRF 
cerebrospinal fluid (CSF) levels in depressed patients 
(Nemeroff et aI, 1984; Banki et al, 1992). Whereas 
decreased CRF binding sites were found in suicide victims 
(Nemeroff et al, 1988; Arato et al, 1989). In addition, 
hippocampal atrophy has been shown to occur in the presence 
of high levels of corticosterone (Magarinos and McEwen, 
1995) • 
Despite the large quantity of data supporting a role for 
the HPA axis in depression, it is not clear whether HPA 
dysfunction is the primary cause of depression or a 
consequence of underlying abnormalities exerting influence 
on the axis. Novel drugs aimed at rectifying HPA system 
dysfunction include steroid synthesis inhibitors, CRF 
antagonists and glucocorticoid inhibitors (McQuade and 
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Young, 2000). Initial trials indicate varying degrees of 
success (Manji et aI, 2003). 
1.4.2. Involvement of monoamines in depression 
1.4.2.1. Noradrenaline 
The initial finding that led many to believe that NA played 
a significant role in the pathophysiology of depression 
carne from the effect of the reserpine, which rapidly 
depletes amines in the CNS and periphery and subsequently 
induced depressive symptoms (Fries, 1954). A compound with 
similar amine-depleting actions: tetrabenzine had a similar 
effect and this effect was reversed when treatment was 
discontinued (Bartonicek et aI, 1964). Furthermore, 
supplementation with the catecholamine pre-cursor L-DOPA 
reversed the psychological effect of reserpine 
(Schildkraut, 1965). The main NA metabolite 3-methoxy-4-
hydroxyphenylglycol (MHPG) has been used as an index of 
brain NA turnover in depressed patients. Initial studies 
showed a decrease in MHPG levels in the urine of depressed 
patients (Maas et aI, 1972). Subsequently however, 
increases as well as decreases in urinary MHPG have been 
reported in patients, with a lack of correlation occurring 
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between patients and studies (Potter et al, 1984; Roy et 
al, 1986; Potter and Manji, 1993). Correlations between 
increases in urinary MHPG and anxiety have been more 
frequent (Sevy et al, 1989). Hyper-secretion of NA in 
plasma and CSF have been reported in patients suffering 
unipolar depression and anxiety states (Wyatt et al, 1971; 
Roy et al, 1988; Sevy et al, 1989). 
1.4.2.2. 5-hydroxytryptamine (Serotonin) 
The main 5-HT metabolite 5-HlAA has been widely used as an 
index of 5-HT turnover. Numerous findings have implicated 
decreases in 5-HlAA in the plasma and CSF of depressed 
patients, as well as 'violence-impulsivity' behaviour and 
in suicide victims (Dencker et al, 1966; Mendels et al, 
1972; Van Pragg and de Hann, 1979; Asberg et al, 1976; 
Faustmann et al, 1991; Mann et al, 1996; Mann and Malone, 
1997). However, the degree of the reduction in CSF 5-HlAA 
level does not generally correlate with the severity of the 
depression (Martensen et al, 1989; Mann, 1999). 
Plasma prolactin has been used as an indicator of central 
5-HT function in response to 5-HT releasing agents in 
numerous studies. Generally, a blunted plasma prolactin 
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response has been found after fenfluramine (a 5-HT 
releasing agent) administration in depressed patients, 
compared with controls (Mitchell and Smythe, 1990; Maes et 
al, 1989; 1991; Lichtenberg et al, 1992). Inhibition of TPH 
by parachlorophenylalanine (pCPA), which causes a reduction 
in 5-HT synthesis and subsequent turnover, has been shown 
to produce a relapse in depressive symptoms in patients 
receiving TCP treatment (Shopsin et al, 1976). Likewise, 
depletion by dietary means using an amino acid mixture 
drink lacking the 5-HT precursor TRP has been shown to 
cause a relapse in depressive symptoms in drug-free 
patients with a history of depression (Delgado et al, 
1994). 
1.4.3. The monoamine hypothesis 
The discovery of MAOI and TCA classes of antidepressants in 
the early 1950s suggested a fundamental role for the 
monoamines (and possibly DA) in the pathology of 
depression. This led to the relatively simple and concise 
theory of the aetiopathology of depression: the "monoamine 
hypothesis", which implicated a deficiency of monoamine 
neurotransmission in depressed individuals (Schildkraut, 
1965; Bunney and Davis, 1965). Thus, it was postulated 
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that drugs facilitating activity could correct the 
perceived deficiency in brain monoamines. 
In the years since the monoamine hypothesis was proposed it 
has become obvious that the theory is insufficient in 
itself due to the failure to explain numerous findings. For 
instance, drugs that also rapidly increase brain 
monoaminergic (and DA) activity such as cocaine and 
amphetamine are not effective as antidepressants. Also, 
patients receiving the same antidepressant regimen do not 
always respond equally. The theory can also not explain why 
the agent tianeptine, which enhances 5-HT uptake is an 
effective antidepressant (Loo et aI, 1999; Pineyro and 
B1ier, 1999). However, administration of a typical 
antidepressant causes an increase in synaptic monoamines 
and monoamine facilitation very rapidly, however there is a 
2-3 week lag period before measurable therapeutic onset 
(Oswald et aI, 1972; Heninger and Charney, 1987). Despite 
its obvious drawbacks the monoamine hypothesis still 
provides a benchmark behind which rationales are formed in 
the development of new generations of antidepressants. 
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1.4.3.1. The antidepressant therapeutic latency period 
A major drawback in the monoamine hypothesis of depression 
is its inability to explain the apparent gap between the 
widespread acute biochemical changes and the onset of 
psychological therapeutic change (Oswald et aI, 1972; 
Heninger and Charney, 1987). Antidepressants must be taken 
over a prolonged period of time in order to gain 
therapeutic response, thus exposing the patient to 
deleterious side effects for a longer period of time, 
without any apparent mood-enhancing effect. Interestingly, 
ECT also requires chronic administration (6-12 treatments) 
for antidepressant efficacy to occur (Pearlman, 1991). 
1.5. Intracellular signaling transduction pathways 
The apparent latency period between the acute 
antidepressant action (i.e. the blockade of uptake or 
metabolism of synaptic levels of 5-HT or NA) and the onset 
of therapeutic effects has led to research focusing on 
possible monoamine receptor-linked intracellular signal 
transduction pathways. A prominent hypothesis predicts that 
the therapeutic delay is a result of the period required 
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for targeted changes to occur in gene expression initiated 
by 5-HT and/or NA-receptor mediated activation (Nestler et 
aI, 1989; Duman et aI, 1994, 1997; Manji et aI, 1995). The 
various 5-HT and NA receptor subtypes are known to 
selectively couple and regulate several intracellular 
transduction pathways. The long-term activation of such 
receptor coupled second messenger cascades could lead to 
adaptations via specific target genes that result in 
therapeutic efficacy. 
1.S.1. G-proteins 
All NA and 5-HT receptors are linked to coupling guanyl 
nucleotide-regulated (G)-proteins. G-protein coupled 
(metabotropic) receptors trigger intracellular pathways 
that control enzyme activity usually via phosphorylation, 
or dephosphorylation of serine or threonine residues 
(Gerber, 2002). Four main categories of G-protein have been 
identified: Gs , Gi' Gq and G12 (Gilman, 1989; Gould and 
Manji, 2002). Gs stimulate the enzyme AC and regulate Ca2+ 
and K+ channels. Gsproteins dissociate after transmitter-
receptor interaction and in turn activate effector systems 
e.g. AC, PLC, phospholipase A, ion channels (Gilman, 1987; 
Birnbaumer, 1990). Gi stimulation results in inhibition of 
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AC, whereas Gq interact with PLC (Gilman, 1989). The 
function of GI2 remains unknown, however GI2 activation has 
been linked with the release of the transcriptional 
activator ~-catenin (Meigs et aI, 2002). 
1.5.2. cAMP signaling pathway 
The cAMP signaling cascade represents a common target for 
several classes of antidepressant (Ozawa and Rasenick, 
1991; Nestler et aI, 1989; Tinelli et aI, 1989; Thome et 
aI, 2000). Blunted cAMP signalling through decreases in 
stimulated AC has been recorded in patients with major 
depressive disorder (Stewart et aI, 2001). 
Activation of numerous receptor subtypes including ~-AR, 5-
HT 4 , 5-HTs, 5-HT6 and 5-HT7, lead to the stimulation of AC by 
the Gs-protein, which results in cAMP generation. Increased 
levels of cAMP result in the activation of cAMP-dependent 
protein kinase (PKA). PKA regulates cellular function by 
phosphorylation of many types of regulatory proteins 
including receptors, ion channels, enzymes and 
transcription factors (Duman, 1998). Amongst the substrates 
affected is the transcription factor cyclic AMP response 
element binding protein (CREB). 
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1.5.3. Phosphoinositide signaling pathway 
Another well-characterised G-protein-linked signaling 
pathway involves the breakdown of the cell membrane 
component: phosphoinositide 4,5-biphosphate (PIP2; Majerus, 
1992). The phosphoinositide pathway (PI) is coupled to 
noradrenergic ai' 5-HT2 as well as muscarinic Ml, M3 and M5 
receptors via the Gq subunit (Raulli et al, 1989; Gould and 
Manji, 2002). Following the binding of a ligand to its 
extracellular receptor, GTP binding induces hydrolysis of 
PIP2 to form diacylglycerol (DAG) and inositol-1, 4, 5-
triphosphate (IP3). DAG activates phosphorylation enzyme 
protein kinase (PKC) and increases the affinity for the 
enzyme to Ca2+ (Nishizuka, 1992). Once activated, PKC 
phosphorylates specific proteins including CREB, which are 
critical in cellular and physiological functions e.g. 
transcription and long-term potentiation (LTP; Berridge, 
1993; Jakobs et aI, 1986). The second product of PIP2 
breakdown, IP3 binds to the IP3 receptor which facilitates 
the release of calcium reservoirs in the endoplasmic 
reticulum (Gould and Manji, 2002). The released calcium 
interacts with various proteins including calmodulin 
receptors (CaM). Calmodulin activates ion channels, 
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signalling molecules and transcription factors (Ishidu et 
al, 1978; Soderling et aI, 2000). 
Several studies have implicated PI signalling abnormalities 
in patients with mood disorders and suicide victims (Jope 
et aI, 1996; Pacheco et aI, 1996; Karege et aI, 1996). For 
example, 5-HT and thrombin-stimulated formation of 1P3 has 
been found to be increased in the platelets of depressed 
patients (Mikuni et aI, 1991; Karege et al, 1996). It has 
also been reported that PKC binding sites and PLC 
expression are down-regulated in the pre-frontal cortex of 
teenage suicide victims (Pandey et aI, 1997). 
1.5.4. cAMP response element binding protein 
As mentioned earlier, a common target for both the cAMP 
(via ~-NA, 5-HT4, 5-HTs 5-HT6 5-HT7 receptor activation; 
Duman, 1997; Saxena, 1995; Pandey et al, 1995) and PI (via 
al-NA, 5-HT2A' 5-HT2B and 5-HT2c receptor activation; Mori et 
aI, 1991; Berg and Clarke; 2001; Kurrasch-Orbaugh, 2003) 
cascades is the transcription factor Ca2+/cAMP response 
element binding protein (CREB). CREB therefore regulates 
gene response due to stimulation of the cAMP and PI 
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cascades (Mayer and Habener , 1993 ; Ghosh and Greenberg , 
1999) . 
CREB is a member of the ATF1 , leucine zipper family of 
transcription factors (Lee and Masson , 1993) . 
Phosphorylation of CREB occurs at serine- 133 and serine 119 
sites , which leads to the dimerisation and dramatically 
increases the functional and transcriptional potential of 
CREB . 
Circadian 
entrainment 
Synaptic 
plasticity 
Stressors 
INPUTS 
Growth 
factors 
.,./ Growth and survival 
Neuroprotection 
OUTPUTS 
Figure 1.6. Diagram showing various stimuli and conditions 
implicated in influencing CREB gene expression (INPUTS) and 
postulated physiological and pathological consequences of 
CREB activation (OUTPUTS ; Adapted from Lonze and Ginty , 
2002) . 
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1.5.4.1. Evidence for enhanced CREB signaling in 
antidepressant function 
Nibuya et al (1996) demonstrated that chronic, but not 
acute administration of several diverse types of 
antidepressant drugs (fluoxetine, TCP, desipramine and 
sertraline), as well as ECS caused an increase in 
expression of CREB protein and mRNA in the rat hippocampus. 
The phosphorylation and transcriptional activity of CREB is 
also up-regulated by chronic, but not acute administration 
of a diverse range of antidepressants (Duman et aI, 1997, 
1999; Thome et aI, 2000). An over-expression of CREB has 
been shown to have an antidepressant effect in rats 
performing a behavioural model of learned helplessness 
(Chen et aI, 2001a). Clinical post-mortem studies have 
revealed a decrease in total CREB in the temporal cortex of 
patients with a history of major depression not treated 
with antidepressants at the time of the experiments 
(Dowlatshahi et aI, 1998). Therefore, it has been 
postulated that the inability to regulate the expression 
and function of CREB and henceforth induce adaptive gene 
expression may contribute to the aetiopathology of 
depression (Vaidya and Duman, 2001). Thus, recent research 
has focussed on CREB and its target genes in response to 
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antidepressant challenge. One such heavily implicated gene 
is that of Brain-Derived Neurotrophic Factor (BDNF) 
(Condorelli et aI, 1994; Nibuya et aI, 1995; Siuciak et aI, 
1996; Duman, 1998; Duman et aI, 1999). 
1.6. Brain-Derived Neurotrophic Factor 
BDNF is part of the family of neurotrophins. These proteins 
are structurally and functionally related and also include 
nerve growth factor (NGF; Levi-Montalcini and Angeletti, 
1968; Thoenen and Barde, 1980), neurotrophin 3 (NT-3; 
Maisonpierre et aI, 1990; Rosenthal et aI, 1990); 
neurotrophin 4/5 (NT 4/5; Ip et aI, 1992; Halbrook et al, 
1991; Widmer and Hefti, 1994) and neurotrophin 6 (NT-6; 
Gotz et aI, 1994). 
Neurotrophins have long been known as endogenous signalling 
molecules, which provide extracellular control over the 
development and maintenance of neurones. This control 
occurs due to the selective inhibition of apoptosis through 
the binding of neurotrophins to the cell surface receptors 
on specific populations of neurones in adulthood (Davies, 
1994). Recent findings however expanded the profile of 
neurotrophin function, suggesting roles in synaptic 
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transmission and neuronal plasticity (Lohof et aI, 1993; 
Stoop and Poo, 1996: Liou and Fu, 1997: Mcallister et aI, 
1996). In essence, neurotrophins are now being heralded as 
a new class of neuromodulators that mediate activity-
dependent modifications of neuronal connectivity and 
synaptic efficacy. 
1.6.1. The structure of BONF 
BDNF, like all members of the neurotrophin gene family is 
synthesised as a pre-cursor and is processed at classical 
dibasic cleavage sites into a biologically active 
neurotrophin which contains approximately 50% conserved 
domains (Jungbluth et aI, 1994). The structure comprises of 
seven ~-strands, which contribute to three anti-parallel 
pairs of twisted ~-strands (Robinson, 1995). These strands 
are locked by a 'cysteine knot' of three disulfides 
(McDonald and Hendrickson, 1993). 
1.6.2. BONF receptors 
BDNF function is mainly mediated through interaction with 
the tropomyosin-related kinase B (trkB) receptor. trkB is a 
member of the tyrosine kinase receptor family, which also 
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includes trkA, which binds to NGF and trkC, whose ligand is 
NT-3. BDNF may also exert some actions through the p75 
neurotrophin receptor (Rodriguez-Tebar et aI, 1990; 1992), 
though this receptor may not play a direct role in 
neurotrophic function. 
1.6.2.1 trkB receptors 
Structure 
trkB receptors occur as splice variants of the trkB gene. 
trkB receptors comprise of two cysteine-rich domains 
separated by a leucine-rich domain, two extracellular 
immunoglobulin (IgG) domains and two intracellular tyrosine 
kinase domains (Lamballe et aI, 1991; Klein et aI, 1991; 
Tsoulfas et aI, 1993). All trkB isoforms share a common 
extracellular domain and are thought to be produced as 
alternative splice variants encoded by the same gene (Fryer 
et aI, 1996). There is one apparent full-length trkB 
receptor possessing a (full) trkB domain and two identified 
variants of truncated, physiologically inactive trkB 
receptor lacking the intracellular kinase domain (Middlemas 
et aI, 1991). 
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Distribution 
trkB receptor mRNA is expressed in high levels in the brain 
cortex, striatum and hippocampus and a high degree of co-
localisation has been reported between trkB and BDNF mRNA 
(Merlio et aI, 1993; Salin et aI, 1995). Morphologically, 
catalytic trkB appears to be expressed primarily in 
neurones, however truncated trkB is expressed in both 
neurones and glia. 
Signalling 
As BDNF binds to the trkB receptors, the receptor dimerises 
(Marsh et al, 1993) leading to the autophosphorylation of 
specific tyrosine residues within the intracellular domains 
(Kaplan et al, 1991, Lamballe et aI, 1991; Soppet et aI, 
1991). The phosphorylated tyrosine residues act as protein 
interaction sites for the src homologous and collagen-like 
(shc) adaptor protein (Stephens et al, 1994). The shc 
adaptor protein links the activated trk receptor to two 
distinct intracellular pathways (Chao, 2003; See Figure 
1.7). One pathway, which promotes neuronal survival, 
involves the activation of phosphatidylinositol 3-kinase 
(PI3K) and its putative effector the serine and threonine 
kinase AKT (Burgering and Coffer, 1995; Franke et al, 
1995). trk phosphorylation of the shc adaptor also leads to 
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the activation of GRB2/S0S causing ras activation. 
Activation of Ras leads to a chain of phosphorylation 
reactions including that of raf, mek, erk and mitogen 
activated protein kinase (MAPK; Segal and Greenberg, 1996; 
Grewal et aI, 1999; Ballif and Blenis, 2001). This in turn 
leads to the activation of transcription factors such as 
CREB, which may ultimately influence cell survival, neurite 
outgrowth and synaptic plasticity (Lonze and Ginty, 2002; 
Chao, 2003). 
In addition to src adaptor linked pathways, PLC may bind to 
phosphorylated TrkB residues. The activated PLC cleaves 
phosphatidylinositol 4, 5-biphospate to generate Inositol-
1, 4, 5-triphosphate (IP3; which induces Ca2+) and 
diacylglycerol (DAG; which activates PKC). 
1.6.2.2. p75N~ Receptors 
p75 receptors bind with all neurotrophins with a similar 
affinity (Rodriguez-Tebar et aI, 1990; 1992; Squinto et aI, 
1990). However, several investigators have suggested that 
the receptor may not play a direct role in neurotrophic 
actions of cells (Taniuchi et aI, 1986; Barbacid, 1993; 
Bothwell, 1995). Alternative functions such as buffering 
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the concentration of available extracellular neurotrophin, 
which would maintain a high concentration of neurotrophin 
near the site of release have been suggested (Taniuchi et 
aI, 1986). This would allow neurotrophin bound to p75 on 
one cell to be presented to trk receptor on another cell 
(Barbacid, 1993), or facilitating trk signalling by acting 
as an accessory subunit to trk receptors (Bothwell, 1995). 
One established function of p75 receptors is to promote 
cell death. p75 receptor activation causes increases in 
pro-apoptotic jun-N terminal kinase (JNK; Roux and Barker, 
2002). This may be useful for refining incorrect neuronal 
innervation during development, thus eliminating unwanted 
connections (Majdan and Miller, 1999). 
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Figure 1. 7. BDNF receptor signaling . (Adapted from Chao, 
2 003) . 
1 . 6 . 2 . 3 . Functional consequences of BDNF signaling 
During development in vertebrates BDNF is vital for 
survival , maintenance and growth of neurones in the central 
nervous system (Barde et aI , 1982 ; Leibrock et aI , 1989) . 
BDNF has been demonstrated to promote survival for 
serotonergic (Altar et aI , 1994) , dopaminergic (Knusel et 
aI , 1991 ; Altar et aI , 1994) , cholinergic (Nonner et aI , 
1996) and GABAergic (Altar et aI , 1994 ; Ventimiglia et aI , 
1995) neurones . 
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Role in LTP and synaptic plasticity 
In addition to the normal development of the nervous 
system, it has been widely reported that neurotrophins 
(including BDNF) are capable of modulating transmission at 
central synapses by pre- and post-synaptic mechanisms 
(Mcallister et aI, 1999) in the adult CNS. LTP can be 
separated into distinct phases: the early phase (E-LTP) and 
the late phase (L-LTP). E-ETP is short lasting (1-3 hours) 
and independent of protein synthesis mechanisms, whereas L-
LTP requires induction of cAMP and protein synthesis 
mechanisms (Frey et ai, 1988; Nguyen et aI, 1994). Evidence 
exists that BDNF is capable of influencing both phases. 
BDNF has the ability to act rapidly at pre- and post-
synaptic receptors to modulate LTP (Xu et aI, 2000; 
Kovalchuk et aI, 2002). Indeed, with respect to synaptic 
function, BDNF is capable of depolarising neurones as 
rapidly as glutamate via the trkB receptor (Kafitz et aI, 
1999). Acutely, BDNF is capable of enhancing glutamate 
synaptic transmission (Lohof et aI, 1993; Lessmann et aI, 
1994) and phosphorylating subunits of NMDA receptors in the 
hippocampus (Suen et aI, 1997). In addition to acute 
effects, more stable synaptic changes occur that may 
involve altered gene expression and protein synthesis (Kang 
and Schuman, 1996; Finkbeiner et aI, 1997), which may 
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subsequently modulate the strength of synaptic 
transmission. Prolonged treatments with neurotrophins have 
been demonstrated to promote LTP and maturation of synaptic 
sites (Wang et aI, 1995; Thakker-Varia et aI, 2001). This 
observation is reinforced in mice with targeted deletion of 
the BDNF gene, which display impaired synaptic plasticity 
(Korte et aI, 1995). 
Role in axonal sprouting 
BDNF has been shown to have trophic effects on 5-HT 
neurones (Mamounas et aI, 1995) and the gene for the trkB 
receptor has been identified on 5-HT neurones (Madhav et 
aI, 2001). Local BDNF infusion is capable of producing 
sprouting in mature, uninjured 5-HT axons as well as those 
damaged by p-chloroamphetamine (PeA) pre-treatment 
(Mamounas et aI, 1995; 2000). Indirect BDNF induction via 
repeated ECS induction (Nibuya et ali 1995; Zetterstr6m et 
aI, 1998) has also been demonstrated to greatly enhance 5-
HT axonal sprouting in rats with lesioned hippocampi 
(Madhav et aI, 2000). 
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1.6.2.4. Evidence linking BDNF with depression 
Evidence implicating BDNF with both aetiopathology and the 
treatment of depression has been slowly accumulating from 
numerous lines of investigation. 
Antidepressant effect of BDNF infusion 
A seminal study showed direct infusion of the BDNF protein 
into the rat midbrain produced an antidepressant effect in 
two models of depression in rats: the forced swim test and 
the learned helplessness model (Siuciak et aI, 1997). The 
site of injection in the midbrain was in the proximity of 
the periaqueductal grey matter, DRN and MRN, thus allowing 
BDNF exposure to the highest number of 5-HT cell bodies in 
the brain, suggesting a possible augmentation of 5-HT 
activity. Indeed, central administration of BDNF has been 
shown to exert widespread changes in 5-HT activity (Altar 
et aI, 1994; Maumounas et aI, 1995; Pellymounter et aI, 
1995; Siuciak et aI, 1994; 1998). Infusion of BDNF into the 
dentate gyrus (DG) region of the hippocampus also exerted 
antidepressant affects in forced swim and learned 
helplessness models (Shirayama et aI, 2002). 
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Neurotrophic effects of BDNF 
BDNF has been demonstrated to have widespread trophic 
effects on existing 5-HT (Maumounas et aI, 1995; 2000) and 
noradrenergic (Sklair-Tavron et aI, 1995) neurones 
following neurotoxic lesions. Enhanced neurogenesis has 
also been shown in numerous areas of the rat brain 
following over-expression (Benraiss et aI, 2001) and 
infusion (Pencea et aI, 2001) of BDNF. 
Effect of stress on BDNF levels 
BDNF is thought to play a role in cellular and behavioural 
responses to stress. Chronic stress models in rats have 
been shown to lower BDNF mRNA in the hippocampus. 
Immobilisation and inescapable exposure to noxious stimuli 
diminish hippocampal BDNF mRNA (Smith et aI, 1995; Ueyama 
et aI, 1997), as does elevation of exogenous corticosterone 
levels (Schaaf et aI, 1998), an effect which is blocked by 
subsequent antidepressant treatment (Nibuya et aI, 1995). 
The apparent atrophy of hippocampal neurones in animals 
exposed to experimental stressors has been hypothesised to 
be a result of decreased BDNF expression (Duman et aI, 
1997; 1999). 
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Effect of antidepressants on BDNF levels 
Numerous studies have indicated that chronic, but not acute 
administration of various antidepressant drugs increase 
BDNF gene expression in the hippocampus and cortex in rats 
(Nibuya et ai, 1995: Zetterstr6m et ai, 1998: Russo-
Neustadt, 1999; 2000; Coppell et ai, 2003), over a time 
period similar to that experienced when administering 
antidepressants clinically. In addition, electroconvulsive 
seizure (ECS), the animal model of ECT, strongly increases 
BDNF mRNA in the cortex and the areas of the hippocampus 
(Nibuya et ai, 1995; Zetterstr6m et ai, 1998b). 
Voluntary physical exercise (wheel running) has also been 
shown to produce a rapid increase in BDNF mRNA in the 
hippocampus and cortex of the rat (Neeper et ai, 1996; 
Russo-Neustadt et ai, 2000), as well as augmenting 
monoaminergic function (Dunn et ai, 1996; Dishman et ai, 
2000). Physical exercise in humans has been shown to 
enhance mood and psychological coping mechanisms (Emery et 
ai, 1992; Hill et ai, 1993), as well as cognitive 
functioning (Blomquist et ai, 1987). In rats exercise has 
been shown to counteract the decreased BDNF effect of 
forced swim tests (Russo-Neustadt et ai, 2001) 
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1.6.3. BONF transcripts 
The structure of the rat BDNF gene was elucidated by 
Timmusk's group (Timmusk et a1, 1993). A rat genomic 
library was screened using sequences from three different 
regions of BDNF cDNAs. Following hybridisation of rat 
genomic sequences to rat brain mRNA and reverse 
transcription-assisted polymerase chain reaction (peR), the 
presence of five exons within the rat BDNF gene was 
discovered (Timmusk et aI, 1993). The rat BDNF gene 
includes four short 5' exons (exons I-IV) that are each 
associated with a separate promoter, and one 3' exon (exon 
V) that encodes for the mature BDNF protein (Timmusk et aI, 
1993; Nakayama et a1, 1994). As any exon can be 
po1yadeny1ated in two positions, four different promoters 
give rise to eight predominant transcripts, each of these 
transcripts will contain one of the four variable 5' exons, 
in addition to an exon V segment (Lauterborn at al, 1996; 
Timmusk et a1, 1993; See Figure 1.8). 
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Figure 1.8. The organisation of the BDNF gene . (A) The BDNF 
gene spans over 40KB and contains five exons (I - V) . Each of 
the four exons contains a unique promoter and one or more 
transcription initiation site . (B) Each BDNF message can be 
transcribed from any of exons I to IV (exon III in this 
example) . (e) A precursor form of BDNF protein (prepro-
BDNF) is encoded within exon V and undergoes cleavage to 
yield mature BDNF protein (Adapted from Finkbeiner , 2000) . 
The transcripts are expressed differentially across 
different brain areas (Timmusk et ai , 1993 ; Bishop et ai , 
1994) and regulated differentially from a variety of 
manipulations (Nakayama et ai , 1994 ; Kokaia et ai , 1995) . 
In the hippocampus ischemia has been shown to selectively 
increase expression of the transcript form containing exon 
III , while kainate injections increase all of the 
transcript forms (Falkenberg et ai , 1993 ; Metsis et ai , 
1994 ; Timmusk et aI , 1995) . The apparent presence of 
multiple transcript forms of BDNF, translating to one 
identical protein is unique amongst neurotrophins and is 
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potentially a means of multiple levels of regulation 
(Russo-Neustadt et al, 2000). 
Protein synthesis inhibition on activity-dependent 
expression of BDNF transcripts revealed that exon I and II 
required intervening protein synthesis mechanisms to alter 
levels (Lauterborn et al, 1996). In contrast, exons III and 
IV are fairly inductable in the presence of protein 
synthesis blockers (Lauterborn et al, 1996), suggesting 
that these transcripts are immediate early gene (IEG)-like 
in function. 
1.7. The hippocampus 
The hippocampus is one of the most commonly examined areas 
of the brain in relation to the effect of depression and 
antidepressant actions. It also has been shown to contain 
the greatest expression of BDNF mRNA and protein in the 
CNS. 
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1.7.1. Evidence linking the hippocampus with depression 
MRI studies 
Using high-resolution magnetic resonance imaging (MRI), 
significant bilateral hippocampal atrophy has been reported 
in patients with a history of recurrent, major depression 
against matched controls (Sheline et al, 1996; 1999; 
Bremner et al, 2000). Shah et al (1998) also reported 
hippocampal atrophy in patients with chronic depression, 
but found no atrophy in patients with "remitted" depression 
over controls, the clinical characteristics of remitted 
depression were however not described, making comparison 
difficult. Two further studies (Swayze et al 1992; Axelson 
et al 1993) found no hippocapmpal atrophy in depressive 
patients, however a less sensitive MRI methodology was used 
that was unable to differentiate between the hippocampus 
and amygdala (Sheline, 2000). 
Animal models of stress 
Animals subjected to recurrent episodes of stress have been 
shown to possess damaged hippocampal neurones. Chronic 
restraint stress produced significant atrophy of dendrites 
of CA3 neurones (Watanabe et al, 1992). Multiple stressors 
(shaking in addition to restraint) produced dendritic 
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atrophy and a robust increase in corticosterone (Magarinos 
and McEwen, 1995). After repeated stressor episodes, ultra-
structural changes in mossy fibre projections have been 
demonstrated (Magarinos and McEwen, 1995). These changes 
however are reversible and may be prevented by 
antidepressant (tianeptine) treatment (Watanabe et al, 
1992; Czeh et a1, 2001). Lesioning of the hippocampus has 
been shown to eliminate the behavioural deficits induced by 
the learned helplessness model of animal depression (Elmes 
et al, 1975). 
1.7.2. Anatomy 
The mammalian hippocampal formation comprises of two main 
multi-layered components: the hippocampal gyrus and dentate 
i 
gyrus (DG; area dentata) . i 
The synaptic connections within the hippocampal formation 
are described as the 'trisynaptic circuit' (Andersen et al, 
1966; Witter et al, 1989). The first connection is formed 
by fibres of the perforant pathway, layers II and III of 
the entorhinal cortex project into the DG to terminate on 
granule cell dendrites in the molecular cell layer (Hjorth-
Simonsen, 1972; Steward, 1976). The second connection 
46 
Ahmad Adam Khundakar Chapter One 
arises from the granule cell layer , which sends axons 
(mossy fibres) to form synapses with the CA3 pyramidal 
cells of the hippocampal gyrus . The axons of the pyramidal 
cells form the main output for the hippocampus (Hinoi et 
ai , 2002) . However pyramidal cells also project 
collaterals , which make contact with pyramidal cells in the 
CAl (Andersen et ai , 1971 ; Ishizuka et ai , 1990) , thus 
completing the loop (See Figure 1 . 12). 
Perforant Path Fiber 
from Entorhinal Cortex 
Figure 1.9. Simplified schematic diagram showing the 
pathways comprising the ' tri - synaptic loop ' (adapted from 
Levitan and Kaczmarek , 1997) 
All the neurones comprising the tri - synaptic loop 
architecture are glutamatergic . These principle cells 
represent 90% of hippocampal neurones (Vizi and Kiss , 
1998) . The remaining 10% non- principal cells are 
interneurones and are thought to use gamma aminobutyric 
acid (GABA) as a neurotransmitter (Gaiarsa et ai , 2001) . 
47 
Ahmad Adam Khundakar Chapter One 
They form well-organised neural networks, which control and 
regulate the operation of principal cells (Freund and 
Buzsaki, 1996). 
1.8. Aims of the Present Study 
• To assess the effect of acute administration of 
various antidepressant drugs on total (exon V) BDNF 
mRNA, as well as a representative form of a protein 
synthesis dependent exon transcript form (exon I) and 
a variable 'lEG-like' exon transcript form (exon IV) 
in the rat hippocampus (See Chapter 3). 
• To further examine the apparent acute inhibitory 
effect of antidepressant drugs on BDNF mRNA by the 
application of various GABAergic receptor compounds in 
the rat hippocampus (See Chapter 4). 
• To assess the effect of chronic administration of 
various antidepressant drugs on total (exon V) BDNF 
mRNA, as well as a representative form of a protein 
synthesis dependent exon transcript form (exon I) and 
a variable 'lEG-like' exon transcript form (exon IV) 
in the rat hippocampus (See Chapter 5). 
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• To assess the effect of acute and chronic ECS 
application on total (exon V) BDNF mRNA, as well as a 
representative form of a protein synthesis dependent 
exon transcript form (exon I) and a variable 'IEG-
like' exon transcript form (exon IV) in the rat 
hippocampus (See Chapter 6). 
• To examine the effect of chronic administration of an 
antidepressant drug and chronic ECS application on 
BDNF protein expression within the rat hippocampus 
(See Chapter 7). 
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Chapter Two 
Materials and Methods 
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2.1. Animals 
All animal procedures were performed according to 
guidelines set by the Ethics and Animal Welfare Committee, 
De Montfort University, in accordance with the Animals 
(Scientific Procedures) Act, 1986. Animals were kept in 12h 
light: 12h dark conditions, with food and water available 
ad liberatum. Male Sprague-Dawley rats (Charles River, UK) 
were purchased 10 days before drug administration to 
minimise environmental impact and housed four per cage. 
Animals weighed between 225g and 250g upon drug 
administration. Injections were administered 
interperitoneally (i.p) in the lower left or right quadrant 
of the abdomen, with the needle angled at 45° to the skin. 
Electroconvulsive shock (ECS) was administered under 
halothane-induced anaesthesia via earclips placed 
bilaterally (See Section 2.1.1.2). 
Animals were killed according to Schedule 1 of the Animals 
(Scientific Procedures) Act, 1986 by rapid dislocation of 
the neck. Every effort was made to ensure a quick and 
humane sacrifice. 
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2.2. Experimental protocol 
2.2.1. Drug administration 
2.2.1.1. Acute administration 
Groups of six animals were injected i.p once with the 
relevant compound and observed every 30min for 4h for any 
behavioural changes, prior to sacrifice. Drug doses are 
listed in Sections 3.2 and 4.2. 
2.2.1.2. Chronic administration 
Groups of six animals were injected i.p once daily with the 
relevant compound for 21d and observed periodically for 
behavioural changes and illness. Animals were sacrificed 
24h after the last injection. Drug doses are listed in 
Section 5.2. 
2.2.2. ECS administration 
ECS was administered under halothane-induced anaesthesia. 
ECS induction was elicited using a small animal 
electroplexy unit (Theratronics Ltd, Guernsey). Induction 
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was set at 150V, 50 Hz for 1 second via earclip electrodes, 
resulting in tonic-clonic seizures lasting 15 to 20 
seconds. Sham ECS involved the induction of halothane 
anaesthesia and the placement of earclips for a comparable 
length of time, without seizure induction. 
2.2.2.1. Acute ECS administration 
Animals were exposed to either a single ECS or sham 
treatment, before being sacrificed at 4h. 
2.2.2.2. Chronic ECS administration 
Animals were exposed to repeated ECS or sham treatment (5 
treatments over a 10d period, i.e. one ECS every 48h). They 
were then sacrificed 24h after the last application. 
2.3. In-situ hybridisation 
2.3.1. Tissue pre-treatment 
Brains were rapidly removed post-mortem, frozen in cooled 
isopentane and stored at -80°C until further use. Coronal 
sections (10~) were cut using a cryostat (Bright, UK) set 
to -20°C, and thaw-mounted onto gelatinised microscope 
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slides (3 per slide) . Sections were then post - fixed in 4% 
paraformaldehyde (PFA) in phosphate - buffered saline (PBS , 
pH 7.4) for 5 min , then rinsed twice in PBS . Sections were 
then acetylated by 0 . 25% acetic anhydride in 
triethanolamine buffer (O . lM triethanolamine in 0 . 9% 
saline , pH 8) for 10 minutes , then dehydrated through a 
series of graded ethanol solutions (70 , 80 , 95 and 100%) , 
delipidated in chloroform for 10 min and further dehydrated 
with 100% and 95% ethanol . Sections were air-dried and 
stored at - 20 °C, prior to use in labelling procedures. 
2.3.2. Oligonucleotide probe labelling 
2 . 3 . 2 . 1 . Oligonucleotide probes 
Oligonucleotide DNA probes complimentary to BDNF mRNA , BDNF 
exon I mRNA, BDNF exon II, BDNF exon III and BDNF exon IV 
mRNA were obtained (Eurogentec DNA Service Ltd . 
Southampton , UK) . No significant homology between any probe 
and other previously identified gene sequences was found 
using a basic BLAST search , present on the National 
Institute for Health website 
(www . ncbi . nlm . nih . gov/blast/blast . cgi ). Probe sequences 
were as follows: 
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BDNF - GGT CTC GTA GAA ATA TTG CTT CAG TTG GCC TTT TGA 
(Sequence code F75377; Eurogentec, UK. G C content 41.7%). 
BDNF (SENSE STRAND) - CCA GAG CAT CTT TAT AAC GAA GTC AAC 
CCG AAA ACT (Sequence code F75378i Eurogentec, UK. G C 
content 41.7%) 
BDNF (Exon I) - ACC CAA AGC AAT ATC GCA AGC TTC AAC TCT CAT 
CCA CTT (Sequence code F56636, Eurogentec, UK. G C content 
45%) . 
BDNF (Exon II; PROBE A) - ATG AAG TAC TAC CAC CTC GGA CAA 
ATC CGC TGG (Sequence code G28478, Eurogentec, UK. G C 
content 52%) 
BDNF (Exon II; PROBE B) - AGT AAC AGA CCT CAC TAA AGC CAT 
ATG CTT CCC AGC AGA (Sequence code F56637, Eurogentec, UK. 
G C content 50%) 
BDNF (Exon III) - TAA TAC TCG CAC GCC TTC AGT GAG AAG CTC 
CAT (Sequence code G282479, Eurogentec, UK G C content 48%) 
BDNF (Exon IV) - TTC CTT TAG GAA TGT CTC AAG TAC CAT TCC 
eCA eCT eCA T (Sequence code F67353, Eurogentec, UK. G C 
content 45%) 
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2.3.2.2. Labelling 
Oligonucleotide probes were radiolabelled at the 3' end 
with [a-[35S] thio]-dATP (specific activity 1250 Ci/mmol; 
NEN life sciences, Stevenage, UK) using terminal 
deoxynucleotidyl transferase (TdT, Promega, UK). A reaction 
mixture was made containing 6pmol oligonucleotide, 30-60 
units TdT, 60 pmol [35S]-dATP in sterile water, 100 mmol 
potassium cacodylate, 1mM CoC12 and 100nM dithiothreitol 
(OTT) in diethyl pyrocarbonate (OEPC; 1%) treated purified 
water (final volume 35~1). After incubation at 37°C for 30 
minutes, the reaction was stopped by adding 400~1 of Reagent 
A solution (0.1M Tris hydrochloride, 10mmol trietyhlamine 
(TEA), 1mmol ethylenediaminetetraacetic acid (EOTA, pH 
7.7). The reaction mixture was passed through a spin column 
containing Sephadex G-50 in order to separate the labelled 
probe from unincorporated nucleotide. Two more applications 
of 500~1 Reagent A were passed through the column, resulting 
in three end solutions. The specific activity of each 
solution was determined using a scintillation counter 
(Beckman L55000ce, USA). A labelling procedure was deemed 
successful if the majority of the activity was present in 
the second tube and 50% of the radioactivity had been 
successfully incorporated. 
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2.3.2.3. Hybridisation 
The microscope slides containing the previously thaw-
mounted sections (See Section 2.1.2) were removed from the 
freezer, before being thawed and placed on RNA-ase free 
filter paper soaked in 4x standard saline citrate (SSC) 
(equivalent to 600mmol sodium chloride, 60mmol sodium 
citrate) in bioassay dishes. Labelled probe (2xl0 6 
cpmol/slide) which comprised of 50% deionised formamide, 
20% 20 x SSC (4 x SSC), 5% sodium phosphate buffer 
(0.5mol), 1% sodium pyrophosphate buffer (O.lmol), 10% v/v 
SOx Denhardt's solution (0.2% Ficoll, 0.2% 
polyvinylpyrrolidone and 0.2% bovine serum albumin in 
sterile water), 10mg/ml herring sperm DNA, Smg/ml 
polyadenelic acid, 120mg/ml heparin and 1'0% dextran sulfate 
powder and SOmM dithiothreitol (DTT) was applied to thawed 
sections (3 per slide). After application of the reaction 
mixture the sections were cover-slipped, the bioassay boxes 
covered and incubated in humid chambers at the relevant 
calculated temperature for incubation of the probe (See 
Section 2.1.6). 
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2.3.3. Washinq of sections 
Cover slips were washed off in room temperature 1 X sse. 
Sections were then washed in 1 x SSC at a pre-calculated 
washing temperature for a specific probe (See Section 
2.1.6) for 3x20min, then at room temperature for 2 x 60min. 
To remove excess salt present, the sections were rinsed in 
sterile water and air-dried at room temperature. The slides 
were then placed into X-ray cassettes with a 14C micro-scale 
standard (Amersham, UK) and exposed to Bio-Max film© 
(Kodak) in darkness for 7d at room temperature. 
2.3.3.1. Hybridisation and washing temperature calculations 
Hybridisation depends on the ability of the DNA to re-
anneal to a complementary strand, just below its melting 
point. The melting temperature (Tml of DNA-RNA hybrids (in 
this series of experiments the oligonucleotide DNA probe-
target mRNA hybrids) is influenced by many factors, which 
in turn contribute to the stringency of hybridisation. The 
stringency of hybridisation determines the degree to which 
mismatched hybrids are permitted to form. The factors which 
affect stringency and therefore (Tm) include: (i) the 
guanine and cytosine percentage content the base 
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composition, (ii) the length of the probe, (iii) the 
concentration of monovalent cations (the Na+ concentration) 
and (iv) the concentration of formamide present in buffer. 
The (Tm) was calculated using the following formula 
(Meinkoth and Wahl, 1984). 
(Tm) = 81.5°C + 16.6 log ([monovelent cations]) + 0.41 (%G-C 
content of probe) - 0.61 (% formamide) - (675/probe length) 
All incubation and washing procedures were carried out at 
15°C below the Tm. 
(iJ A, Total BDNF (exon V) oligo probe 
HYBRIDISATION 
G C content 41.7%, Number of bases 36 
Tm= 16.61og (4xO.165) +0.41(41.7) +81.5 -0 -675 -0.65 x50 
36 
= -2.99 +17.1 +81.5 -18.75 -32.5 
= 44.36 
= Ti = Tm -15 = 29.3°C 
WASHING 
Tm= 16.61og (0.165) +0.41(41.7) +81.5 -0 - 675 
36 
-12.99 +17.1 +81.5 -18.75 
= 66.86 
Tw = 66.9 -15= Sl.9°C 
(ii) BDNF exon I oligo probe 
HYBRIDISATION 
G C content 45%, Number of bases 40 
59 
Ahmad Adam Khundakar Chapter Two 
Tm= 16.61og (4xO.165) +0.41(45) +81.5 -0 -675 -0.65 x50 
40 
= -2.99 +18.5 +81.5 -16.88 -32.5 
= 47.63 
= Ti = Tm -15 = 32. 6°C 
WASHING 
Tm= 16.61og (0.165) +0.41(45) +81.5 -0 - 675 
40 
-12.99 +21.32 +81.5 -16.88 
= 72.95 
Tw= 72.95 -15= S7.9°C 
(iii) BDNF exon II oligo probe (PROBE A) 
HYBRIDISATION 
G C content 52%, Number of bases 33 
Tm= 16.61og (4xO.165) +0.41(52) +81.5 -0 -675 -0.65 x50 
33 
= -2.99 +21.3 +81.5 -20.45 -32.5 
= 46.86 
= Ti= Tm-15 = 31.8°C 
WASHING 
Tm= 16.61og (0.165) +0.41(52) +81.5 -0 - 675 
33 
-12.99 +21.32 +81.5 -20.45 
= 69.36 
Tw = 69.4 -15 = S4.4°C 
(PROBE B) 
HYBRIDISATION 
G C content 50%, Number of bases 36 
Tm = 16.6 (4xO.165) +0.41(50) +81.5 -0 -675 -0.65 x50 
36 
= -2.99 +20.5 +81.5 -18.75 -32.5 
= 45.24 
Ti= Tm- 15 = 30.2°C 
WASHING 
Tm= 16.61og (0.165) +0.41(50) =81.5 -0 -675 
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-12.99 +20.5 +81.5 - 18.75 
= 70.26 
Tm = 70.26 -15 = 55.3°e 
(iv) BDNF exon III oligo probe 
HYBRIDISATION 
G C content 48%, number of bases 33 
36 
Tm = 16.61og (0.165x4) +0.41(48) +81.5 -0 -675 -0.65 x50 
33 
= -2.99 +19.68 +81.5 -20.45 -32.5 
= 45.3 
WASHING 
Tm= 16.61og (0.165) +0.41(48) +81.5 -0 - 675 
33 
-12.99 +19.68 +81.5 -20.45 
= 67.76 
Tw = 67.76 -15 = 53°e 
(V) BDNF exon IV oligo probe 
HYBRIDISATION 
G C content 45%, Number of bases 40 
Tm = 16.61og (4xO.165) +0.41(45) +81.5 -0 -675 -0.65 x50 
40 
-2.99 +18.4 +81.5 -16.9 -32.5 
= 47.51 
= Ti= Tm -15 = 32.5°e 
WASHING 
T m = 16. 610g ( 0 • 165 ) + 0 • 41 ( 45 ) + 81. 5 - 0 - 675 
40 
-12.99 +18.4 +81.5 -16.8 
= 70.11 
Tw = 69.4 -15= 55.l o e 
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2.3.4. Autoradiogram Analysis 
2.3.4.1 Film development 
Following exposure to the tissue slices, the Bio-max film 
was developed by immersion in developer for 1 min 30 s, 
rinsed in tap water, then immersed in a fixing solution for 
5 min, followed by a further rinse in tap water. The Kodak 
GBX developer and fixer were obtained from Sigma-Aldrich 
Co. UK. 
2.3.4.2. Film analysis 
Densitometric analysis of the radioemissions was conducted 
using the NIH Image (version 1.61) program on a Macintosh~ 
G4 computer. Autoradiogram images were captured via an 
Epson~ Stylus Photo scanner set to 1200 x 1200 pixel 
optical resolution. The optical densities of specific brain 
regions were quantified and converted to nCi/g tissue 
weight using a standard curve generated by autoradiographic 
[ 14C] microscale standards (Amersham Biotech Ltd. UK). A 9 x 
9 pixel sampling area was chosen and placed over the 
corresponding area to be analysed. 100 readings were taken 
for each region assessed in each slice (three slices per 
animal) and a mean value was calculated to give a single 
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mean for each particular area in an animal (See Figure 
2 .1) . 
2 . 3.4 . 3 . Statistical analysis 
Statistical analyses of the effects of drug/ECS 
intervention were made using either Student ' s t-test for 
two sets of data (vehicle control vs. drug-treated) , or 
one-way/two-way analysis of variance (ANOVA) for multiple 
sets of data, with Bonferoni ' s multiple comparison post-hoc 
test , using GraphPad Prism Version 3 . 00 (GraphPad Software 
Inc ., Califronia , USA) . Significance was determined at 
p<0 . 05, all data is presented as mean ± standard error of 
mean ( S . E . M. ) . 
... 
.•..• , 
•• CAl /= ..... ~ ~<5Al 
, 0 0000 ~G CA3 • ....... ......... ,. 
Figure 2 . 1 . Schematic diagram of coronal section through 
the rat hippocampus showing approximate location of 
principal cell layers where optical densities were studied 
(adapted from Gibbs , 1998) 
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2.3.5. Control sections 
Two methods of controls were employed to check for 
specificity of the anti-sense probes used in this study. 
For the total (exon V) BDNF, a cDNA sense sequence was 
obtained, corresponding to the parallel anti-sense 
sequence. The sense control was used to detect a background 
signal indicating the level of non-specific interactions. 
Minimal background signal was present for any control 
experiment, confirming the specificity of the 
oligonucleotide probe used. In addition, sections were 
hybridised with radiolabelled anti-sense probes 
corresponding to the total BDNF sequence used, as well as 
BDNF exon I and BDNF exon IV probe used, in the presence of 
over lOO-fold excess of cold unlabelled nucleotide. 
Expression in key areas was eliminated using this 
technique. 
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ANTISENSE 100 X EXCESS 
BDNF 
Exon I 
B 
Exon IV 
.. 
C 
Figure 2.2. Control sections. In-situ hybridisation images 
demonstrating BDNF labelling with A, BDNF antisense probe ; 
B, BDNF exon I antisense probe ; C, BDNF exon IV antisense 
probe D, lOO - fold excess BDNF i E, lOO - fold excess exon I 
probe ; F, lOO- fold excess exon I probe . 
D 
E 
F 
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2.4. Immunocytochemistry 
2.4.1. Perfusion procedure 
Animals were deeply anaesthetised with sodium 
pentobarbitone (200mg/kg, i.p) and transcranially perfused 
with 150ml of ice-cooled phosphate buffer saline (PBS, pH 
7.4) using a perfusion pump set at a rate of 55ml/min. This 
was proceeded by 450ml of ice-cooled O.lM phosphate buffer, 
containing 4% PFA and 0.1% glutaraldehyde (pH 7.4) at a 
rate of 55ml/min. Brains were then removed from the skull 
and post-fixed in 2% PFA for 1.5h, before being 
cryoprotected by submerging in 10% dimethyl sulfoxide 
overnight. Following cryoprotection, brains were flash-
frozen in cooled isopentane. A series of coronal sections 
(30~ thick) through the frontal cortex, striatum and 
hippocampus were then cut on a cryostat. Free-floating 
sections were collected in cold PBS in 24-well plates. 
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2.4.2. Immunostaininq 
Pre-incubation 
Sections were placed in sterile well plates covered in a 
pre-incubation of PBS and 0.25% Triton X-lOO for l5mins 
then washed twice in PBS and placed in a pre-blocking agent 
of PBS, 0.25% Triton X-lOa and 5% bovine serum albumin for 
lh. 
Primary incubation 
Sections were washed twice in PBS then transferred by a 
glass tool into sterile well plates containing primary 
antibody (pAb) solution consisting of 10~g/ml chicken anti-
hBDNF IgY pAb and 0.25% Triton X-lOa in PBS for 24h at room 
temperature. 
Secondary incubation 
The sections were washed three times in PBS and transferred 
to well plates containing a secondary antibody solution 
consisting of 5~g/ml rabbit biotinylated anti-chicken IgY 
IgG in PBS for 2h at room temperature. 
Avidin-biotin-horseradish peroxidase complex and 
diaminobenzine reactions 
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Sections were then covered in Vector elite avidin-biotin-
horseradish peroxidase complex (ABC) reagent~ for 2h at 
room temperature, before being washed twice in PBS and 
washed once in 50nM TRIS (hydroxymethyl) aminomethane 
(TRIS) buffer (pH 7.7). Each section was then incubated in 
3,3'-diaminobenzidine (DAB, 0.5mg/ml) in 50mM Tris saline 
buffer, containing 0.009% hydrogen peroxide. In addition 
2xdrops of nickel stain were added to the mixture. After 5 
mins the reaction was terminated by removing the sections 
from the solution. The sections were the rinsed three times 
in 50mM TRIS buffer, then stored in PBS, before being 
mounted on gelatinised microscope slides. 
Mounting sections 
Individual sections were placed on gelatinised slides and 
delipidated though immersion in graded 2min ethanol washes 
(50%, 70%, 90%, 100% in distilled water), then 100% xylene 
for 8mins. Sections were then mounted using DPX Histoclear 
mount ant and cover-slipped, lightly applying pressure to 
ensure against bubbles. 
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Photomicrography 
Sections were examined using a Leitz-Diaplan 
photomicroscope and images were captured with a digital 
camera using Openlab software (Improvision, UK). 
Image and data analysis 
Relative abundance was measured in selected areas using a 
computerised analysis system (MCID-4, Imaging Research, St 
'Catherine's, Ontario, Canada) and expressed as an optical 
density unit, which was corrected for background (non-
specific) signal by subtracting white matter (corpus 
callosum) from the raw figures. The immunoreactivity of 
BDNF protein was measured in four areas, the CAl, CA3 and 
DG of the hippocampus, and the parietal cortex. Differences 
between saline/sham and treatment groups were assessed 
using Student's t-test. 
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Parietal 
Cortex 
MFZ 
A3 
Figure 2.3. Anatomical locations of regions studied in the 
irnrnuncytochemistry experiments (Adapted from Paxinos and 
Watson , 1997 ; Plate 33) . 
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2. 4 .3. Control s e ctions 
Controls were performed on sections in each corresponding 
group by following the same procedure except for incubating 
in Triton X-lOO instead of primary antibody . All other 
stages were performed identically to experimental sections . 
Figure 2.4. ICC experiment coronal hippocampal control 
section image (A) , compared with section with BDNF primary 
antibody present (B) . The anatomical location is 
highlighted on a schematic diagram above (Adapted from 
Paxinos and Watson , 1997 ; Plate 34) . 
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2.5. Chemicals and drugs 
2.5.1. Chemicals 
The chemicals used (with supplier) used in ISH and ICC 
experiments are tabulated below. 
Table 2.1. Chemical sources for ISH and ICC experiments. 
Supplier 
Promega UK; Southampton) 
Sigma UK; Poole, Dorset). 
Chemical 
Potassium cacodylate, cobalt 
chloride, herring sperm DNA, 
primary antibody, secondary 
antibody 
Phosphate buffer saline 
tablets, triethanolamine, 
acetic anhydride, 
diethylpyrocarbonate, 
dithiothreitol, Sephadex G-
sa, triethylamine, Trizma 
hydrochloride, deionised 
formamide, formamide, sodium 
citrate, Denhart's solution, 
polyadenylic acid, heparin, 
dextran sulphate, bovine 
serum albumin, TRIS buffer 
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Fisher Scientific UK; Glacial acetic acid, 
Loughborough, Leicestershire paraformaldehyde, chloroform, 
sodium chloride, xylene 
BDH Laboratory Supplies; Powdered gelatin, chromium 
Poole, Dorset potassium sulphate, 
Vector Laboratories Inc. 
Burlingame, California, USA 
ethylenediaminetetraacetic 
acid disodium salt, sodium 
phosphate, sodium 
orthophosphate, sodium 
pyrophosphate, glass slides, 
cover slips 
ABC kit, DAB substrate kit 
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2.5.2. Drugs 
The drugs used (with supplier) used in ISH and ICC 
experiments are tabulated below. 
Table 2.2. Drug sources for ISH and ICC experiments. 
Supplier 
Tocris Cookson Ltd; Bristol, 
UK 
Sigma; Poole, Dorset, UK 
Lundbeck Pharmaceticals; 
Hartlepool, UK 
Glaxo Smith-Kline 
Lilly 
Drug 
CGP 46381, CGP 55845, GBR 
12909, maprotiline, 
tranylcypromine, THIP, 
flunitrazepam, 
methylphenidate 
Baclofen, desipramine 
Citalopram 
Paroxetine 
Fluoxetine 
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Chapter Three 
The Effect of Acute Antidepressant Drug 
Administration on BDNF mRNA and BDNF exon 
mRNA in the Rat Hippocampus 
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3.1. Introduction 
The present chapter relates to the effect of acute 
administration of various classes of antidepressant drugs on 
the expression of total BDNF mRNA (exon V), as well as 
variable transcript forms which are generated from the gene 
(containing exons I-IV), in the adult rat hippocampus. A 
series of in-situ hybridisation experiments were performed 
examining the effect of a single injection of six different 
antidepressant drugs on BDNF mRNA, as well as the transcript 
forms containing BDNF exon I and exon IV mRNA. Attempts were 
made to measure exon II and exon III mRNA, however basal 
levels were deemed insufficient to ensure reliable 
measurements. 
The hippocampus was chosen as the region of focus for the 
series of experiments. Initial experiments indicated the 
highest level of basal expression of BDNF mRNA was present 
in this region in comparison with other areas measured, 
where low levels of basal expression were found (See Section 
3.3.1). In addition, as explained in Section 1.7.3, 
alterations in hippocampal function have long been 
implicated in the pathophysiology of depression. 
Furthermore, a high degree of neuronal plasticity is known 
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to take place in the hippocampus and BDNF has been shown to 
influence synaptic function and induce neuronal sprouting in 
this region (See Section 1.6.2.3). 
The antidepressants used comprised of the SSRIs fluoxetine, 
paroxetine and citalopram; and the selective NARIs 
desipramine and maprotiline. The antidepressants were chosen 
because of their varying affinities and potency for the 
serotonin and noradrenaline reuptake sites (Hytel, 1994). 
The non-selective MAO! tranylcypromine (TCP) was also 
tested. 
In addition for comparison, the effect of the non-selective 
noradrenaline (NA) / dopamine (DA) reuptake blocker 
methylphenidate and the selective DA transporter blocker GBR 
12909 were assessed. Methylphenidate is a psycho-stimulant 
that binds with a similar affinity to the DA and NA 
transporters that produces an increase in extracellular 
brain concentrations of both DA and NA in rodents (Gatley et 
aI, 1996; Kuczenski and Segal, 1997). GBR 12909 has been 
shown to show bind with a high affinity to the DA 
transporter (Rothman et aI, 2003), and has been shown to 
bind with a substantially less (over 100 times) affinity to 
the 5-HT transporter (Andersen, 1989). It has also been 
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shown to have no effect on NA metabolism or LC firing rate 
(Nissbrandt et al , 1991) . 
F 
F 
Methylphenidate GBR 12909 
Figure 3.1. The structure of methylphenidate and GBR 12909 
3.1.1. The effect of acute administration of antidepressant 
drugs on BDNF mRNA 
As explained earlier (See Section 1 . 6 . 2 . 4), several groups 
have shown an enhancement in BDNF mRNA after chronic 
administration of antidepressant drugs (Nibuya et al , 1995 ; 
Russo - Neustadt et al , 2000 ; Coppell et al , 2003) . However , 
considerable variations exist in the magnitude of the 
increase between these studies . It has been suggested that 
such anomalies may be due to the time period after the last 
injection . Coppell et al (2003 ) found that administration of 
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antidepressant drugs produced a "bi-phasic effect" on BDNF 
mRNA within the rat hippocampus. Thus, a single injection of 
antidepressant (paroxetine, fluoxetine, sertraline) 
inhibited BDNF mRNA levels in the CAl, CA3 and DG regions 
after 4h. This effect however was transient, as after 24h 
levels had returned to baseline. Chronic administration (2 
daily injections for 14d) also inhibited BDNF mRNA at 4h, 
however levels were up-regulated after 24h. The initial 
down-regulatory response was attributed to the enhancement 
of local extracellular 5-HT levels, as a iesult of acute 5-
HT reuptake blockade (Coppell et aI, 2003). Zetterstrom et 
al (1999) demonstrated that acute elevation of brain 5-HT 
levels either by administration of the 5-HT release agent p-
chloroamphetamine (pCA), the SSRI paroxetine, or a 
combination of the 5-HT precursor I-tryptophan and the non-
selective MAOI TCP, significantly reduced BDNF mRNA in the 
DG at 4h. In contrast, rapid depletion of 5-HT levels with 
multiple injections of the tryptophan hydroxylase-selective 
inhibitor p-chlorophenylalanine (pCPA) significantly 
increased BDNF mRNA in the DG (Zetterstr6m et aI, 1999). The 
results suggest that acute enhancements in S-HT levels have 
a transient inhibitory effect on BDNF mRNA expression in the 
hippocampus. The role of 5-HT receptors in the acute 
regulation of BDNF mRNA was demonstrated by Vaidya et al 
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(1997). Acute administration of the 5-HT2 receptor agonist 
DOl reduced BDNF mRNA in the DG at 4h. This effect was 
attenuated by the 5-HT2A receptor antagonist MDL 100907, but 
not by the 5-HT2C antagonist SB 206553, indicating a central 
role for the 5-HT2Areceptor in the inhibitory BDNF mRNA 
response (Vaidya et al, 1997). 
It is not clear however whether the acute down-regulatory 
response is due specifically to acute manipulations in 5-HT, 
or occurs due to generalised changes in monoamine 
concentrations. For this reason the present study examined 
various antidepressant compounds with varying affinities to 
5-HT and NA reuptake sites, as well as the non-selective 
MAOI TCP. Additionally, the role of acute DA manipulation 
was studied with the selective DA transporter blocker GBR 
12909 and the non-selective NAIDA reuptake blocker 
methylphenidate. 
The BDNF gene has been suggested as a possible target in 
antidepressant treatment (Condorelli et aI, 1994; Nibuya et 
aI, 1995; Siuciak et aI, 1996; Duman, 1998; Duman et al, 
1999), thus further examination of the initial down-
regulatory response (at 4h) is vital in order to elucidate 
the mechanism of action of antidepressant action on BDNF. 
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The unique complexity of the BDNF gene among neurotrophins 
allows the opportunity to study the effect of 
antidepressants, when given acutely, on specific exon-
containing transcripts. During the course of this series of 
experiments, a similar study was published demonstrating 
evidence of differential BDNF mRNA exon expression (exons I-
IV), following the acute administration of antidepressants 
(Dias et aI, 2003). However, a full appraisal of the effects 
in the previous study was hampered by the lack of inclusion 
of data for the full BDNF gene (exon V), which codes for 
BDNF protein. In the present study we have simultaneously 
included total BDNF mRNA data (exon V), as well as a 
representative form of protein-dependent exon mRNA (exon I) 
and a non-protein synthesis-dependent 'lEG-like' exon mRNA 
(exon IV; Lauterborn et aI, 1996; Russo-Neustadt et aI, 
2001; See Section 1.6.3). 
The aim of this chapter therefore is to examine the effect 
of acute (single injection) of numerous antidepressant 
compounds, as well as methylphenidate and GBR 12909 on BDNF 
mRNA, as well as exon I and exon IV mRNA expression in the 
hippocampus at 4h. 
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3.2. Methods 
Male Sprague-Dawley rats (225-250g) were injected intra-
peritoneally (i.p) once with either: saline (lml/kg), or 
fluoxetine (10mg/kg), paroxetine (5mg/kg), citalopram 
(10mg/kg), desipramine (lOmg/kg), maprotiline (4mg/kg), TCP 
(Smg/kg), methylphenidate (4mg/kg) or GBR 12909 (10mg/kg) in 
0.9% saline, before being sacrificed 4h later. Brains were 
isolated, then flash-frozen in cooled isopentane and then 
stored at -70°C until further use. In-situ hybridisation and 
densitometric analysis procedures are described in Chapter 
2. 
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3.3. Results 
3.3.1. Basal distribution of total BDNF mRNA and individual 
BDNF exon mRNA in the rat brain 
3.3.1.1. Basal total BDNF mRNA expression 
Coronal sections through frontal cortex, striatum and 
hippocampal areas were assessed for total (exon V) BDNF mRNA 
distribution. Signals were detected in the cingulate (Figure 
3.2, A and B) and piriform (Figure 3.2, B and C) cortices, 
however they were generally low and difficult to quantify by 
densitometry. A signal was also detected in the parietal 
cortex (Figure 3.2, C), this signal was very weak and there 
were no differences in expression through the different 
layers of this region. 
Basal levels were found to exist in a measurable quantity 
the hippocampal region only (Figure 3.2, C and D). Within 
the hippocampus, the highest levels were present in the CA3 
and DG regions, with lower levels present in the CAl 
(Figures 3.2, C and D). 
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Figure 3 . 2 , D displays total BDNF mRNA expression in a 
saggital section through the adult rat brain . Higher levels 
of expression are seen the granular cell layer of the 
cerebellum, as well as the hippocampus . 
/ 
Parietal corte~ 
Piriform Cortex 
Cingulate gyrus 
I 
A 
~:::~ 
Cerebellum -7 
C 
Dentate gyrus 
B 
D 
Figure 3.2. Basal total BDNF mRNA expression . A, coronal 
section through the frontal cortex region ; B, coronal 
section through the striatum region ; C, coronal section 
through the hippocampus region ; D, saggital section through 
the rat brain . 
Piriform 
Cortex 
84 
Ahmad Adam Khundakar Chapter Three 
3.3.1.2. Basal individual BDNF exon transcript mRNA 
expression 
The oligonucleotide probes used corresponding to mRNAs 
encoding for each individual exon yielded varying levels of 
expression among exons I, II, III and IV. However, any 
significant expression of each exon was confined to the 
hippocampus from the areas measured. Exon I mRNA was 
distributed fairly evenly throughout the hippocampus, with 
CAl, CA3 and DG areas all showing relatively abundant 
signals (Figure 3.3, A). In contrast, basal exon IV mRNA 
expression appeared far higher in the DG than CA3 or CAl, 
which displayed similar levels of expression (Figure 3.3, 
D). The basal expression of exons II (Figure 3.3, B) and III 
(Figure 3.3, C) appeared to be very weak. No significant 
exon II signal was detected from any stimuli given from two 
probes used, which contained different sequences. A slight 
basal signal was detected in exon III mRNA in the 
hippocampus and a significant response was detected after 
strong stimuli (acute ECS), suggesting that the probe used 
was able to hybridise with exon III. However, as the basal 
level was so weak, the accuracy of analysis could be 
questioned. It was therefore decided that the series of 
experiments in this and proceeding chapters would focus on 
85 
Ahmad Adam Khundakar Chapter Three 
the differential effects on exon I and IV mRNAs , in addition 
to total BDNF mRNA (exon V) . 
, 
B 
C D 
Figure 3.3. Basal expression of BDNF exon transcript mRNA : 
A, exon I ; B, exon II (PROBE B) ; C, exon III ; D, exon IV . 
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3.3.2. Effects of acute admnistration of antidepressant 
drugs on total BDNF mRNA and individual BDNF exon mRNA 
3.3.2.1. Effect on total BDNF mRNA expression 
See Tables 3.1 for numerical values. See Figures 3.4 to 3.11 
for graphs. See Figures 3.12 to 3.19 for autoradiographs. 
A single injection of fluoxetine at 10mg/kg caused a 
significant down-regulation of total BDNF mRNA in the DG (-
27.5%; p<0.05 Table 3.1; Figures 3.4 and 3.12). Likewise, 
paroxetine at 5mg/kg elicited a significant inhibition in 
mRNA levels in the DG (-20.6%, p<0.05; Table 3.1; Figures 
3.5 and 3.13), as well as the CA3 (-18.6%; p<O.05). 
Citalopram administration inhibited DG levels significantly 
(-37.8%, p<0.01; Table 3.1; Figures 3.6 and 3.14). Among the 
noradrenargic-selective antidepressants tested, desipramine 
(-39.6%, p<0.05; Table 3.1 Figures 3.7 and 3.15) and 
maprotiline (-33.4%, p<O.Ol; Table 3.1. Figures 3.8 and 
3.16) significantly inhibited DG BDNF mRNA levels. The MAOr 
TCP (5mg/kg) caused the largest inhibition in BDNF levels in 
the DG among antidepressant drugs tested (-42.6%, p<O.001; 
Table 3.1, Figures 3.9 and 3.17). 
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Acute administration of either the non-selective NAIDA 
transporter blocker methylphenidate (-33.4%, p<0.05; Table 
3.1; Figures 3.10 and 3.18) or the DA transporter blocker 
GBR 12909 (-39.9%, p<O.OOl; Table 3.1; Figures 3.11 and 
3.19) significantly inhibited BDNF mRNA expression in the DG 
region. 
3.3.2.2. Effect on BDNF exon I mRNA expression 
See Table 3.2 for numerical values. See Figures 3.4 to 3.11 
for graphs. See Figures 3.12 to 3.19 for autoradiographs. 
The acute injection of any antidepressant tested had no 
significant effect on BDNF exon I mRNA in any region of the 
hippocampus at 4h. However, there was a small, but not 
significant fall in exon I mRNA in CAl, CA3 and DG subfields 
after desipramine and fluoxetine administration. In 
addition, modest, non-significant reductions were seen after 
Tep administration in the CAl and DG and in the CA3 subfield 
after citalopram administration. 
88 
Ahmad Adam Khundakar Chapter Three 
3.3.2.3. Effect on BDNF ex on IV mRNA expression 
See Table 3.2 for numerical values. See Figures 3.4 to 3.11 
for graphs. See Figures 3.12 to 3.19 for autoradiographs. 
In accordance with BDNF mRNA, acute injection of all 
antidepressants tested produced an inhibitory effect on BDNF 
exon IV mRNA in the DG. Fluoxetine elicited a significant 
36.5% (p<O.Ol) inhibition in the DG (Table 3.3; Figures 3.4 
and 3.12). Paroxetine administration caused a significant 
24.7% (p<0.05) reduction in the DG (Table 3.3; Figures 3.5 
and 3.13). Acute citalopram caused significant inhibition in 
both DG (34.4%; p<0.05) and CA3 (-35.1% p<0.05; Table 3.3; 
Figures 3.6 and 3.14). Desipramine administration produced a 
significant inhibitory effect in the DG (-32.1%, p<0.05); 
Table 3.3; Figures 3.7 and 3.15). Maprotiline also produced 
a significant reduction within the DG (-37.9%, p<0.05) and 
CA3 (-34.7%; p<0.05; Table 3.3 Figures 3.8 and 3.16). Acute 
TCP administration also resulted in a significant reduction 
in exon IV mRNA expression in the DG (-30.2%, p<0.05; Table 
3.3; Figures 3.9 and 3.17). Additionally, the DA~/NA­
selective reuptake inhibitor methylphenidate also produced a 
significant inhibitory effect in the DG (-37.7%; p<0.05) and 
CA3 (-34.7%; p<0.05; Table 3.3; Figures 3.10 and 3.18). The 
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DA-selective compound GBR 12909 resulted in the largest 
inhibition in DG levels (-50.0%; p<O.Ol; Table 3.3; Figures 
3.11 and 3.19). CA3 levels were also significantly reduced 
by 34.1% (p<0.05). CAl levels were not significantly 
affected by acute treatment of any compound tested at 4h. 
The data presented in the proceeding tables (chapters 3-6) 
is presented in indexed form. This enabled figures from 
different experiments to be standardised for comparison 
(Zetterstr6m et aI, 1999; Coppell et aI, 2003). 
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Xable 3.1. Effect of acute drug treatment on BDNF mRNA 
expression in the rat hippocampus 4h after injection. Data 
presented as percentage of control ***p<O.OOl, **p<O.Ol, 
*p<O.05 compared to control (ANOVA with Bonferroni's post-
hoc test) 
CAl CA3 DG 
Vehicle n=6 lOO±5.3 IOO±4.8 lOO±Il.3 
Fluoxetine n=6 82.3±18.1 82.7±7.8 72.5±6.0* 
Saline n=6 lOO±2.3 IOO±1.9 IOO±7.1 
J?aroxetine n=6 IOO±4.9 81.4±3.4* 79.4±5.6* 
Saline n=5 lOO±IO.l IOO±13.2 lOO±11.2 
Citalopram n=5 90.0±8.9 75.6±3.0* 62.2±6.3u 
Vehicle n=6 IOO±5.3 lOO±4.8 lOO±1l.3 
Desipramine n=6 76.0±23.4 78.7±7.8 60.4±12.8* 
Saline n=5 lOO±lO.l lOO±13.2 IOO±1l.2 
Maprotiline n=S 96.8±12.5 86.0±8.8 66.6±8.4*· 
Saline n=6 IOO±2.3 lOO±1.9 lOO±7.l 
Tranylcypromine n=S 94.0±3.3 79.1±3.3* 57.4±4.0··* 
Saline n=6 lOO±6.0 lOO±7.1 lOO±5.3 
Methylphenidate n=S lO9.3±8.1 85.2±3.8 66.6±1O.0· 
Saline n=5 lOO±lO.l lOO±13.2 lOO±1l.2 
GBR 12909 n=S 94.1±9.3 81.4±9.3 60.1±9.1··· 
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Table 3.2. Effect of acute drug treatment on BDNF exon I 
mRNA expression in the rat hippocampus 4h after injection. 
Data presented as percentage of control ***p<O.OOl, 
**p<O.Ol, *p<O.05 compared to control (ANOVA with 
Bonferroni's post-hoc test) 
CAl CA3 DG 
Vehicle n=6 lOO±6.1 lOO±7.0 lOO±12.9 
Fluoxetine n=6 87.6±18.1 85.3±4.7 84.4±7.3 
Saline n=6 IOO±5.4 IOO±5.8 IOO±3.9 
Paroxetine n=6 lOO±7.0 lO5±2.0 101.1±3.1 
Saline n=4 IOO±8.9 IOO±13.2 IOO±13.0 
Citalopram n=4 98.4±8.3 84.8±19.0 99.1±9.9 
Vehicle n=6 IOO±6.1 IOO±7.0 IOO±12.9 
Desipramine n=6 84.3±13.4 84.3±13.3 84.4±7.3 
Saline n=4 IOO±8.9 IOO±13.2 lOO±13.0 
Maprotiline n=4 1I2.9±11.0 80.0±7.0 86.1±4.4 
Saline n=6 lOO±4.4 lOO±2.8 lOO±O.9 
Tranylcypromine n=6 90.6±2.8 I01.l±3.7 87.0±3.7 
Saline n=4 IOO±8.9 IOO±13.2 lOO±13.0 
Methylphenidate n=4 1Il.1±11.1 88.3±10.9 112.3±6.0 
Saline n=4 IOO±8.9 lOO±13.2 lOO±13.0 
GBR 12909 n=4 103.6±11.0 lO9±9.6 l03.5± 19.9 
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Table 3.3. Effect of acute drug treatment on BDNF exon IV 
mRNA expression in the rat hippocampus 4h after injection. 
Data presented as percentage of control ***p<O.OOl, 
**p<O.Ol, *p<O.05 compared to control (ANOVA with 
Bonferroni's post-hoc test) 
CAl CA3 DG 
Vehicle n=6 lOO±16.7 100±10.7 100±16.4 
Fluoxetine n=6 89.4±8.5 87.8±7.3 63.5±6.5** 
Saline n=6 lOO±2.8 lOO±1.7 lOO±3.2 
Paroxetine n=6 91.9±4.l 85.4±3.4 75.3±3.1· 
Saline n=5 lOO±5.8 lOO±8.8 lOO±6.3 
Citalopram n=5 72.1:!:20.6 64.9:!:16.1· 65.6±18.2· 
Vehicle n=6 lOO±16.7 lOO±1O.7 1 OO±l 6.4 
Desipramine n=6 85.3±6.5 76.9±8.1 67.9±5.8· 
Saline n=5 lOO±5.8 lOO±8.8 lOO±6.3 
Maprotiline n=4 71.5±7.8 65.3±11.3· 62.1±15.4· 
Saline n=6 lOO±2.8 lOO±1.7 100±3.2 
Tranylcypromine n=6 85.4±2.8 83.8±3.9 69.8±5.0** 
Saline n=4 lOO±8.9 lOO±13.2 lOO±13.0 
Methylphenidate n=4 71.5±9.3 65.3±8.1· 62.3±6.8· 
Saline n=4 lOO±5.8 lOO±9.4 lOO±6.5 
GBR 12909 n=4 86.1:!:9.3 65.9±9.6· 50.0± 19.9** 
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Figure 3.12. In-situ hybridisation images showing the effect 
of acute fluoxetine (10mg/kg i . p) treatment on AlB total 
BDNF ; C/D exon I ; ElF exon IV mRNA in the rat hippocampal 
region at 4h . Control groups are situated left . 
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Figure 3.13. In-situ hybridisation images showing the effect 
of acute paroxetine (5mg/kg i . p) treatment on AlB total 
BDNF; C/D exon I ; ElF exon IV mRNA in the rat hippocampal 
region at 4h . Control groups are situated left . 
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Figure 3.14. In-situ hybridisation images showing the effect 
of acute citalopram (10mg/kg i . p) treatment on AlB total 
BDNF i c/D exon I i ElF exon IV mRNA in the rat hippocampal 
region at 4h . Control groups are situated left . 
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Figure 3.15. In-situ hybridisation images showing the effect 
of acute desipramine (lOmg/kg i . p) treatment on A/B total 
BDNF; C/D exon I ; E/F exon IV mRNA in the rat hippocampal 
region at 4h . Control groups are situated left. 
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Figure 3.16. In situ hybridisation images showing the effect 
of acute maprotiline (10mg/kg i . p) treatment on A/B total 
BDNF; C/D BDNF exon I mRNA and E/F exon IV mRNA in the rat 
hippocampal region at 4h . Control groups are situated left . 
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Figure 3.17. In-situ hybridisation images showing the effect 
of acute tranylcypromine (5mg/kg i . p) treatment on AlB total 
BDNF; C/D exon I and ElF exon IV mRNA in the rat hippocampal 
region at 4h . Control groups are situated left . 
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Figure 3.18. In-situ hybridisation images showing the effect 
of acute methylphenidate (4mg/kg i . p) treatment on AlB total 
BDNFi C/D exon I mRNA and ElF exon IV mRNA in the rat 
hippocampal region at 4h . Control groups are situated left . 
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Figure 3.19. In-situ hybridisation images showing the effect 
of acute GBR 12909 (10mg/kg i . p) treatment on A/B total 
BDNF i C/D exon I mRNA and E/F exon IV rnRNA in the rat 
hippocampal region at 4h . Control groups are situated left . 
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3.4. Discussion 
3.4.1. Summary of results 
In this series of studies, reliable and measurable basal 
BDNF mRNA expression was confined to the hippocampus. Within 
the hippocampus, the DG and CA3 showed high levels of BDNF 
mRNA expression in comparison to the CAl area. Likewise, 
among the variable exon-containing transcripts, exon I and 
exon IV were also present in measurable levels in the 
hippocampus only. Basal exon IV mRNA expression appeared to 
be highest in the DG, whilst exon I mRNA displayed a more 
uniform distribution among the regions of the hippocampus. 
No significant basal expression was detected among exon II 
or exon III mRNA in any area of the brain measured. 
This chapter aimed to examine the effect of a number of 
antidepressant drugs, when given acutely, on total BDNF 
mRNA, as well as mRNAs corresponding to the variable BDNF 
exons I and IV expression in the rat hippocampus at 4h. The 
antidepressant drugs used comprised of the SSRls fluoxetine, 
paroxetine and sertraline; the noradrenergic TeA 
desipramine; the noradrenergic tetracyclic compound 
maprotiline and the non-selective MAOI tranylcypromine. In 
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addition for comparison, two compounds with varying 
affinities for dopamine reuptake blockade, the non-selective 
NAIDA reuptake blocker methylphenidate and the selective DA 
transporter blocker GBR 12909 were assessed. All compounds 
assessed resulted in a significant inhibition in total BDNF 
mRNA levels in the DG region of the hippocampus, paroxetine 
and TCP also down-regulated BDNF mRNA levels in the CA3. 
Additionally, all compounds assessed significantly inhibited 
BDNF exon IV mRNA in the DG acute citalopram, maprotiline, 
methylphenidate and GBR 12909 also down-regulated CA3 
levels. However, all compounds assessed had no significant 
effect on exon I mRNA expression in any area of the 
hippocampus. 
3.4.2. Basal distribution of total BDNF mRNA 
The present study showed that basal levels were found to 
exist in a measurable quantity in the hippocampal region 
only. Within the hippocampus, the highest levels were 
present in the CA3 and DG regions, with lower levels present 
in the CAl. Signals were detected in the piriform and 
cingulate cortices, however they were generally low and 
immeasurable. A signal was also detected in the parietal 
cortex, this signal was very weak and there were no 
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difference in expression through the different layers of 
this region. No labelling was present in the striatum. The 
lack of mRNA expression against background levels in areas 
other than the hippocampus may have led to inaccurate 
analysis, thus the study focussed on hippocampal areas. 
Previous studies have also demonstrated the highest basal 
incidence of total BDNF mRNA in hippocampal areas (Ernfors 
et aI, 1990; Hofer et aI, 1990; Phillips et aI, 1990; 
Schmidt-Kastner et aI, 1996). Additionally, in common with 
this study, differential BDNF mRNA expression has been found 
within the hippocampus. High levels were recorded in the CA3 
band as well as the DG, with low to moderate levels in the 
CAl (Hofer et aI, 1990; Phillips et aI, 1990; Timmusk et aI, 
1993; Schmidt-Kastner et aI, 1996). However, in contrast to 
our study, significant, measurable levels have also been 
found in cerebral and piriform cortices in other in-situ 
hybridisation studies (Hofer et aI, 1990; Timmusk et aI, 
1993). 
A possible reason for the differences in density between the 
current and previous studies may have been due to the type 
of radioactive probes used in the in-situ hybridisation 
experiments. The present study used S35-labelled 
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oligonucleotides, while other studies (Tirnmusk et aI, 1993; 
Schmidt-Kastner et aI, 1996) have used p32 riboprobes, as 
opposed to DNA probes used in the present study. Riboprobes 
are generally more selective and therefore more sensitive, 
and possess the ability to detect very low levels of basal 
mRNA (Braissant and Wahli, 1998). 
In accordance with previous studies a significant level of 
basal exon I transcript expression was detected in the 
hippocampus (Bishop et aI, 1994; Berchtold et aI, 1999; 
Russo-Neustadt et aI, 2000). However, whilst the present 
study found relatively little difference between the various 
hippocampal sub-regions a previous study (Russo-Neustadt et 
aI, 2000) reported a somewhat lower density in the CAl 
compared to the CA3 or DG. Generally, basal exon IV mRNA 
expression appeared to be less abundant than basal exon I 
mRNA and was mainly restricted to the DG region of the 
hippocampus. Exon IV has been shown to be present in the 
brain, with high levels present in the hippocampus (Tirnmusk 
et al, 1993; Bishop et aI, 1994). Previous studies have 
found a similar pattern of expression of exon IV mRNA to 
this study within the hippocampus, with expression being 
predominant in the DG granular cell layer (Tirnmusk et aI, 
1993; Bishop et aI, 1994). 
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In contrast to some previous studies (Timmusk et ai, 1993; 
Lauterborn et ai, 1998; Russo-Neustadt et ai, 2000), the 
oligonucleotide probes used in our experiments failed to 
detect significant basal exon II or exon III mRNA signal in 
any area of the brain. No signal was detected in any 
experiment using two different probes with sequences 
corresponding to exon II mRNA. In contrast to exon II mRNA, 
a strong exon III mRNA signal was detected in hippocampal 
areas after strong stimuli (acute ECS), indicating that the 
exon III probe could hybridise. However, the basal 
expression was deemed too weak against background levels to 
ensure accuracy. The reasons behind the lack of basal exon 
II and exon III signal are unclear, however earlier studies 
mainly used more sensitive riboprobes in favour of DNA 
probes used here. Therefore a weaker signal, such as that 
found with exon III mRNA in the present study, may have been 
more easily detected in earlier studies. 
3.4.3. The effect of acute administration of antidepressant 
drugs on BDNF mRNA in the hippocampus at 4h 
The individual acute administration of a variety of 
antidepressant drugs, as well as two centrally-acting 
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stimulants: the selective DA transporter GBR 12909 and the 
non-selective NAIDA reuptake blocker methylphenidate, all 
elicited a significant inhibition of BDNF mRNA in the DG 
area of the hippocampus at 4h. In addition, acute paroxetine 
or TCP treatment also caused a significant inhibition in 
BDNF mRNA levels in the CA3 region. No significant changes 
were seen in the CAl, after acute administration of any of 
the compounds tested. 
A previous study using similar ISH techniques, doses and 
experimental procedure (Coppell et al, 2003), found similar 
reductions in BDNF mRNA from acute SSRI (fluoxetine at 
10mg/kg, paroxetine at 5mg/kg and sertraline at 10mg/kg) and 
MAOI (TCP; 5mg/kg) treatment in the DG at 4h. However, in 
contrast to the present study, no changes in BDNF mRNA were 
seen after acute administration of the selective NARI 
desipramine (Coppell et al, 2003). As acute desipramine 
elicited a significant response in BDNF mRNA in the present 
study, a further NA-selective compound was tested. Acute 
maprotiline administration also resulted in a reduction in 
BDNF mRNA at 4h in the DG region. The results in the present 
study therefore appear to contradict the assertion that 
acute inhibitory response is predominantly a 5-HT-mediated 
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mechanism (Coppell et al, 2003) and imply an equivocal role 
for NA. 
Acute administration of the MAOI TCP resulted in the acute 
down-regulation of BDNF mRNA in the DG and CA3 in both 
studies (the largest reduction in DG levels of any 
antidepressant tested in our study). TCP is non-selective 
among MAO isoenzymes, therefore it has effects on type B 
MAO, which deaminates DA (Murphy et al, 1987). TCP has been 
demonstrated to cause a significant decrease in DA 
metabolism (Dyck et ai, 1993; Martin et ai, 1995). This 
suggested a possible role for DA-related mechanisms in the 
acute inhibition in BDNF mRNA. Thus, two centrally-acting DA 
stimulants, the mixed DA/NA reuptake blocker methylphenidate 
and the selective DA transporter blocker GBR 12909, were 
administered acutely. A single treatment with either drug 
resulted in the inhibition of BDNF mRNA levels of a similar 
magnitude to the antidepressants tested in the DG at 4h. 
This implicates a role for DA in the acute regulation of 
BDNF mRNA expression in the DG region of the hippocampus. In 
addition, as both methylphenidate and GBR 12909 have a 
negligible effect on serotonergic transmission, suggesting 
that the acute inhibitory BDNF response may occur 
independently of 5-HT. 
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Studies relating to the effect of acute DA receptor blockade 
on BDNF mRNA have revealed interesting findings. Acute 
administration of the unselective DAantagonist haloperidol 
has been shown to lead to a reduction in hippocampal BDNF 
mRNA (Lipska et aI, 2001; Meredith et aI, 2004). Dz 
receptors are linked to cAMP via Giproteins and are 
inhibitory on consequential cAMP-mediated signalling. 
Therefore, if located on DA neurones, they will cause a 
reduction in DA release (Missale et aI, 1998; Meredith et 
aI, 2004). Thus blockade of hippocampal D2 autoreceptors by 
haloperidol may result in a similar effect on extracellular 
DA concentration as a blockade on the DA transporter by GBR 
12909 and methylphenidate. 
Overall, the results in the present study indicate that 
acute inhibition in BDNF mRNA in the DG is a non-selective 
phenomenon that may be induced by general facilitation of 
monoamine NA, 5-HT or possibly DA transmission. 
3.4.4. The effect of acute administration of antidepressant 
drugs on BDNF exon transcript mRNA in the hippocampus at 4h 
Acute administration of various types of antidepressant 
drug, as well as the NAIDA reuptake blocker methylphenidate 
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and the selective DA transporter blocker GBR 12909 had a 
variable effect on mRNA for specific BDNF exon transcripts 
at 4h. In accordance with the effect on total (exon V) BDNF 
mRNA, exon IV mRNA was inhibited after all antidepressants 
tested acutely, as well as methylphenidate and GBR 12909. 
Additionally, acute methylphenidate or GBR 12909, or 
citalopram or maprotiline, also significantly reduced CA3 
exon IV mRNA levels at 4h. 
AS mentioned earlier, exons III and IV have been shown to 
share properties with lEGs (Lauterborn et aI, 1996; 1998). 
This implies that acute alterations in expression may occur 
in exon IV mRNA without intervening protein synthesis-
dependent mechanisms. It is thus feasible that changes could 
occur in the expression within the short space of time post-
injection (4h) in this series of experiments. In contrast, 
the acute administration of the various antidepressants, as 
well as methylphenidate and GBR 12909, had no effect on exon 
I mRNA at 4h in any area of the hippocampus. Changes in exon 
I and II transcription have been demonstrated to protein 
synthesis-dependent (Lauterborn et aI, 1996; 1998) and 
display a delayed induction process (Kokaia et aI, 1994). 
This implies that the time period post-injection may have 
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been insufficient for significant changes in exon I mRNA to 
Occur. 
Net BDNF expression in the brain depends on the cumulative 
activities of its multiple alternative exon-containing 
transcripts (Timmusk et aI, 1993; Nakayama et aI, 1994; 
Bishop et aI, 1997). Therefore, the inhibition in exon IV-
containing transcripts may account in part for the net 
inhibition in BDNF mRNA in the DG. However, the influence of 
exon IV mRNA inhibition in the CA3 area appears more 
complex. Whilst total BDNF mRNA was significantly inhibited 
in the CA3 after acute paroxetine and TCP, exon IV mRNA was 
significantly inhibited in the CA3 by citalopram, 
maprotiline as well as methylphenidate and GBR 12909 at 4h. 
However, there was a general inhibitory trend on both total 
BDNF and exon IV transcripts in the CA3 and DG. The mixed 
pharmacological nature of the compounds which inhibited exon 
IV as well as total BDNF transcription, suggests that the 
inhibitory response in the CA3 and DG areas is not solely 
specific to either 5-HT or NA manipulations, but a more 
general response, possibly also involving DA. 
A recently published BDNF exon study (Dias et aI, 2003), has 
found fairly conflicting findings to the results presented 
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here. A reduction in exon IV mRNA was recorded in the CAl 
area after acute fluoxetine treatment, however acute 
desipramine and TCP treatment did not influence exon IV 
mRNA, no drug affected CA3 or DG mRNA expression. Variation 
in drug doses between the experiments could have accounted 
for this lack of effect. The post-injection time period (2h) 
was also half the length of that in our experiment. It may 
be possible that the time period in this experiment is too 
short for the threshold for a change in exon IV mRNA 
expression to occur. A further finding in the Dias et al 
(2003) study appears to contradict earlier reports 
(Lauterborn et aI, 1996; 1998). Dias et al (2003), found 
that exon II mRNA was inhibited after acute desipramine and 
TCP. Changes in exon II mRNA have been shown to be protein 
synthesis-dependent. This would imply that a prolonged 
period of time would be required for proceeding activation 
of further responsive genes (Clayton, 2000). As our study 
failed to find any significant basal signal using exon II 
mRNA-specific probes this inhibitory effect cannot be 
confirmed, though the lack of effect on exon I mRNA from 
acute treatment of the various compounds tested appears to 
support earlier findings (Lauterborn et aI, 1996; 1998). 
120 
Ahmad Adam Khundakar Chapter Three 
A further recently published study RT-PCR study (Altieri et 
al, 2004) however appears to support the inhibitory effect 
seen on exon IV mRNA in the hippocampus after acute 
antidepressant treatment as seen in the present study. The 
group found similar significant reductions in overall 
hippocampal exon IV, but not exon I, II or III mRNA after 
acute fluoxetine (Smg/kg) administration at Sh. 
In conclusion, it was found in the present study that the 
acute administration of the antidepressants fluoxetine, 
paroxetine, citalopram, desipramine, maprotiline or TCP, or 
the mixed NAIDA reuptake blocker methylphenidate or the 
selective DA transporter blocker GBR 12909, all resulted in 
the significant inhibition in total BDNF mRNA in the DG area 
of the hippocampus. The inhibitory effect on total BDNF mRNA 
in the DG appeared to be due in part to the inhibition of 
BDNF exon IV mRNA, which was significantly down-regulated 4h 
in the same area after acute fluoxetine, paroxetine, 
citalopram, desipramine, maprotiline or TCP administration. 
In addition, acute paroxetine or acute TCP significantly 
reduced CA3 total BDNF mRNA levels. Exon IV mRNA expression 
was significantly inhibited in the CA3 by acute citalopram, 
methylphenidate or GBR 12909. In contrast, no change was 
seen in exon I mRNA after acute administration of the 
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various antidepressants tested in any area of the 
hippocampus at 4h. 
The next chapter aims to elucidate the mechanisms behind the 
apparent acute inhibition in BDNF mRNA in the adult rat 
hippocampus. 
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Chapter Four 
Involvement of GABA Receptor Activation in the 
Acute Down-Regulation of BDNF mRNA 
Expression in the Rat Hippocampus 
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4.1. Introduction 
Chapter three outlined the acute effects of several 
antidepressant compounds on the BDNF gene in the rat 
hippocampus. It was discovered that acute administration of 
several classes of antidepressants, as well as the 
selective DA transporter blocker GBR 12909 or the NAIDA 
reuptake blocker methylphenidate, inhibited BDNF mRNA in 
the DG (as well as in the CA3 after paroxetine or TCP 
treatment) at 4h. This net reduction in the expression for 
the whole gene appeared to be due in part to selective 
inhibition in variable exon IV-containing transcript 
expression. The reasons behind the acute inhibition in 
total BDNF mRNA and corresponding individual exon mRNA 
expression in the hippocampus remain erroneous. 
It has been suggested that the initial transient inhibitory 
effect on BDNF mRNA as a result of acute antidepressant 
administration may be due to the presence of GABA 
interneurone architecture in the polymorphic layers of the 
hippocampus (Vaidya et al, 1997; Zetterstr~m et al, 1999; 
Vaidya and Duman, 2001). Electrophysiological studies have 
revealed the presence of excitatory 5-HT receptors (i.e. 5-
HT2, 5-HT4, 5-HT6, 5-HT7), in high levels on hippocampal 
124 
Ahmad Adam Khundakar Chapter Four 
interneurones (Freund et al , 1990 ; Piguet and Galvan , 
1994) . The acute activation of these receptors is thought 
to facilitate spontaneous GABA release and increase 
inhibitory control over the hippocampal cells (Piguet and 
Galvan , 1994) . GABA has been shown to inhibit BDNF mRNA 
levels (Zafra et al , 1991 ; Marmigere et aI , 2003) . Thus , an 
increase in GABA release as a result of activation of 5-HT 
receptors present on interneurones may underlie the acute 
inhibitory effect of antidepressant drugs on BDNF mRNA . 
t IPSPs 
! BDNF 
GABAergic 
interneuron ~ 
5-HT/NAIDA 
Figure 4.1. Possible mechanism of monoamine - mediated 
inhibition of BDNF MRNA in the DG region of the 
hippocampus . Activation of excitatory monoamine receptors 
increases the firing rate of local GABAergic inteneurones 
and thereby increases IPSPs in the granule cells . Thus 
increased inhibitory control over BDNF mRNA (Adapted from 
Vaidya et al , 1997) . 
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treatment , such as with alcohol (Mhatre and Ticku , 1993 ; 
Grobin et ai , 1998) or benzodiazepines (Holt et ai , 1996 ; 
Impagnatiello et ai , 1996) . The receptor is ligand-gated 
with a heteropentameric structure and integral anion 
channel . THIP is a potent GABAA activator and binds tightly 
to the GABAA receptor (Krogsgaard- Larsen et al , 1977 ; 1979) 
It is capable of activating (with differing potencies) a 
broad range of GABAA receptor subunit configurations (Ebert 
et ai , 1994) . 
HN 
OH 
THIP 
Flunitrazepam 
Figure 4.2. Structures of selected GABAA- related compounds : 
the GABAA agonist THIP and the benzodiazepine agonist 
flunitrazepam 
The GABAA receptor also contains a benzodiazepine- binding 
site , which when activated increases the affinity for GABA 
to bind with the GABAA receptor (Korpi et ai , 2002) . 
Flunitrazepam is a full benzodiazepine agonist , which 
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induces its effects by increasing the opening frequency of 
the integral GABAA Cl- receptor channel (Korpi et al , 2002 ; 
Davies and Alkana , 2003) 
Antagonists-
Inverse Agonists + ~ ___ ~~ 
OBI Peptides + 
Convulsivants 1. - J rJ.~~~~ 
Picrotoxin , )< 
rsps 
t 
.. --- GABA Agonists + 
Muscimol 
~ GABA Antagon ists 1 
Bicuculline , 
~;}'V<x;,vy...c...- Barorturates + 
.... -'_IIlI<;o.-+-tt-Ifflt~ Neuroactive Steroids + 
~~~~~-AlcohOls + 
Anesthetics + 
Figure 4.3. Schematic illustration of the GABAA receptor 
structure containing two a and ~ subunits and a single y 
subunit to form an intrinsic Cl - ion channel . Putative 
ligands and drugs are known to interact at one of the major 
sites associated with the GABAA receptor and to either 
positively or negatively modulate GABA- gated Cl - ion 
conductance are also illustrated (Adapted from Cooper et 
al , 1996) 
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4 . 1 . 1 . 2 . GABAB receptors 
The GABAB receptor is distributed widely throughout the 
rodent and human CNS , including the hippocampus (Bowery et 
ai , 1987 ; Chu et ai , 1990) . In contrast to GABAA, GABAB 
receptors are not ligand- gated channels but instead are 
negatively linked to a variety of cellular effectors via Gi 
proteins , including AC , Ca 2+ and K+ ; Kaupmann et ai , 1998 ; 
Bowery , 2002) . Baclofen is a potent GABAB receptor agonist 
and has been shown to possess widespread inhibitory effects 
on transmitter release including NA, 5- HT , glutamate and 
GABA (Bowery and Hudson , 1979 ; Ong and Kerr , 2000) . 
OH 
Cl 
Figure 4.4. Structure of the GABAB receptor agonist baclofen 
129 
Ahmad Adam Khundakar Chapter Four 
The two antagonist compounds used in this study , CGP 55845 
and CGP 46381 , are both potent to the GABAB receptor . CGP 
46381 is highly brain penetrant and has been demonstrated 
to block late inhibitory postsynaptic potentials (IPSPs) in 
vivo and enhance cAMP production (Lingenhoeh1 and 01pe , 
1993) . CGP 55845 is less penetrant than CGP 46381 , but has 
been demonstrated to be a potent antagonist of hippocampal 
GABAB receptors in the hippocampus (Davies et aI , 1993) . 
o 
11('1 
H2N~P~ 
I 
01 
CGP 46381 
HN~P\~ 
OH f/OK V 
Me 
CI 
CGP 55845 
Figure 4.5. Structure of the GABAB receptor antagonists CGP 
46381 and CGP 55845 
4.1.2. Hippocampal GABA architecture 
GABA interneurones form a core component to the cortico-
limbic circuitry and have been identified using Golgi 
staining and more recently through cytochemical and 
electrophysiological techniques (Freund and Buzsaki , 1996) . 
These cells provide both inhibitory and dis - inhibitory 
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modulation of cortical and hippocampal circuits and 
discriminate sensory information within cortico-limbic 
areas (Benes and Beretta, 2001). 
4.1.2.1. FUnction of hippocampal GABAergic neurones 
Hippocampal electrophysiological studies have revealed that 
the action of GABA is typically inhibitory (Krnjevic, 1981; 
Ben-Ari, 1981) and involved in feedback or feedforward 
inhibition (Benes and Beretta, 2001). Feedback inhibition 
occurs when an excitatory input activates the pyramidal 
neurone, which then facilitates inhibitory neurones 
(Andersen et aI, 1964). In the feedforward system, 
pyramidal neurones of the CA3 project to other pyramidal 
cells in the CAl. These excitatory neurones then feed into 
the inhibitory neurones of the CAl causing a reduction in 
the excitability of pyramidal neurones in the CAl (Buzsaki, 
1984) . 
The present chapter focuses on the effect of acute 
administration of three compounds with varying GABA 
receptor agonistic actions on hippocampal BDNF mRNA, as 
well as BDNF exon I and exon IV mRNA at 4h. Additionally, 
in order to confirm the role of the GABAB receptor 
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activation in the inhibitory BDNF response after acute 
antidepressant drug treatment, two GABAs receptor 
antagonists were tested, given before acute paroxetine 
treatment. 
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4.2. Methods 
4.2.1. Administration of acute GABA receptor agonists 
Male Sprague-Dawley rats (225-250g) were injected (i.p) 
once with either saline (lml/kg), the GABAA receptor agonist 
THIP (10mg/kg), the benzodiazepine flunitrazepam (lOmg/kg) 
or the GABAB receptor agonist baclofen (10mg/kg) in 0.9% 
saline and observed for behavioural changes for 4h before 
being sacrificed. Brains were isolated before being placed 
in cooled isopentane and stored at -70°C until further use. 
BDNF and various BDNF exon mRNA expression was measured by 
densitometric analysis as described in Chapter 2. 
4.2.2. GABAB antagonist pre-treatment 
Male Sprague-Dawley rats (225-250g) were injected (i.p) 
once with either saline (1ml/kg), CGP 55845 (10mg/kg) or 
CGP 46381 (10mg/kg) in 0.9% saline and observed for 
behavioural changes for 30 mins, before being injected 
(i.p) with either saline (1ml/kg), baclofen (lOmg/kg) or 
paroxetine (5mg/kg). Animals were observed for a further 4h 
before being sacrificed. Brains were isolated before being 
frozen in cooled isopentane and stored at -70°C until 
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further use. BDNF and various BDNF exon mRNAs were measured 
by densitometric analysis as described in Chapter 2. 
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4.3. Results 
4.3.1. The effect of acute administration of GABA receptor 
compounds on BDNF mRNA and BDNF exon mRNA expression 
4.3.1.1. Effect on total BDNF mRNA 
The GABAA receptor agonist THIP failed to produce any 
significant effect on BDNF mRNA in any area of the 
hippocampus at 4h. Although CA3 levels were inhibited 
slightly, mRNA increased in the CAl and the DG (Table 4.1; 
Figures 4.6, 4.9). The full benzodiazepine receptor agonist 
flunitrazepam failed to significantly alter BDNF mRNA, 
though levels were inhibited slightly in the CAl, CA3 and 
DG (Table 4.1; Figures 4.7, 4.10). The GABAB receptor 
agonist baclofen significantly inhibited BDNF mRNA in the 
CA3 (-20.9%; p<0.05) and DG (-42.6%; p<O.OOl), though not 
in the CAl (Table 4.1; Figures 4.8, 4.11). 
4.3.1.2. Effect on BDNF exon I mRNA expression 
None of the GABA-ergic agonist compounds used had any 
significant effect on BDNF exon I mRNA in any area of the 
hippocampus (Table 4.2; Figures 4.6 to 4.11). 
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4.3.1.3. Effect on BDNF exon IV mRNA expression 
The three compounds tested had varying effects on BDNF exon 
IV mRNA in the rat hippocampus. THIP (Table 4.3; Figures 
4.6, 4.9) and flunitrazepam (Table 4.3; Figures 4.7, 4.10) 
had no significant effect on exon IV mRNA in any area of 
the hippocampus. Baclofen however significantly inhibited 
levels in the DG (-40.1%; p<O.OOl), but not the CA3 or CAl 
(Table 4.3; Figures 4.8, 4.11). 
4.3.2. The effect of GABAB antagonist pre-treatment on 
baclofen/paroxetine-mediated down-regulation of BDNF mRNA 
4.3.2.1. Effect of acute baclofen and paroxetine 
administration 
When administered without either CGP compound (30 minutes 
after saline), baclofen produced a significant down-
regulation in BDNF mRNA levels in the DG (-48.8%; p<O.OOl) 
and the CA3 (-35.4%; p<O.Ol) regions of the hippocampus, no 
significant effect was seen in the CAl (Table 4.4; Figures 
4.12 and 4.13). Acute paroxetine administration also 
significantly inhibited DG (-25.4%; p<O.05) and CA3 (-
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27.8%; p<0.05) regions, no significant effect was seen in 
the CAl (Table 4.4; Figures 4.12 and 4.13). 
4.3.2.2. Effect of CGP 55845 
CGP 55845 alone (30 minutes after saline) produced a small, 
non-significant reduction in BDNF mRNA in all areas of the 
hippocampus. Pre-administration with CGP 55845 
significantly attenuated the effect of acute baclofen 
treatment in the DG region (CGP 55845/baclofen vs. 
saline/baclofen, 30.7%; p<0.05). CA3 levels were also 
attenuated, though not significantly. However, 55845 failed 
to attenuate the effect of acute paroxetine treatment in 
the CA3 and DG (Table 4.4; Figures 4.12 and 4.13). 
4.3.2.3. Effect of CGP 46381 
CGP 46381 alone (30 minutes after saline) significantly 
increased BDNF mRNA in the DG (35.8%; p<0.05), a smaller 
non-significant increase was also seen in the CAl. In 
addition CGP 48381 pre-treatment caused a significant 
attenuation from baclofen administration (CGP 
46381/baclofen vs. saline/baclofen, 31.3%; p<0.05) in the 
DG, with a smaller non-significant attenuation in the CA3. 
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The acute paroxetine-mediated inhibition of BDNF mRNA was 
also significantly attenuated by pre-treatment with CGP 
46381 in the DG (sa1ine/paroxetine VS. CGP 
46381/paroxetine, 25.6%; p<0.05) and CA3 (31.0%; p<0.05; 
Table 4.4; Figures 4.12 and 4.14). 
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Table 4.1. Effect of GABA-erqic compounds on BDNF mRNA 
expression in the rat hippocampus 4h after injection. Data 
presented as percentage of control ***p<O.OOl, **p<O.Ol, 
*p<O.05 compared to control (ANOVA with Bonferroni's post-
hoc test) 
CAl CA3 DG 
Saline n=6 lOO±5.3 lOO±6.2 lOO±9.1 
Flunitrazepam n=5 86.2±8.0 89.2±6.3 92.5±4.3 
Saline n=5 lOO±7.8 lOO±7.8 lOO±8.8 
TRIP n=5 112.2±8.4 84.4±.15.5 lO6.7±9.8 
Saline n=6 lOO±1.8 lOO±.2.4 lOO±4.6 
Baclofen n=6 94.0±3.4 79.1±.3.3* 57.4±4.0*** 
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Table 4.2. Effect of GABA-ergic compounds on BDNF exon I 
mRNA expression in the rat hippocampus 4h after injection. 
Data presented as percentage of control ***p<0.001, 
**p<0.01, *p<0.05 compared to control (ANOVA with 
Bonferroni's post-hoc test) 
CAl CA3 DG 
Vehicle n=6 lOO±8.8 lOO±7.6 lOO±ll.O 
Flunitrazepam n=5 93.2±8.7 84.0±4.6 81.5±4.8 
Saline n=5 lOO±4.6 lOO±5.1 lOO±5.3 
TRIP n=5 97.3±10.6 lO1.2±13.0 93.4±6.1 
Saline n=6 lOO±9.8 lOO±ll.4 lOO±6.8 
Baclofen n=6 101.5±4.7 88.3±16.4 90.4±12.7 
Table 4.3. Effect of GABA-ergic compounds on BDNF exon IV 
mRNA expression in the rat hippocampus 4h after injection. 
Data presented as percentage of control ***p<0.001, 
**p<0.01, *p<0.05 compared to control (ANOVA with 
Bonferroni's post-hoc test) 
CAl CA3 DG 
Vehicle n=6 lOO±5.3 lOO±6.2 lOO±9.1 
Flunitrazepam n=5 86.2±8.0 89.2±6.3 92.5±4.3 
Saline n=5 lOO±7.8 lOO±7.8 IOO±8.8 
TRIP n=5 1 12.2±8.4 84.4±15.5 I06.7±9.8 
Saline n=6 IOO±3.3 lOO±4.0 lOO±2.9 
Baclofen n=6 96.0±7.7 80.0±6.3 59.1±3.0** 
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Figure 4.6. Effect of acute THIP treatment on total BDNF mRNA, BDNF exon I and BDNF exon 
IV mRNA expression in the rat hippocampus 4h after injection. Data presented as 
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Figure 4.8. Effect of acute baclofen treatment on total BDNF mRNA, BDNF exon I and BDNF 
exon IV mRNA expression in the rat hippocampus 4h after injection. Data presented as 
percentage of control ***p<O . OOl , **p<O . Ol , *p<O . 05 compared to control (ANOVA with 
Bonferroni ' s post - hoc test) 
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Figure 4.9. I n situ hybridisation images showing the effect 
of acute THIP (10mg / kg) treatment on AlB total BDNF mRNA, 
C/ D BDNF exon I mRNA, ElF BDNF ex on IV in the rat 
hippocampal region at 4h . Control groups are situated left . 
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Figure 4.10. In-situ hybridisation images showing the 
effect of acute flunitrazepam (10mg/kg) treatment on AlB 
total BDNF mRNA, C/D BDNF exon I mRNA, ElF BDNF e xon IV in 
the rat hippocampal region at 4h . Control groups are 
situated left . 
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Figure 4.11. In-situ hybridisation images showing the 
effect of acute baclofen (10mg/kg) treatment on Al B total 
BDNF mRNA, C/D BDNF exon I mRNA, ElF BDNF exon IV in the 
rat hippocampal region at 4h . Control groups are situated 
left . 
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Table 4.4. Effect of acute paroxetine and baclofen 
administration on total BDNF mRNA expression after CGP 
55845 or CGP 46381 pre-treatment in the rat hippocampus 4h 
after last injection. Data presented as percentage of 
control ***p<O.OOl, **p<O.Ol, *p<O.05 compared to control 
(Bonferroni's post-hoc test) 
Saline/ 
Saline n=10 
Saline/ 
Baclofen n=10 
Saline/ 
Paroxetine n=10 
CGP 55845 
Saline n=5 
CGP 55845/ 
Baclofen n=5 
CGP 55845/ 
Paroxetine n=5 
CGP 46381/ 
Saline n=5 
CGP 46381/ 
Baclofen n=5 
CGP 46381/ 
Paroxetine n=5 
CAl 
lOO±1O.8 
81.7±9.6 
91.9±7.6 
80.3±11.8 
85.9±14.1 
84.6±14.4 
118.9±11.8 
109.5±12.1 
123.9±13.7 
CA3 DG 
lOO±9.1 lOO±11.8 
64.6±8.5** 51.2±14.4*** 
72.2±6.4* 74.6±12.0* 
85.0±4.6 80.5±9.4 
85.7±11.1 89.l±15.l 
79.9±7.6 73.8±11.4* 
99.9::!:1 1.4 135.4±12.9* 
86.4±2.5 82.9±17.8 
104.7±7.0 lOO.3±12.3 
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Figure 4.12. Effect of acute paroxetine and bac10fen administration on tota1 BDNF mRNA 
expression after CGP 55845 and CGP 46381 pre-treatment in the rat hippocampus at 4h after 
1ast injection . Data presented as percentage of control ; ***p<O . OOl , **p<O . Ol , *p<O . 05 
compared with control or saline pre - treated control animals (vs . CGP treated animals) . 
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Figure 4.13. In-situ hybridisation images showing the 
effect of acute paroxetine and baclofen on total BDNF mRNA 
expression after CGP 55845 pre- treatment in the rat 
hippocampus , 4h after last injection . KEY : A, 
saline/saline ; B, saline / baclofen ; C saline/paroxetine ; D, 
CGP 55845/saline ; E, CGP 55845 / baclofen ; F, CGP 
55845/paroxetine . 
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Figure 4.14. In-situ hybridisation images showing the 
effect of acute paroxetine and baclofen on total BDNF mRNA 
expression after CGP 46381 pre- treatment in the rat 
hippocampus , 4h after last injection . KEY : A, 
saline/saline ; B, saline/baclofen ; C saline/paroxetine ; D, 
CGP 46381 / saline ; E, CGP 46381/baclofen ; F, CGP 
46381 / paroxetine . 
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4.4. Discussion 
4.4.1. Summary of findings 
Acute administration of baclofen, but not flunitrazepam or 
THIP, significantly inhibited BDNF mRNA in the CA3 and DG 
at 4h. In addition, baclofen down-regulated BDNF exon IV 
mRNA, but not exon I mRNA in the DG. The selective GABAB 
antagonist CGP 46381 significantly attenuated the 
inhibitory effect on BDNF mRNA caused by acute baclofen or 
paroxetine administration in the CA3 and DG. However, CGP 
46381 alone significantly increased BDNF mRNA levels in the 
DG region to a similar magnitude as the attenuation. Pre-
treatment with CGP 55845 significantly attenuated baclofen-
mediated down-regulation of BDNF mRNA expression in the DG, 
however it failed to attenuate paroxetine-mediated down-
regulation in the CA3 and DG region of the hippocampus. 
4.4.2. The effect of acute GABA-ergic receptor agonist 
administration on BDNF mRNA and BDNF exon mRNA at 4h 
The main aim of this chapter was to elaborate on the role 
of GABAergic transmission in the acute regulation of BDNF 
mRNA in the rat hippocampus, in an attempt to link 
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facilitation in GABA transmission to antidepressant drug-
induced reductions in BDNF mRNA levels. Three GABA receptor 
agonists were tested which had varying effects on BDNF mRNA 
levels. The two agonists working on the GAB~ receptor, the 
GAB~ receptor agonist THIP and the benzodiazepine receptor 
agonist flunitrazepam, both failed to produce any 
significant effect on BDNF mRNA in any area of the 
hippocampus at 4h. This was in direct contrast to baclofen, 
a GABAB receptor agonist, which significantly inhibited 
levels in the CA3 and DG. GABAergic mechanisms have been 
suggested to be involved in the acute inhibitory effect of 
antidepressants (Vaidya et aI, 1997; Zetterstr5m et aI, 
1999; Vaidya and Duman, 2001; Section 4.1). The present 
results therefore indicate a preferential role for GABAB 
receptor-mediated mechanisms in the acute inhibition of 
BDNF mRNA in the CA3 and DG of the hippocampus. GABAB 
receptors have been observed in high quantities in the CA3 
and DG in comparison to the CAl (Knott et aI, 1993). 
In correspondence with the effect of acute antidepressant 
treatment, acute baclofen administration also significantly 
reduced BDNF exon IV (lEG-like), but not BDNF exon I 
(protein synthesis-dependent) mRNA in the DG region. 
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4.4.3. The effect of GABABreceptor antagonists on 
baclofen/paroxetine-mediated inhibition of BDNF mRNA at 4h 
In order to confirm the influence of GABAB receptor 
activation in the paroxetine/baclofen-mediated down-
regulation of BDNF mRNA, two selective GABAs receptor 
antagonists were employed at non-convulsive doses 
(10mg/kg), 30 minutes prior to injection with either 
baclofen or the SSRI paroxetine. Baclofen, when 
administered with saline, inhibited BDNF mRNA to a similar 
magnitude as the previous experiment. Likewise, acute 
paroxetine also significantly inhibited BDNF mRNA levels to 
similar levels as previous experiments (See Section 
3.3.1.1). 
Non-convulsive doses of CGP 55845 did not significantly 
enhance (or reduce) BDNF mRNA in any area of the 
hippocampus. Thus, the apparent attenuation of the acute 
baclofen-mediated inhibitory response on DG BDNF mRNA by 
CGP 55845 pre-treatment appears to be as a result of true 
GABAB receptor blockade, as opposed to the any overriding 
effect of the antagonist. However, the compound failed to 
attenuate the paroxetine-mediated BDNF mRNA down-regulation 
in the DG. Therefore, if it had successfully blocked local 
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GABAB receptor transmission, one may conclude that CGP 55845 
blocks acute baclofen-, but not paroxetine-mediated down-
regulation in the DG region. 
In comparison, when administered with saline at non-
convulsive doses, CGP 46381 significantly up-regulated BDNF 
mRNA in the DG. Similar, transient increases in BDNF mRNA 
have been reported following acute administration of the 
GABAB receptor antagonists (CGP 56999 and CGP 56433) in the 
hippocampus and cortex at 6h, with levels returning back to 
baseline at 24h (Heese et aI, 2000). Such increases may be 
anticipated due to the reduction in GABAB-mediated 
inhibition of BDNF mRNA in the DG, due to local receptor 
blockade. Thus, whilst pre-treatment with CGP 46381 
significantly attenuated the acute down-regulatory response 
of BDNF mRNA in the DG after acute baclofen or paroxetine, 
when the up-regulatory effect CGP 46381 (+35.4%) is 
considered, the attenuation is minimal. Therefore, it may 
be debated whether the lack of reduction of BDNF in the DG 
region was due primarily to an additive effect of CGP 46381 
via glutamatergic induction, or true antagonism of the 
effects of baclofen or paroxetine. 
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However in the CA3 area, CGP 46381 alone had little effect 
on BDNF mRNA levels. Thus, the significant attenuating 
effect of CGP 46381 pre-treatment before paroxetine 
treatment was not influenced by any enhancing effect from 
the compound. Thus, it appears that the attenuation in CA3 
levels may be genuine and may implicate the activation of 
the GABAB receptor in the acute inhibition of BDNF after 
acute paroxetine treatment in the CA3. 
Returning to the supposition that forms the basis behind 
these experiments, which suggested a role for localised 
GABAergic interneurone activation via excitatory 5-HT 
receptor activation in the down-regulation of BDNF mRNA in 
the hippocampus (Vaidya et al, 1997; Zetterstr5m et al, 
1999; Vaidya and Duman, 2001). It appears that the results 
from this chapter partially confirm this hypothesis. 
Firstly, acute baclofen, but not THIP or flunitrazepam 
administration significantly down-regulated BDNF mRNA in 
the DG region, this effect was blocked by both CGP 55845 
and CGP 46381 pre-treatment. This suggests a predominant 
role for GABAB receptor-mediated inhibition in BDNF mRNA in 
the DG. In addition, administration of the GABAB antagonist 
CGP 46381, but not CGP 55845 significantly attenuated 
paroxetine-mediated down-regulation in the DG. However, the 
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additive effect of CGP 46381 may have influenced the 
attenuating effect in the DG. Nevertheless, the results 
suggest activation in GABAB receptor-mediated transmission 
in the down-regulatory effect of paroxetine in the CA3 
region of the hippocampus. 
The results in this chapter appear to confirm the 
hypothesis that suggests a role for excitatory 5-HT 
receptors on GABAergic interneurones within the 
hippocampus. However, it was demonstrated in Chapter 3 that 
acute administration of antidepressant drugs with varying 
affinities to NA/5-HT reuptake or metabolism (as well as 
two compounds with no potency to 5-HT) had an equivocal 
effect on BDNF mRNA inhibition. Thus, it was concluded that 
the inhibition of BDNF mRNA at 4h after acute 
antidepressant treatment was not exclusively 5-HT-mediated 
and may be induced by a general facilitation of 5-HT, NA 
(or possibly DA) transmission in the hippocampus. 
Excitatory ~-adrenoceptor stimulation has been shown to 
depolarise groups of interneurones within the hippocampus 
and increase IPSP amplitude in CAl and CA3 pyramidal cells 
(Bergles et aI, 1996). In addition, both GAB~and GABAB-
receptor-mediated inhibition in DG granule cells is 
enhanced by ~-adrenoceptor activation (Bijak and Misgeld, 
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1995). Electrophysiological data also suggests that 
GABAergic interneurones can be excited via al adrenoceptors 
resulting in pyramidal and granule cell inhibition (Bergles 
et aI, 1996). This therefore suggests the presence of 
excitatory adrenoceptors on hippocampal interneurones, 
activation of which may result in the inhibition of BDNF 
mRNA in the DG and CA3 areas of the hippocampus. The role 
of DA in BDNF mRNA inhibition within the hippocampus is 
unclear. Little evidence exists for the presence of 
excitatory DA receptors on GABAeregic interneurones. 
However, inhibitory D2 receptors have been shown to be 
present in the DG and at the layer of the mossy fibre zone 
(Khan et al, 1998). Facilitation in extracellular 
hippocampal DA levels therefore may result directly in the 
activation of inhibitory control over DG granule cells, 
thereby inhibiting local BDNF mRNA levels. 
In conclusion, it appears that BDNF mRNA is regulated 
acutely via GABAB-mediated mechanisms in the DG and CA3 
regions of the hippocampus. Moreover, the inhibitory effect 
of the SSRI paroxetine on BDNF mRNA appears to be 
significantly influenced by GABAB receptor blockade in the 
CA3, possibly implicating GABAB activation in the inhibitory 
effect of paroxetine on BDNF mRNA. Overall, this suggests 
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that GABAB transmission participates in the early effects of 
antidepressant drug action on BDNF mRNA in the hippocampus. 
The next chapter examines the effect of chronic 
antidepressant administration on total BDNF mRNA, as well 
exon I and exon IV mRNA in the rat hippocampus. 
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Chapter Five 
Effect of Chronic Administration of 
Antidepressant Drugs on BDNF mRNA and 
BDNF exon mRNA in the Rat Hippocampus 
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5.1. Introduction 
As explained earlier (See Section 1.5), a central flaw in 
monoamine hypothesis is the failure to explain the need for 
chronic treatment of antidepressant drugs, despite their 
acute effects on monoamine transmission. This has led to 
research focusing on post-synaptic events beyond the 
monoamine receptor. The actions of 5-HT and NA receptors at 
both pre- and post-synaptic sites are mediated by their 
coupling to respective intracellular signal transduction 
pathways (Duman, 1998; Shelton, 2000). These monoamine-
linked cellular mechanisms therefore would be expected to 
mediate the actions of antidepressants, via increased 
extracellular 5-HT/NA and the subsequent stimulation of 
monoamine receptors. Furthermore, the long-term activation 
of such mechanisms has been postulated to result in 
adaptation that may result in the eventual therapeutic 
efficacy of antidepressant drugs (Nestler et aI, 1989; 
Manji et aI, 1995). 
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5.1.1. The effect of chronic antidepressant drug treatment 
on receptor-coupled signalling cascades 
Several studies have demonstrated an up-regulation in the 
components comprising the cAMP signalling cascade after the 
chronic administration of antidepressants via noradrenergic 
~-AR; or serotonergic 5-HT4, 5-HTs, 5-HT6 and 5-HT7 receptor 
activation (Nestler et al, 1989: Perez et al, 1991; Ozawa 
and Rasenick, 1991; Thome et al, 2000). Additionally, the 
phosphoinositide (PI) pathway, which is linked via Gq 
proteins to noradrenergic Ul and 5-HT2 receptors, has also 
been shown to be affected by chronic antidepressant 
treatment. However, its precise role is more complex. Some 
studies have reported increased PI turnover (Newman et aI, 
1989: Pandey et aI, 1991), while others have reported 
decreases (Li et al, 1988: Dwivedi et al, 2002) or no 
effects (Coull et aI, 2000) after chronic antidepressant 
drug treatment. 
A downstream target of both the cAMP at PI pathways that 
has been suggested to mediate the action of antidepressants 
is the cAMP response element binding protein (CREB; Meyer 
and Habener, 1993; Thome et al, 2000). CREB is a 
transcription factor, which is activated by increased cAMP 
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production as a consequence of stimulation by Gs-coupled 
receptors. CREB mediates the actions of cAMP on gene 
expression and could thereby underlie some of the effects 
of chronic antidepressant treatment. Nibuya et al (1996) 
demonstrated that chronic, but not acute administration of 
several different types of antidepressants (SSRls, NA-
selective reuptake inhibitor, MAOI, atypical) enhanced CREB 
mRNA and its corresponding protein in the rat brain. 
Phosphorylation of CREB is increased after chronic, but not 
acute antidepressant treatment (Duman et aI, 1997; 1999; 
Thome et aI, 2000) and the function of CREB is regulated by 
its state of phosphorylation at serine residue 133 (Mayr et 
aI, 2001). Phosphorylation of CREB by kinases (PKA, PKC) 
leads to increased binding to the CREB response element 
(CRE) sequence sites in promoters (Nichols et aI, 1992; 
Lonze and Ginty, 2002). 
Deletion and mutational analysis of the promoter directly 
upstream of the BDNF gene has revealed that gene activation 
is dependent on an element 5' to the mRNA start site. The 
element (located between 40 and 30 bp upstream of the mRNA 
start site) within the BDNF gene matches the consensus 
sequence of the CRE and is required for activation of the 
promoter (Shieh et aI, 1998; Tao et aI, 1998). The CRE-
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dependent component of the response appears to be mediated 
by CREB as it is part of the complex that binds to this CRE 
and since negative mutants of CREB attenuate activation of 
the promoter (Shieh et aI, 1998). 
An additional area within the BDNF gene, upstream from the 
CRE promoter region (between 47 and 72bp upstream of the 
mRNA start site) has been identified. This site is a novel 
calcium response element site and is required for calcium-
dependent BDNF expression (Shieh et aI, 1998; Tao et aI, 
1998). BDNF has been suggested to be a likely target gene 
of calcium signalling (Shieh and Ghosh, 1999). Activation 
of voltage-sensitive Ca2+ channels or NMDA type glutamate 
receptors leads to the enhancement of BDNF mRNA and 
stimulates the release of BDNF protein (Zafra et aI, 1990; 
1991; Ghosh et aI, 1994). Ca2 + influx also triggers 
phosphorylation of CREB and interfering with CREB inhibits 
calcium-dependent BDNF transcription (Finkbeiner, 2000), 
thus indicating a common reciprocal pathway. 
The possibility that induction of BDNF is mediated by CREB 
is further supported by the apparent anatomical co-
localisation after chronic antidepressant treatment. Both 
CREB and BDNF mRNA have been shown to be significantly up-
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regulated in hippocampal, as well as cortical areas (Nibuya 
et aI, 1995; 1996; Duman et aI, 1997; Coppell et aI, 2003). 
A role for the cAMP pathway in regulating this response in 
these areas is supported by studies using phosphodiesterase 
(PDE) inhibitors, which inhibit the breakdown of cAMP 
molecules. Chronic administration of the PDE inhibitor 
rolipram enhances CREB and BDNF mRNA expression (Nibuya et 
aI, 1996; Fujimaki et aI, 2000). 
Many previous studies have demonstrated an increase in BDNF 
mRNA levels after chronic, but not acute antidepressant 
drug treatment (Nibuya et aI, 1996: Zetterstr~m et aI, 
1998; Russo-Neustadt et aI, 1999; Coppell et aI, 2003). 
However, significant differences exist in the magnitude of 
the BDNF mRNA response to chronic antidepressant 
intervention. Using ISH and Northern blot techniques, 
Nibuya et al (1996) found a robust (2-3 fold) increase in 
BDNF mRNA in the CAl area hippocampus, after administration 
of a wide range of drugs (SSRIs, TCAs, MAOIs, atypical). 
Subsequent studies have found less pronounced changes also 
localised to the hippocampus and not common to all 
antidepressants (Zetterstr~m et aI, 1998; Russo-Neustadt et 
aI, 1999). For instance, a recent study (Coppell et aI, 
2003) found Significant elevation in BDNF mRNA after 
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chronic administration of the SSRls paroxetine, fluoxetine 
and sertraline, but not with the non-selective MAOI TCP or 
the noradrenergic TCA desipramine. 
As explained earlier (See Section 1.6.3), the BDNF gene has 
multiple transcripts, each with unique promoters. 
Transcripts consist of a variable 5' region (exons I-IV) 
and a common 3' segment (exon V), which codes for mature 
BDNF protein. Previous studies have revealed differential 
use of the individual BDNF exon mRNA transcripts, which 
vary in response to chronic antidepressant. Russo-Neustadt 
et al (2000) found chronic administration of the non-
selective MAOI TCP, but not the TCA imipramine 
Significantly up-regulated exon I rnRNA in the CA3 and DG 
region of the hippocampus, but no significant change was 
seen in exon II mRNA. The study however did not examine the 
corresponding effect on exon III or IV. In contrast, a more 
recent study (Dias et al, 2003) found chronic 
administration of TCP or the noradrenergic TCA desipramine 
significantly up-regulated exon II and exon III mRNA, but 
not exon I or exon IV rnRNA. 
Both studies however lacked data on total BDNF mRNA making 
conclusions regarding predicted net effects on the 
translation of the corresponding protein difficult. 
165 
Ahmad Adam Khundakar Chapter Five 
In Chapter 3, it was found that that acute (single 
injection) administration of several antidepressant 
compounds had varying effects on individual BDNF exon 
transcripts in the rat hippocampus at 4h. Acute 
antidepressant treatment resulted in an overall inhibition 
in total BDNF mRNA expression, which seemed to be due in 
part to exon IV, but not exon I mRNA down-regulation. 
Therefore as a continuation of this series of experiments, 
this chapter aims to investigate which of the exon 
transcripts studied is influenced by chronic administration 
of antidepressant drugs. 
In order to clarify the influence of chronic antidepressant 
drug treatment on varying individual exon mRNA, as well as 
total BDNF mRNA regulation, this series of experiments 
investigates the effect of chronic administration of three 
antidepressants. Two antidepressants with varying 
affinities to the NA/5-HT reuptake sites (the noradrenergic 
TCA desipramine and the SSRI fluoxetine), together with the 
non-selective MAOI TCP were administered for a 3-week 
period. In the following series of ISH experiments, we 
utilised oligonucleotide probes selective to total BDNF 
mRNA (exon V), as well as a representative form of protein-
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dependent exon mRNA (exon I) and a non-protein synthesis-
dependent 'lEG-like' exon mRNA (exon IV; Lauterborn et aI, 
1996; 1998; See Section 1.6.3). 
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5.2. Methods 
Male Sprague-Dawley rats (225-250g) were injected (i.p) 
once daily for 2ld with either: saline (lml/kg) or 
fluoxetine (lOmg/kg), desipramine (lOmg/kg) or TCP (5mg/kg) 
in 0.9% saline, and sacrificed 24h after the last 
injection. Brains were isolated and flash-frozen in cooled 
isopentane, before being stored at -70°C until further use. 
In-situ hybridisation and densitometric analysiS procedures 
are described in Chapter 2. 
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5.3. Results 
5.3.1. Effect of chronic administration of antidepressant 
drugs on BDNF mRNA and BDNF exon mRNA at 24h 
5.2.1.1. Effect on total BDNF mRNA 
Three different antidepressant drugs were assessed for 
their effect on BDNF mRNA at 24h, the SSRI fluoxetine, the 
TCA desipramine and the non-selective MAOI TCP. Daily 
injections were administered over a three-week period. 
Fluoxetine (lOmg/kg) caused a significant up-regulation of 
BDNF mRNA in the DG area (36.4%iP<O.05) of the 
hippocampus. No significant changes were observed in the 
CAlor CA3 regions (Table 5.1; Figures 5.1 and 5.4). 
Repeated administration of desipramine (lOmg/kg) also 
caused a significant up-regulation in the DG (36%; p<O.05), 
no significant changes were observed in the CAlor CA3 
areas (Table 5.1; Figures 5.2 and 5.5). Likewise, chronic 
TCP (5mg/kg) administration caused a significant up-
regulation in BDNF mRNA in the DG (48%; p<O.Ol) at 24h. In 
addition, chronic TCP administration caused a significant 
up-regulation in the CA3 (37.5%; p<O.05) field of the 
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hippocampus, but not the CAl (Table 5.1; Figures 5.3 and 
5.6) . 
5.3.1.2. Effect on BDNF exon I mRNA 
Chronic treatment with fluoxetine caused a significant up-
regulation in BDNF exon I mRNA at 24h in the DG (64.4%; 
p<O.OOl) and also in the CA3 (37.5%; p<O.05), but not in 
the CAl (Table 5.2; Figures 5.1 and 5.4). Unlike the effect 
on whole BDNF mRNA, desipramine had no significant effect 
on BDNF exon I mRNA in any area of the hippocampus (Table 
5.2; Figures 5.2 and 5.5). Chronic TCP treatment resulted 
in a significant up-regulatory effect in the DG (51.2%; 
p<O.Ol) and the CA3 (47.5%; p<O.05; Table 5.2; Figures 5.3 
and 5.6). No significant effect was seen in the CAl. 
5.3.1.3. Effect on BDNF exon IV mRNA 
Chronic treatment with either fluoxetine, TCP or 
desipramine had no significant effects on BDNF exon IV mRNA 
in any area of the rat brain tested (Table 5.3; Figures 5.1 
to 5.6). 
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~able 5.1. Effect of chronic drug treatment on BDNF mRNA 
expression in the rat hippocampus 24h after the last 
injection. Data presented as percentage of control 
***p<O.OOl, **p<O.Ol, *p<O.05 compared to control (ANOVA 
with Bonferroni's post-hoc test) 
CAl CA3 DG 
Saline n=6 lOO±.3.8 lOO±5.9 lOO±.4.9 
Fluoxetine n=6 105.5±6.4 113.4±.6.1 136.4±.6.3'" 
Saline n=6 lOO±.3.8 lOO±5.9 100±4.9 
Desipramine n=6 118.4±4.6 123.6±.5.1 136.0±.6.0'" 
Saline n=6 lOO±.3.8 100±5.9 100±4.9 
Tranylcypromine n=6 123.6±11.1 137.5±3.9* 148.0±.11.4** 
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Table 5.2. Effect of chronic drug treatment on BDNF exon X 
mRNA expression in the rat hippocampus 24h after the last 
injection. Data presented as percentage of control 
***p<O.OOl, **p<O.Ol, *p<O.05 compared to control (ANOVA 
with Bonferroni's post-hoc test) 
CAl CA3 DG 
Saline n=6 lOO±8.8 lOO±14.5 lOO±10.5 
Fluoxetine n=6 113.4±6.1 137.8±7.7 164.4±5.2** 
Saline n=6 lOO±8.8 lOO±14.5 100±10.5 
Desipramine n=6 81.4±9.7 lO1.9±18.0 119.0±18.3 
Saline n=6 lOO±8.8 lOO±14.5 lOO±lO.5 
Tranylcypromine n=6 113.6±7.6 147.5±11.9* 151.2±11.0** 
Table 5.3. Effect of chronic drug treatment on BDNF exon XV 
mRNA expression in the rat hippocampus 24h after the last 
injection. Data presented as percentage of control 
***p<O.OOl, **p<O.Ol, *p<O.05 compared to control (ANOVA 
with Bonferroni's post-hoc test) 
CAl CA3 DG 
Saline n=6 100±10.1 lOO±8.6 lOO±7.5 
Fluoxetine n=6 115.0±6.4 121.0±5.6 lOO.7±7.3 
Saline n=6 10O±10.1 100±8.6 lOO±7.5 
Desipramine n=6 89.4±4.6 93.3±14.1 84.3±7.6 
Saline n=6 100±1O.1 lOO±8.6 100±7.5 
Tranylcypromine n=6 80.4 ± 13.4 lO3.3±9.8 81.8±6.7 
172 
180 * 
r-f 
0 
t 160 ~ 
0 
u 
~ 140 
<Il 
:> 
o 12 0 ~ 
0 
D Saline rTFI ~ ·~ 100~ • Fluoxetine 0. 
:< 80 <Il 
-t: 
Z 
60 0:: E 
~ 
.,-i 
40 
<Il 
0' 
~ 
III 20 .c: 
u 
x 
0 
BDNF Exon 1 Exon 4 
Figure 5.1. The effect of chronic fluoxetine (21 days at lOmg/kg) administration on total 
BDNF mRNA, exon I mRNA and exon IV mRNA at 24h in the CAl , CA3 and dentate gyrus (DG) 
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*p<O . 05 compared to control (Bonferroni ' s post - hoc test) . 
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Figure 5. 4 . In- situ hybridisation images showing the effect 
of chronic fluoxetine (10mg/kg) treatment on AlB total BDNF 
mRNA; C/D exon I mRNA and ElF exon IV mRNA in the rat 
hippocampal region at 24h . Control groups are situated left . 
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Figure 5.5. In-situ hybridisation images showing the effect 
of chronic desipramine (10mg/kg) treatment on AlB total BDNF 
mRNA; C/D e xon I mRNA and ElF e xon IV mRNA in the rat 
hippocampal region at 24h . Control groups are situated left . 
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Figure 5.6. In situ hybridisation images showing the effect 
of chronic tranylcypromine (5mg/kg) treatment on AlB total 
BDNF mRNA; C/D exon I mRNA; ElF exon IV mRNA in the rat 
hippocampal region at 24h . Control groups are situated left. 
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5.4. Discussion 
5.4.1. Summary of results 
The major finding in this chapter related to the 
differential variable exon transcript expression at 24h 
after chronic antidepressant drug treatment and how this 
contributed to the net effect on total BDNF mRNA in the rat 
hippocampus. Chronic administration of the SSRI fluoxetine, 
the noradrenergic TCA desipramine or the non-selective MAOI 
TCP resulted in the up-regulation of BDNF mRNA in the DG 
region of the hippocampus. In addition, chronic TCP 
administration also increased BDNF mRNA expression 
significantly in the CA3 area. 
Among the variable exon transcripts, exon I mRNA was 
significantly up-regulated after chronic fluoxetine and TCP, 
but not desipramine administration. In contrast, chronic 
treatment of fluoxetine or TCP (as well as desipramine) had 
no significant effect on exon IV mRNA expression in any area 
of the hippocampus. 
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5.4.2. The effect of chronic antidepressant drug 
administration on total BDNF mRNA 
Chapter Five 
As with earlier experiments (Nibuya et aI, 1996; Russo-
Neustadt, 1999; Coppell et aI, 2003), different 
antidepressants, when given chronically, up-regulated total 
BDNF mRNA in areas of the hippocampus. However, there are 
some differences between the present findings and previous 
experiments. 
Nibuya et al (1996) chronically administered two 
antidepressants the SSRr fluoxetine or MAOr TCP. Unlike the 
present study, they found the largest up-regulatory effect 
on BDNF mRNA in the CAl after chronic fluoxetine (161%) 
administration. Chronic TCP administration also 
significantly increased CAl levels (75%), though not to the 
extent of fluoxetine. However, similar significant increases 
in BDNF mRNA expression to the present study were recorded 
in the CA3 and DG after chronic fluoxetine and TCP 
administration. The reason for the apparent differences 
between the present and the previous studies are unclear. 
However, the period after the last injection however was 
shorter in the Nibuya et al (1996) study (18h). Thus, it may 
be that such increases may have subsided in the subsequent 
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period (6h) from where the current study was measured. 
Russo-Neustadt et al (1999) found similar significant 
increases in the DG (57%) to the present study after chronic 
TCP treatment from a similar treatment regimen (20d, once 
daily). CAl levels were also significantly increased (25%), 
though to a less extent than the Nibuya study. No 
significant change was seen in CA3 levels. 
Coppell et al (2003) found repeated injection of fluoxetine, 
paroxetine, sertraline or TCP (14d, twice daily) increased 
BDNF expression in the hippocampus at 24h. This effect 
however was confined to the DG, with the exception of 
chronic TCP, which also caused an increase in the CAl 
region. In comparison to the present study, which found a 
significant increase in total BDNF mRNA levels after chronic 
desipramine treatment, Coppell et al (2003) failed to find 
any change in BDNF mRNA after chronic administration of the 
noradrenergic TCAs desipramine and maprotiline at 24h. As 
explained in Section 3.4.3, the Coppell study also failed to 
find any significant change (inhibition) after acute 
administration of desipramine, whilst other SSRI compounds 
inhibited BDNF mRNA in the DG, this indicated a predominant 
role for 5-HT-mediated mechanisms in acute (at 4h) and 
chronic (at 24h) regulation of BDNF mRNA in the hippocampus. 
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The present study found changes in BDNF mRNA after 
desipramine treatment at both these time points therefore 
counteracting this assertion. It is unclear why these 
anomalies exist, however it may be speculated that a 
significant inhibitory response is required acutely in order 
to gain a significant increase after chronic treatment. 
The results from this chapter appear to correspond with 
previous studies, which have identified the BDNF as a target 
gene for chronic antidepressant drug treatment (Nibuya et 
aI, 1996; Russo-Neustadt et aI, 1999; Coppell et aI, 2003). 
Additionally, the up-regulation in BDNF mRNA levels appears 
to follow the time-course for the commencement of 
therapeutic effect from antidepressants (i.e. 10-21d; 
Heninger and Charney, 1987; Vaidya and Duman, 2001). 
Previous studies (Nibuya et al, 1996; Ying et al, 2002) have 
revealed significantly similar up-regulatory effects of the 
transcription factor CREB in proximity to that of BDNF mRNA 
(i.e. the DG region of the hippocampus). CREB function is 
augmented by the up-regulation of the cAMP system, which 
results in the phosphorylation of CREB by PKA (Meyer and 
Haebner, 1993; Ghosh and Greenberg, 1995). Activation of the 
cAMP cascade may occur as a result of increased excitatory 
monoamine receptor (i. e. 5-HT4, 5-HTsA, 5-HT6, 5-HT7, ~NA) 
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activation due to prolonged increases in extracellular 
monoamine concentration (Duman, 1998; Russo-Neustadt et aI, 
2003). This has suggested a common series of signal 
transduction events, resulting in the increase in BDNF mRNA 
expression in the hippocampus. Indeed, culture studies have 
indicated that activation of cAMP increases BDNF mRNA 
expression (Tao et aI, 1998; Shieh et aI, 1998) and 
identified a CRE binding element within the promoter region 
of the BDNF gene (See Section 1.5.2). The PI pathway also 
may be activated by prolonged 5-HT2, al NA receptor 
stimulation, which also has been shown to target CREB (See 
Section 1.5.3). CREB may therefore represent a common target 
for various antidepressant drug types (Duman et aI, 1997; 
1999; Shelton, 2000). 
5.4.3. The effect of chronic antidepressant administration 
on BDNF exon mRNA 
Chronic antidepressant administration produced differential 
effects among the various BDNF transcripts tested in the DG 
area of the hippocampus at 24h. Chronic administration of 
the SSRI fluoxetine and the MAOI TCP resulted in significant 
increases in exon I mRNA expression, however no significant 
increase was seen after chronic desipramine treatment. In 
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contrast, no effect was seen in exon IV mRNA in any area of 
the hippocampus after any drug tested. These findings 
contrast those found after acute administration of various 
antidepressants at 4h, where exon IV mRNA was significantly 
altered (inhibited) and exon I mRNA was unchanged (See 
Chapter 3). This may therefore suggest the differential 
usage of the variable exon transcripts in response to 
differing antidepressant interventions at different time 
points, which contribute to the overall change in total BDNF 
mRNA. 
It has been suggested that altered transcription of exon I 
and II mRNA is regulated by intervening protein synthesis 
mechanisms (Lauterborn et aI, 1996) and influenced by 
calcium/calmodulin-dependent protein kinase activation 
(Murray et aI, 1998). Facilitation of such mechanisms has 
been implicated in the function of chronic antidepressant 
treatment. Indeed, a cAMP-response element has been 
identified in the promoter region of exon I sequence (Sheih 
et aI, 1998; Tabuchi et aI, 2002). Using a similar treatment 
regimen to the current study (7.5mg/kg; 20d, once daily), 
Russo-Neustadt et al (2000) also found a similar up-
regulatory effect in exon I mRNA after chronic TCP treatment 
in the DG region at 24h. This may suggest a pivotal role for 
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exon I mRNA transcription in the up-regulatory response of 
antidepressants on the BDNF gene and may reflect the 
initiation of a stable long-term change in 
neurotransmission. Exon IV-containing transcripts, which 
were predominantly affected by acute antidepressant 
administration at 4h, were unaffected by chronic 
antidepressant administration at 24h. Regulation of exon III 
and IV mRNA is not protein synthesis-dependent, they are 
thought to share properties with lEGs. Thus, time course 
studies indicate that exon III and IV mRNAs are changed more 
rapidly and maximal or minimal levels are attained earlier 
than exon I and II mRNAs (Lauterborn et aI, 1996). As the 
chronically-treated groups were assessed 24h after the last 
injection, any acute alteration in exon IV mRNA 
transcription may have elapsed, with levels returning to 
normal. 
A difference in the effects of chronic SSRI fluoxetine or 
the non-selective MAOI TCP occurred with the noradrenergic 
TCA desipramine. Though chronic desipramine administration 
significantly up-regulated total BDNF mRNA levels in the DG, 
a corresponding significant up-regulation in exon I 
transcript mRNA was not seen (though an upward trend was 
recorded). The net BDNF expression depends on the cumulative 
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effect of the multiple alternative exon-containing 
transcripts (Timmusk et aI, 1993; Nakayama et aI, 1994; 
Bishop et aI, 1997). This may therefore implicate the up-
regulation of either exon II and/or exon III in the DG after 
chronic desipramine treatment, which contributes to the 
overall increase in total BDNF mRNA. As the present study 
was unable to reliably measure exon II or exon III-
containing transcripts, it was not possible to confirm which 
exon primarily contributed to the overall effect. However, 
the findings may represent the differential use of BDNF exon 
transcripts in response to the chronic administration of 
varying types of antidepressant drugs. In addition, there 
was no induction of any BDNF exon transcript in frontal 
cortex and striatal areas (data not shown). 
In conclusion, the chronic administration of three 
antidepressant drugs each resulted in the up-regulation of 
BDNF mRNA in the DG region of the hippocampus at 24h. 
Chronic TCP administration also up-regulated BDNF mRNA in 
the CA3 region. Chronic treatment with fluoxetine or TCP 
also significantly up-regulated exon I mRNA levels. Chronic 
fluoxetine, TCP or desipramine administration had no effect 
on exon IV mRNA in any area of the hippocampus at 24h. 
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There was no induction in BDNF, BDNF exon I or BDNF exon IV 
in either striatal or frontal cortex areas (data not shown). 
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Chapter Six 
The Effect of Electroconvulsive Shock on BDNF 
mRNA in the Rat Hippocampus 
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6.1. Introduction 
Chapters three and five outlined the bi-phasic effect of 
antidepressant drugs on total BDNF mRNA in the rat 
hippocampus, whereby acute antidepressant drug treatment 
inhibited BDNF mRNA in the CA3 and DG of the hippocampus at 
4h. Whereas chronic, but not acute treatment, up-regulated 
BDNF mRNA in the same areas at 24h. Additionally, it was 
shown that these changes are achieved by the differential 
use of the variable exon-containing transcripts. The acute 
down-regulatory response appeared to be mainly due to the 
inhibition in the immediate early gene-like (Lauterborn et 
al, 1996; 1998) exon IV mRNA transcription. The chronic up-
regulatory response however, appeared to be due to the 
comparable increase in the protein synthesis dependent exon 
I transcription, changes in expression of which has been 
shown to be protein synthesis dependent (Lauterborn et al, 
1996; 1998). 
Electroconvulsive therapy (ECT) is considered to be one of 
the most effective forms of therapy available for severe 
types of depression (Greenberg et aI, 1988; Fink, 1990; 
Mann, 1998). Like antidepressant drug treatment however, 
ECT requires the induction of a series of convulsions over 
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a period of weeks and the mechanisms behind its efficacy 
remain ambiguous (Greenberg et aI, 1988; Fink, 1990). 
6.1.1. The effect of ECS treatment on central monoamine 
function 
Several studies have reported marked effects on both 5-HT 
and NA function after chronic application of ECS. Repeated 
ECS in rodents was found to produce a significant increase 
in 5-HT2 receptor binding in the cortex and hippocampus. 
These changes corresponded with behavioural alterations 
indicative of such a change ('head twitch behaviour'; Green 
et aI, 1983; Goodwin, 1984). Repeated ECS application has 
also been shown to increase 5-HT1A receptor mRNA and binding 
site densities in the DG (Hayakawa et aI, 1994; Burnet et 
aI, 1995). An increase in interstitial 5-HT concentration 
in the hippocampus has been recorded in microdialysis 
studies after chronic ECS application (Zis et aI, 1992). 
This facilitation in 5-HT release appears to be as a result 
of neuronal activation as such an increase is blocked by 
the sodium channel blocker tetrodoxin (Zis et aI, 1992). 
It has been demonstrated that locus coeruleus (LC) electro-
physiological activity is decreased after chronic ECS 
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treatment (Grant and Weiss, 2001), despite elevation in 
tyrosine hydroxylase (TH) activity in the LC area (Weiner 
et aI, 1991; Kapur et aI, 1993; Brady et aI, 1994), though 
decreases in TH immunoreactivity activity have also been 
recorded in the LC area (Nestler et aI, 1990). It has been 
suggested that this inhibition in activity may be due to 
stimulation of somatodendritic a2 adrenoceptors on LC 
neurones (Cedarbaum and Aghajanian, 1976; Aghajanian and 
Vandermaelen, 1982; Simson and Weiss, 1987). Thus, the 
elevation in interstitial NA levels may result in an 
increase in stimulation of such receptors, which will 
inhibit depolarisation of LC neurones. 5-HT receptors have 
also been found on LC cell bodies (Pickel et aI, 1997). 
These are also thought to be inhibitory in nature (Segal, 
1979), thus increases in interstitial 5-HT levels arising 
from ECS application may also inhibit LC neuronal 
depolarisation. Interestingly, Teppet et al (1992) found a 
decrease in responsiveness of somatodenritic a2 adrenoceptor 
of LC NA neurones to the inhibitory effect of intravenous 
clonidine after repeated ECS, which may suggest an adaptive 
response to ECS. However, the desensitising effect was also 
seen after acute ECS, which does not produce a therapeutic 
response in humans. 
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6.1.2. The effect of ECS treatment on receptor-coupled 
signalling cascades 
Seizure is known to produce dramatic and diverse effects on 
a variety of signalling components including 
neurotransmitters (Nomikos et aI, 1991; Zis et aI, 1991; 
1992; McGarvey et aI, 1993; Stenfors et aI, 1995; 
Zetterstrom et aI, 1998; Gur et aI, 2002), neurotransmitter 
receptors (Burnet et aI, 1999; Ishihara et aI, 2001; Gur et 
aI, 2002; Dremencov et aI, 2003), G-proteins (Ozawa and 
Rasenick, 1991), protein kinases (Nestler et aI, 1989) and 
transcription factors (Nibuya et aI, 1995; Jeon et aI, 
1997), potassium channels (Pei et aI, 1997) and structural 
proteins (Pei et aI, 1998). The similarities in many key 
components activated by both chronic antidepressant 
treatment and ECS has suggested that prolonged ECS and 
antidepressant application may activate similar cascades, 
leading to a common therapeutic response. Chronic ECS has 
been demonstrated to augment the cAMP signalling system at 
various levels. The coupling of stimulatory G-proteins to 
adenylate cyclase is increased (Ozawa and Rasenick, 1991), 
as well as the expression of cAMP phosphodiesterase 
(Sattin, 1971; Lust et aI, 1976; Clarenbach et aI, 1978). 
ECT has been demonstrated to result in an increase in 
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plasma and urine cAMP concentration in depressed patients 
(Lykouras et aI, 1990). The expression of downstream 
targets of cAMP, including PKA (Nestler et al 1989) and 
CREB (Nibuya et aI, 1995; 1996) are enhanced by ECS 
application. Seizure induction is known to have widespread 
effects on the regulation of neurotrophic factors. 
Chemically- and electrically- induced seizures elicit a 
dramatic up-regulation in BDNF mRNA and its receptor, trkB 
(Zafra et aI, 1991; Ballarin et aI, 1991; Gall et aI, 1991; 
Nibuya et aI, 1995; Zetterstrom et aI, 1998). 
This chapter aims to elaborate on the effect of acute and 
chronic ECS treatment on the BDNF gene, focussing on the 
effect on individual BDNF transcript (exon I and exon IV) 
mRNA as well as on the whole gene. 
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6.2. Methods 
6.2.1. ECS application 
The protocol used for ECS application is listed in Section 
2.1.1.3. 
Animals were sacrificed 4h after acute ECS application and 
24h after chronic application. The time-points were chosen 
to correspond with the antidepressant drug treatment 
protocols (See Chapters 3 and 5). 
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6.3. Results 
6.3.1. Effect of acute ECS on total BDNF mRNA 
Acute ECS elicited more than a four-fold increase in total 
BDNF mRNA in the DG (385.4%; p<O.OOl) at 4h, compared with 
the sham treated animals. However, CAl and CA3 levels were 
not significantly altered (Table 6.1; Figures 6.1, 6.3). 
Exon I mRNA levels increased three-fold in the DG (221.5%; 
p<O.OOl) after acute ECS treatment at 4h, no significant 
changes were seen in the CA3 or CAl areas (Table 6.1; 
Figures 6.1, 6.3). 
Acute ECS resulted in over a five-fold increase (446.0%; 
p<O.OOl) in DG exon IV mRNA levels at 4h, no significant 
changes were seen in CAlor CA3 levels (Table 6.1; Figures 
6.1, 6.3). 
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6.3.2. Effect of chronic ECS on total BDNF mRNA, exon I 
mRNA and exon IV mRNA 
Chronic ECS treatment resulted in an increase in whole BDNF 
gene mRNA in the DG at 24h after the last shock (144.3%; 
p<O.OOl). In comparison, BDNF mRNA levels were not 
significantly altered in CAl and CA3 areas (See Table 6.2; 
Figures 6.2, 6.4). 
Exon I mRNA was significantly increased in the DG (77.4%; 
p<O.Ol), 24h after chronic ECS administration. No change 
was seen in CAlor CA3 areas (See Table 6.2; Figures 6.2, 
6.4) . 
Chronic treatment had no effect on exon IV mRNA in the DG 
at 24h, in addition to CAl and CA3 (See Table 6.2; Figures 
6.2,6.4). 
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Xable 6.1. Effect of acute ECS treatment on total BDNF 
mRNA, exon I mRNA and exon IV mRNA expression in the rat 
hippocampus 4h after shock. Data presented as percentage of 
control ***p<O.OOl, **p<O.Ol, *p<O.05 compared to control 
(Student's t-test) 
BDNF 
Acute Sham. n=4 
Acute ECS n=4 
Exon I mRNA 
Acute Sham. n=4 
Acute ECS n=4 
Exon IV mRNA 
Acute Sham n=4 
Acute ECS n=4 
CAl 
lOO±ll.4 
ll0.5±4.2 
100±8.l 
l23.4±5.6 
lOO±14.4 
123.2±7.6 
CA3 
lOO±lO.1 
91.9±4.5 
lOO±8.1 
lOO.3±6.8 
lOO±l?3 
132.4±5.6 
DG 
lOO±l7.0 
485.4±l4.2·" 
lOO±l2.4 
321.5±lO.8·" 
lOO±21.9 
546.0±l5.0·" 
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Table 6.2. Effect of chronic ECS treatment on total BDNF 
mRNA, exon I mRNA, and exon IV mRNA expression in the rat 
hippocampus 24h after shock. Data presented as percentage 
of control ***p<O.OOl, **p<O.Ol, *p<O.05 compared to 
control (Student's t-test) 
CAl CA3 DG 
BDNF 
Chronic Sham n=5 lOO±14.8 lOO±11.0 lOO±15.3 
Chronic ECS n=5 79.3±11.4 77.5±17.7 244.3±11.6u * 
BDNF Exon I 
Chronic Sham n=5 lOO±6.8 lOO±5.4 lOO±12.4 
Chronic ECS n=5 82.3±12.5 92.5±9.6 177.4±10.4** 
BDNF Exon IV 
Chronic Sham n=5 lOO±12.7 lOO±12.1 lOO±16.4 
Chronic ECS n=5 76.5±17.7 92.4±19.8 78.1±8.4 
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Figure 6 . 1 . Effect of acute ECS treatment on total BDNF mRNA, exon I mRNA and e xon IV 
mRNA expression in the rat hippocampus 4h after administra tion. Data presented as 
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Figure 6.2. Effect of chronic ECS treatment on total BDNF exon mRNA expression in the rat 
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A B 
c D 
E r 
Figure 6.3. In-situ hybridisation images showing the effect 
of acute ECS administration on AlB total BDNF , C/D exon I 
mRNA and ElF exon IV mRNA in the rat hippocampal region at 
4h . Sham groups are situated left . 
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A B 
c D 
E 
Figure 6.4. In-situ hybridisation images showing the effect 
of chronic ECS administration on AlB total BDNF , C/D exon I 
and ElF exon IV mRNA in the rat hippocampal region at 24h . 
Sham groups are situated left . 
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6.4. Discussion 
6.4.1. Summary of findings 
Acute and chronic application of ECS substantially 
increased BDNF mRNA expression in the DG region of the 
hippocampus. Acute ECS resulted in a large increase in DG 
BDNF mRNA abundance, this increase declined upon further 
chronic ECS application. The substantial initial rise in 
BDNF mRNA appeared to be due in part to the large up-
regulation in exon I and exon IV mRNA. Chronic ECS however, 
resulted only in an up-regulation in exon I mRNA, exon IV 
was not significantly altered. 
6.4.2. The effect of ECS treatment on total BDNF mRNA 
In contrast to antidepressant drug treatment, where a bi-
phasic BDNF mRNA response was found (an initial acute down-
regulatory effect followed by up-regulation after chronic 
treatment), both acute and chronic ECS up-regulated BDNF 
mRNA in the DG. Similar rapid facilitation of BDNF mRNA has 
been shown in response to numerous seizure paradigms 
including kainic acid-induced seizure (Zafra et aI, 1990; 
204 
Ahmad Adam Khundakar Chapter Six 
1991), kindling stimulation (Ernfors et aI, 1991; Kokaia et 
aI, 1994; 1996; Sato et aI, 1996), electrolytic lesions 
(Isackson et aI, 1991), as well as ECS (Nibuya et aI, 1995: 
Zetterstrom et aI, 1998a). However the up-regulation in 
total BDNF mRNA after acute ECS was transient, with levels 
returning to controls within 24h (Zetterstrom et al, 
1998a) . 
The mechanisms behind the rapid induction of BDNF after 
seizure are unclear. However, as mentioned earlier (Section 
4.4), BDNF is acutely regulated by neuronal activity and 
interplay between glutamate and GABA transmission (Zafra et 
aI, 1991; 1992; Bonanno et aI, 1998). ECS has been shown to 
produce a long-term 'LTP-like' enhancement in 
neurotransmission in the DG (Stewart et aI, 1994; Burnham 
et al, 1995). This effect has also been demonstrated after 
kindling stimulation. The kindling phenomenon, where sub-
convulsive electrical stimulations become convulsive upon 
chronic application, has been associated with enhancement 
in the potency of glutamate at its respective receptor. 
Thus, kindling seizures have been shown to produce 
substantial change within NMDA receptor subunits (Kraus et 
aI, 1994; Vezzani et aI, 1995; Watkins et al, 1998). 
Activation of NMDA receptor subtypes leads to the 
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enhancement of BDNF mRNA levels (Zafra et al 1990; 1991). 
In addition, stimulation of DG granule cells that evoke LTP 
has been shown to enhance BDNF mRNA in the same cells 
(Castren et aI, 1993; Dragunow et aI, 1993). Such increases 
appear to be also influenced by non-NMDA glutamate 
receptors, as the non-NMDA receptor antagonist CNQX blocks 
the ECS-induced increase in BDNF mRNA in the hippocampus 
(Zetterstr5m et ai, 1998b). 
Acute ECS application has been demonstrated to elicit 
immediate early gene (lEG) induction. Expression of c-fos 
is rapidly increased after acute ECS in the hippocampus and 
cortex (Cole et ai, 1990; Winston et aI, 1990). The 
induction of c-fos has been shown to be a reliable marker 
of neuronal activity (Morgan et ai, 1987; Sagar et ai, 
1988), thereby indicating hippocampal and cortical activity 
after acute ECS application. Interestingly, acute ECS 
induction of c-fos has been shown to be blocked by the NMDA 
antagonist MK801 in the hippocampus, but not several other 
neurotransmitter receptor antagonists (DI, 5-HT2A/2c, ulNA, 
~NA; Morinobu et aI, 1997), implicating a role for acute 
glutamatergic activity in the hippocampus in response to 
acute ECS. The induction of BDNF mRNA after seizure has 
also been shown to be dependent on Ca2+ signalling and 
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activation of calmodulin-dependent protein kinases (Bading 
et ai, 1993; Lerea and McNamara, 1993; Murray et ai, 1998) 
and BDNF mRNA is regulated in a ca2+/calmodulin-dependent 
manner in vitro (Murray et ai, 1998). In contrast, a fast 
decrease in hippocampal GABA function has been shown after 
seizure (kainic acid-induced) at a pre-synaptic level, 
resulting in a decrease in inhibitory postsynaptic 
potentials (IPSPs; Zafra et ai, 1991). Such an effect could 
be considered the opposite to the effect demonstrated in 
Chapter 4, where the acute administration of the GABAa 
agonist baclofen resulted in the rapid decrease in BDNF 
mRNA expression in the hippocampus (See Section 4.3.1). 
The up-regulatory effect on BDNF mRNA from acute ECS is not 
consistent with the time-course for the therapeutic action 
of ECT. Therefore it seems that up-regulation of BDNF mRNA 
alone is not sufficient to bring therapeutic response in 
humans, it appears that sustained elevation from chronic 
treatment may be necessary for eventual efficacy. ECS has 
been reported to up-regulate the cAMP signalling system at 
several levels (Ozawa and Rasenick, 1991), suggesting 
prolonged cAMP cascade activation may underlie the 
therapeutic mechanism. As explained in Chapter 5, various 
5-HT and NA receptor subtypes are linked to the cAMP 
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systems via G-protein activation. Microdialysis studies 
have revealed enhanced release of both 5-HT (Zis et aI, 
1992) and NA (Thomas et aI, 1991; 1992) after acute and 
chronic ECS application. Additionally, adaptive changes in 
monoamine receptor number and sensitivity have been 
demonstrated. Post-synaptic 5-HTIA receptor mRNA up-
regulation has been found in DG granule cells following 
chronic ECS (Burnett et aI, 1999) and decreased sensitivity 
has been reported among 5-HT1A receptors to agonist 
compounds (Gur et aI, 2002). Down-regulation in p-
adrenoreceptor number has also been observed (Nutt et aI, 
1989; Seo et aI, 1999). As with chronic antidepressant drug 
treatment, persistent increases in monoamine concentration 
from chronic ECS application may activate similar 
downstream components. One possible converging target point 
for both ECS and antidepressant drug treatment may be the 
transcription factor CREB. CREB levels are increased in the 
hippocampus by ECS (Nibuya et aI, 1996; vaidya and Duman, 
1998) and antidepressant drug treatment (Nibuya et al 1996 
Duman et aI, 1997, 1999; Thome et aI, 2000). CREB has been 
associated as a transcription factor for the BDNF gene 
(Nibuya et aI, 1996; See Section 5.1). 
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Overall, it appears that glutamate may be a likely mediator 
of BDNF mRNA induction after acute ECS induction, however 
the maintenance of BDNF mRNA elevation after chronic ECS 
appears more complex. The prolonged facilitation of 
monoamine receptor-linked signalling cascades, resulting in 
CREB induction may lead to longer-term BDNF augmentation 
and may possibly underlie ECS therapeutic action. 
6.4.3. The effect of ECS on individual BDNF exon mRNA 
The induction of acute and chronic ECS produced 
differential effects on the transcription of exon I and IV 
mRNA in the DG region of the hippocampus. Acute ECS 
resulted in an up-regulation in both exon I and IV mRNA. 
Exon IV-containing mRNAs have been shown to share 
properties with lEGs (Lauterborn et aI, 1996; 1998). 
Therefore chanqes in exon IV mRNA may have been expected 
after 4h, reflecting the overall change in BDNF. However, 
the induction of exon I mRNA has been shown to be dependent 
on ongoing Ca2+/calmodulin protein synthesis mechanisms 
(Lauterborn et aI, 1996; 1998) and displays a delayed 
induction process (Kokaia et aI, 1994). It is therefore 
surprising that the response in exon I mRNA is evident 
after only 4h post-injection. Acute ECS results in a 
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massive depolarising effect on granular cells of the DG, 
resulting in Ca2+ influx into neurones. Several studies have 
indicated that activation of L-type voltage-sensitive Ca2+ 
channels can lead to a transient increase in exon I (as 
well as exon II and III) containing transcripts (Timmusk et 
aI, 1993; Metsis et aI, 1993; Tao et aI, 1998), increases 
may take place as early as 3h after acute ECS application 
(Tao et al, 1998). Indeed, putative calcium-responsive 
elements have been detected within the promoter region of 
exon I, it may be a possibility therefore that fast exon I 
transcription may occur in response to rapid depolarising 
stimuli, such as from acute ECS. 
As with the effect acute antidepressant drug treatment, 
alteration in exon IV mRNA transcription mirrored the 
change to total BDNF mRNA. This suggests a primary role for 
exon IV transcripts in the BDNF mRNA response to acute 
stimuli. Like chronic antidepressant drug treatment, 
chronic ECS application resulted in increases in exon I 
mRNA, but not exon IV mRNA in the DG region of the 
hippocampus. This further implicates exon I activation in 
long-term interventions involving intervening protein 
synthesis mechanisms. 
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In conclusion, the effect of acute application of ECS on 
total BDNF mRNA and two individual exon transcripts differs 
from that of acute antidepressant drug treatment. Unlike 
acute drug treatment where total BDNF mRNA as well as exon 
IV mRNA were inhibited, acute ECS up-regulated total BDNF 
rnRNA as well as both exon I and IV mRNA. As the up-
regulatory effect on BDNF mRNA from acute ECS is not 
consistent with the time-course for the therapeutic action 
of ECS it appears that that up-regulation of BDNF mRNA 
alone is not sufficient to bring therapeutic response. 
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Chapter Seven 
The Effect of Chronic Antidepressant Treatment 
on BDNF Immunoreactivity in the Rat 
Hippocampus 
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7.1. Introduction 
The majority of studies relating to the regulation of BDNF 
after chronic antidepressant treatments have been based on 
the analysis of BDNF mRNA and not on the corresponding 
protein product. This has been due in part to technical 
limitations, such as lack of sensitive tissue assays for 
BDNF protein, as well as difficulties in quantifying (Altar 
et aI, 2003). However, examination of protein expression is 
vital in order to elucidate the functional properties of 
BDNF. In addition, its localisation in relation to BDNF 
mRNA alludes to how the protein is synthesised and 
transported. 
7.1.1. Basal distribution of BDNF protein in the rat brain 
Previous animal (Conner et aI, 1997; Yan et aI, 1997) and 
human studies (Iritani et aI, 2003) using similar 
immunocytochemistry (ICC) strategies to those in this 
chapter have revealed distinct BDNF immunoreactivity in 
several structures of the brain. These included the frontal 
and parietal cortices, as well as the hippocampus (Yan et 
aI, 1997; Conner et aI, 1997). Within the hippocampal 
formation, relatively dense staining has been found in the 
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CA3, particularly in the mossy fibre zone (MFZ), which 
connects granule cells of the DG with the CA3 pyramidal 
cells (Conner et al, 1997). Less basal staining has been 
reported in the CA3 area, and DG staining minimal (Conner 
et al, 1997, Iritani et aI, 2003). 
7.1.2. The effect of chronic ECS treatment on BDNF 
immunorectivity in the rat hippocampus 
Previous studies examining the effect of chronic ECS on 
BDNF protein have generally found an up-wards trend in 
expression in several areas of the brain. A recent enzyme-
linked sorbent assay (ELISA) study (Altar et al, 2003) 
found 10 consecutive days of ECS treatment elicited rapid, 
large and widespread increases in BDNF protein in the 
parietal cortex (219%), hippocampus (132%), frontal cortex 
(94%) and neostriatum (67%). These increases peaked at 15 
hours after the last treatment and were sustained for a 3-
day period. Another ELISA study (Angelucci et aI, 2002) 
found increased immunoreactivity restricted to the 
hippocampus and frontal cortex after 8 consecutive days of 
ECS. However, these findings were not replicated by the 
same group (Angelucci et aI, 2003). 
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Within the hippocampus, Smith et al (1997) found increased 
immunoreactivity localised in the hippocampal mossy fibres 
projecting from the DG granule cells to the CA3 pyramidal 
cells after chronic ECS application. 
The present study used the ICC technique, with specific 
affinity-purified antibodies selective to BDNF, to assess 
the effect of chronic application of ECS within the rat 
hippocampus. In addition, basal levels of BDNF protein in 
coronal sections through three major areas of the rat 
brain: the frontal cortex, striatum and hippocampus were 
established. 
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7 • 2. Methods 
Immunocytochemistry and densitometric analysis procedures 
are described in Chapter 2. 
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7.3. Results 
7.3.1. Basal distribution of BDNF protein in the rat brain 
Basal BDNF immunoreactivity was found in the hippocampus, 
as well as cortical and striatal areas. Significant 
labelling was established in the parietal (See Figure 7.4) 
and frontal cortices (See Figure 7.5). Within the 
hippocampus, basal BDNF immunoreactivity was found in the 
pyramidal cells of the CAl and CA3. However, the most 
intense staining appeared to be within the MFZ. No 
significant basal expression was seen in the granule cells 
of the DG (See Figure 7.3). As the DG basal level was so 
weak the accuracy of analysis could be questioned, 
therefore the effect of antidepressant treatments was 
focussed on the CAl, CA3 and MFZ within the hippocampus. 
A high level of magnification appeared to highlight BDNF 
protein labelling in somatic and axonal regions of cortical 
pyramidal neurones. Labelling appeared to be concentrated 
in somatic areas, which occasionally extended along axonal 
areas. However, under close scrutiny considerably less 
staining appeared to be present in central areas of the 
soma in many cells (See Figure 7.4B). 
217 
DG 
Ahmad Adam Khunda kar Chapter Seven 
Figure 7.1. Photomicrograph showing basal expression of 
BDNF protein in the rat hippocampus . The anat omical 
location is highlighted on a schematic diagram above 
(Adapted from Paxinos and Watson , 1986; Plate 34) . 
MFZ 
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Figure 7.2. Photomicrograph showing the basal e xpressio n of 
BDNF protein in the rat parietal cortex . The anatomical 
location is highlighted on a schematic diagram above 
(Adapted from Paxinos and Watson , 1986 ; Plate 34) . 
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Figure 7.3. Photomicrograph showing basal expression of 
BDNF protein in the rat frontal cortex . The anatomi cal 
location is highlighted on a schematic diagram above 
(Adapted from Pax inos and Watson , 1986; Plate 8 ) . 
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Figure 7.4. Photomicrograph showing basal expression of 
BDNF protein in the rat striatum (caudate putamen) . The 
anatomical location is highlighted on a schematic diagram 
above (Adapted from Paxinos and Watson , 1986 ; Plate 22 ) . 
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7.3.2. Effect of chronic ECS treatment on BDNF 
immunoreactivity in the rat hippocampus at 24h 
Chronic application of ECS elicited significant increases 
in BDNF protein expression in all areas assessed over sham-
treated animals. CAl (+143.3%, p<O.Ol) and CA3 (+144.6, 
p<0.05) and parietal cortex (+166.0%, p<0.05) levels 
increased over two-fold. The largest change was in the MFZ, 
where over a twelve-fold increase was recorded (+1159.3%, 
p<O.Ol; See Table 7.1; Figure 7.5; 7.6). 
7.3.3. Effect of chronic antidepressant treatment on BDNF 
immunoreactivity in the rat hippocampus at 24h 
An attempt was made to measure the effect of chronic 
antidepressant (TCP) treatment on BDNF immunoreactivity in 
the rat brain. However, only a cursory examination was 
possible due to low sample numbers (n=2; data not shown). 
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Tab~e 7.1. Effect of chronic ECS treatment on BDNF protein expression in the rat 
hippocampus 24h after injection. Raw data presented ***p<O.OOl, **p<O.Ol, *p<O.05 
compared to control (Unpaired two-tailed Student's t-test). Units corrected for non-
specific signalling over white matter (corpus callosum) 
CAl CA3 MF Par Ctx 
Sham n=3 0.1007±0.015 0.1073±0.028 0.0133±0.0133 0.047+0.006 
ECS n=4 0.245±0.027** 0.2625±0.042 * 0.1675±0.032 ** 0.125+0.017* 
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CAl CA3 
Figure 7.6. Photomicrographs showing the effect of chronic 
ECS treatment on BDNF immunoreactivity in the hippocampus 
in comparison with sham treated animal (A) . The anatomical 
location is highlighted on a schematic diagram above 
(Adapted from Paxinos and Watson , 1986 ; Plate 33) . 
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7.4. Discussion 
7.4.1. Basal distribution of BDNF protein in the adult rat 
brain 
In conjunction with previous studies (Yan et al, 1997; 
Conner et al, 1997) basal immunoreativity was found with 
frontal and parietal cortices, striatum and the 
hippocampus. Within the hippocampus, similar basal BDNF 
expression has been recorded in the pyramidal cells of the 
CA3 and the MFZ connecting the DG granule cells and the 
CA3. In addition, the present study also found significant 
basal BDNF protein expression was found in the CAl. 
However, no significant basal BDNF expression was detected 
throughout the DG. Interestingly, at a cellular level, a 
distinct pattern of BDNF distribution appeared to exist. A 
high level of immunoreactivity was present in the periphery 
of the soma, sometimes extending along axons, however a 
lack of staining was observed in the centre of the soma. 
This appears to confirm previous findings (Conner et aI, 
1997), that unlike BDNF mRNA, BDNF protein is not present 
within the nucleus and is localised to the cytoplasm, 
extending into proximal processes. 
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7.4.2. The effect of chronic ECS treatment on BDNF 
immunoreactivity 
Chronic ECS treatment produced widespread, significant 
increase in BDNF protein in all areas assessed. Within the 
hippocampus, the largest increase in protein levels was 
seen in the MFZ. Such large increases in MFZ levels have 
also been recorded in a previous ICC study (Smith et al, 
1997). Previous ELISA studies (Altar et al, 2003; Angelucci 
et al, 2002) have found significant increases in overall 
hippocampal BDNF protein levels. 
From the data gained in this chapter, as well as the data 
concerning BDNF gene alterations after chronic ECS 
treatment, it is seems that chronic ECS administration 
elicits a profound effect on both BDNF mRNA and it protein 
product in the hippocampus. It must be stressed that 
considerable limitations of ICC exist from the inherent 
inability to quantify changes in immunoreactivity. 
Technique such as western immunobotting or 
immunoautoradiography may have provided more accurate 
readings (Xu et aI, 2002; Altar et aI, 2003). 
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In addition, variability exists in the localisation of 
alterations in BDNF gene and protein expression within the 
hippocampus. Basal expression of BDNF mRNA was high in 
granule cells of the DG, with lower expression in the CAl 
(See Section 3.3.1). However, basal BDNF protein level in 
DG granule cells was minimal, with expression present in 
the pyramidal cells of the CAl and CA3, as well as the MFZ. 
As explained in Section 1.7.3, soma arising from the DG 
area project mossy fibres axons through the MFZ to the CA3 
pyramidal layer cells. ICC visualisation studies on BDNF at 
a cellular level have confirmed that neurones expressing 
BDNF mRNA also synthesise their corresponding protein 
(Wetmore et aI, 1991: Wetmore et aI, 1994; Dugich-
Djordjevic et aI, 1995). The soma of such neurones have 
been shown to be rich in BDNF mRNA (Altar and DiStefano, 
1998). BDNF protein has been shown to be mainly expressed 
in axonal and terminal areas (Altar et aI, 1997). Thus, it 
has been suggested that the predominant direction for 
transport of BDNF is anterograde (Altar and DiStefano, 
1998). Indeed, transection of the dorsal root ganglion axon 
has revealed accumulation of BDNF protein on the proximal 
side of the ligature (Tonra et aI, 1998). This phenomenon 
may also explain the apparent lack of BDNF mRNA signal in 
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striatal areas, compared with rich BDNF protein labelling 
in the same area. 
The apparent co-localisation of increases in BDNF protein 
after ECS application with the sprouting of the mossy fibre 
pathway offers a tempting hypothesis that BDNF enhancement 
may act as a precursor to impending structural change in 
areas associated with depression after antidepressant 
treatment. Furthermore, this analogy appears to suggest a 
central role for granule cells in the DG and their axons in 
the mossy fibre tract in the aetiopathology of depression. 
Indeed, stress models in rodents have been shown to induce 
atrophy in mossy fibres and dendritic trees of the CA3 
pyramidal neurones (Popoli et al, 2002; McEwen, 1999), 
indicating decreases in synaptic transmission in this 
critical neuronal pathway (Castren, 2004). In addition, 
hippocampal neurogenesis has been suggested in areas 
similar to those where BDNF mRNA is enhanced after 
antidepressant treatment. Repeated administration of a 
variety of antidepressant drugs and ECS causes an increase 
in the number of Brd-U labelled cells in the hippocampus 
(Malberg et al, 2000; Jacobs and Fornal, 1999; Manev et al, 
2001). The new cells have been shown to migrate into the 
granule cell layer, before extending axons along the mossy 
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fibre pathway to the CA3 pyramidal layer (van Praag et al, 
1999). It appears that new cells exhibit similar 
characteristics as mature granule cells and integrate into 
hippocampal circuitry (Duman et al, 2001). 
In conclusion, the present study found that chronic 
application of ECS significantly increased BDNF 
immunoreactivity in the CAl, CA3 and the MFZ of the 
hippocampus, as well as in the parietal cortex. Chronic 
administration of the non-selective MAOI antidepressant 
drug TCP failed to elicit any significant increase in these 
areas, however these results were very preliminary due to 
low group sample numbers. 
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Chapter Eight 
General Discussion 
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8.1 Background 
Major depression is one of the most common and devastating 
psychiatric disorders and is characterised by a number of 
mental, as well as somatic symptoms (DSM-Ivm, 1997). The 
serendipitous discovery of antidepressant treatments in the 
1950s led to the establishment of numerous theories into 
the pathophysiology of depression and the mechanism of 
action of antidepressant drugs. The most prominent of these 
the "monoamine hypothesis" implicated a role for 
noradrenaline (NA) and serotonin (5-HT) transmitter systems 
(Schildkraut, 1965). Most antidepressant drugs facilitate 
the signalling of 5-HT or NA either by inhibiting their 
reuptake back into pre-synaptic terminals (e.g. SSRls, 
TeAs) or by inhibiting their catabolism (e.g. MAOls). 
However, alterations in monoamine turnover take place 
quickly, within hours of drug administration, but the 
therapeutic antidepressant effect may take several weeks of 
chronic drug treatment to manifest (Nestler et aI, 2002). 
In addition, one of the most effective forms of 
antidepressant treatment electroconvulsive therapy (ECT; 
animal model, ECS) requires several applications in order 
for full efficacy to occur (Fink, 1990). This suggests that 
alterations in monoamine transmission alone cannot explain 
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the efficacy of antidepressants and has led to research 
focusing on events beyond the monoamine receptor. The cAMP 
signalling cascade is regulated by several 5-HT and NA 
receptor subtypes. Increased levels of cAMP induces protein 
kinase A (PKA) activation, which in turn catalyses a 
variety of regulatory proteins including transcription 
factors such as cAMP response element binding protein 
(CREB). CREB mRNA and protein has been shown to be 
increased after chronic antidepressant treatment (Nibuya et 
aI, 1995; 1996). CREB regulates gene transcription by 
binding to a cAMP response element on the regulatory region 
of various genes. One such target gene identified as 
containing such a region is brain-derived neurotrophic 
factor (BDNF). 
The BDNF gene has multiple transcripts with unique 
promoters. The BDNF transcripts consist of a variable 5' 
region (exons I-IV) and an invariable 3' segment (exon V) . 
The common 3' exon codes for the mature BDNF protein, 
whereas exons I to IV arise from the differential use of 
four different promoters (Russo-Neustadt et aI, 2000). The 
transcripts are differentially expressed across areas of 
the brain (Bishop et aI, 1994) and differing stimuli has 
been shown to regulate the expression of distinct BDNF exon 
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transcripts in the brain. It has been demonstrated that 
exon 111- and exon IV-containing transcripts share 
properties with immediate early genes, whereas changes exon 
1- and exon II-containing transcript expression is 
dependent on ongoing protein synthesis mechanisms 
(Lauterborn et aI, 1996; 1998). 
Several studies have demonstrated an up-regulatory effect 
on BDNF after chronic, but not acute antidepressant drug 
(Nibuya et aI, 1995; Zetterstrom et aI, 1998; Russo-
Neustadt, 1999; 2000; Coppell et aI, 2003) and ECS (Nibuya 
et aI, 1995; Schmidt-Kastner et aI, 1996; Zetterstrom et 
aI, 1998b) treatment. However, a recent study (Coppell et 
aI, 2003) demonstrated an apparent bi-phasic effect of 
antidepressant drug treatment on BDNF mRNA, involving an 
initial down-regulation of the BDNF gene in the hippocampus 
at 4h after acute and chronic treatment, and an up-
regulatory effect at 24h following chronic treatment. 
Against this background, this thesis aimed to study the 
effect of numerous antidepressant drugs as well as ECS, 
when given chronically or acutely, on the total BDNF gene 
mRNA as well as as a representative form of protein-
dependent exon mRNA (exon I) and a non-protein synthesis-
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dependent 'lEG-like' exon mRNA (exon IV; Lauterborn et aI, 
1996; Russo-Neustadt et aI, 2001) in the rat hippocampus. 
Further research into the apparent acute inhibitory effect 
on BDNF mRNA at 4h was also conducted. In addition, the 
effect of antidepressant drug and ECS treatment on BDNF 
immunoreactivity was examined. A summary of the findings, 
ranked in perceived order of importance is listed below. 
8.2. Summary of main findings 
8.2.1. Differential effect of acute and chronic 
antidepressant drug administration on total BDNF mRNA and 
BDNF exon mRNA distribution in the adult rat hippocampus 
One of the key findings within this body of research 
related to the differential effect of acute (at 4h) and 
chronic (at 24h) antidepressant drug treatment on BDNF mRNA 
within the hippocampus and the corresponding effect on the 
variable exon-containing transcript expression within the 
hippocampus. A previous study had revealed an apparent "bi-
phasic effect" (Coppell et aI, 2003), whereby acute 
antidepressant administration inhibited BDNF mRNA within 
the DG region of the hippocampus at 4h, whereas chronic 
antidepressant administration increased BDNF mRNA at 24h. 
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This effect was confirmed in this thesis, not only after 
compounds potent to 5-HT reuptake inhibition, but also from 
drugs with high affinity to noradrenergic/dopaminergic 
transporters. Furthermore, an apparent differential use of 
the variable exon-containing transcripts was discovered in 
response to acute and chronic antidepressant 
administration. Thus, acute administration of a variety of 
antidepressant drugs (as well as the non-antidepressant 
compounds with high affinity for the DA transporter: 
methylphenidate and GBR 12909), down-regulated BDNF mRNA 
expression within the DG region of the hippocampus at 4h, 
an effect which appeared to be mediated in part by an 
inhibition in exon IV (lEG-like) mRNA transcription, rather 
than exon I mRNA (protein synthesis-dependent), which was 
unchanged (See Section 3.3.2). In contrast, chronic 
administration of the SSRI fluoxetine or the MAOI TCP 
significantly up-regulated BDNF mRNA in the DG at 24h, an 
effect which appeared to be mediated in part by an increase 
in exon I mRNA transcription, rather than exon IV, which 
was unchanged (See 5.3.1). However, chronic administration 
of noradrenergic TCA desipramine significantly increased 
total BDNF mRNA, without a corresponding increase in exon I 
mRNA expression. This suggested a predominant increase in 
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an exon transcription in those not tested (exon II or exon 
III) in NA-mediated up-regulation of BDNF in the DG. 
8.2.2. The acute inhibitory effect of antidepressant drugs 
on BDNF mRNA in the DG is influenced by GABAB-mediated 
mechanisms 
The acute administration of baclofen, but not flunitrazepam 
or THIP, significantly inhibited BDNF mRNA in the CA3 and 
DG at 4h, thus suggesting involvement of GABAs, rather than 
GABAA receptor-mediated mechanisms. The GABAs-selective 
antagonist CGP 46381 significantly attenuated the 
inhibitory effect on BDNF mRNA caused by acute baclofen or 
paroxetine administration in the CA3 and DG. However, CGP 
46381 alone significantly increased BDNF mRNA levels in the 
DG region to a similar magnitude as the attenuation, 
suggesting the existence of an endogenous inhibitory tone 
by GABA on BDNF mRNA in this region. Pre-treatment with an 
additional GABAs receptor antagonist, CGP 55845, 
significantly attenuated baclofen-mediated down-regulation 
of BDNF mRNA expression in the DG, however it failed to 
attenuate paroxetine-mediated down-regulation in the CA3 
and DG region of the hippocampus. 
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8.2.3. The effect of acute and chronic ECS application on 
total BDNF mRNA and BDNF exon mRNA 
Both acute ECS at 4h and chronic ECS at 24h significantly 
up-regulated total BDNF mRNA in the DG region of the 
hippocampus. The magnitude of the increase however, was 
larger in acutely treated animals (See Section 6.3.1 and 
6.3.4). In addition, the induction of acute ECS at 4h and 
chronic ECS at 24h resulted in a variable use of BDNF exon 
transcripts measured in the DG region of the hippocampus. 
Acute ECS resulted in the up-regulation of both exon I and 
IV mRNA at 4h, whereas chronic ECS resulted in an increase 
in exon I mRNA only at 24h, exon IV mRNA expression was 
unchanged (See Sections 6.3.2, 6.3.3, 6.3.5 and 6.3.6) 
8.2.4. BDNF protein levels are increased after chronic ECS, 
but not chronic antidepressant drug treatment 
Chronic administration of ECS resulted in a significant 
increase in immunoreactivity in the CAl, CA3 and mossy 
fibre zone of the hippocampus, as well as the parietal 
cortex. Chronic administration of the MAOI antidepressant 
drug TCP failed to increase BDNF protein in the same areas, 
however these results were preliminary in nature and 
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significance may not have been achieved due to low sample 
numbers (n=2). 
8.3. Discussion 
8.3.1. Implications of the main findings 
B.3.1.1. Differential use of variable BDNF exon transcripts 
in response to antidepressant drug treatment 
As explained in Chapter 3 and Chapter 5, acute and chronic 
antidepressant drug treatment had a differing effect on the 
two exon-containing transcripts measured. Whilst like total 
BDNF mRNA, exon IV-containing transcripts were down-
regulated by acute antidepressant drug treatment, exon 1-
containing transcripts were unchanged. In contrast, 
following chronic administration, exon I mRNA expression 
was up-regulated in conjunction with total BDNF mRNA, while 
exon IV mRNA remained unchanged. The physiological 
consequences of this phenomenon are unclear. However, it 
has been shown previously that exon IV- (as well as exon 
111-) containing mRNAs share properties with lEGs, whereas 
transcription of exon I (and exon II) mRNA is regulated via 
intervening protein synthesis mechanisms (Lauterborn et aI, 
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1996; 1998). As each variable exon (exon I-IV) has a unique 
promoter, it appears that the differential effect on total 
BDNF mRNA after acute and chronic antidepressant treatment 
may be as a result of the recruitment of different 
promoters, which result in the corresponding change in exon 
transcription and total BDNF mRNA expression. Thus, the 
presence of numerous transcripts, each with unique promoter 
regulatory mechanisms might act as fine-tuning mechanism, 
mediating control over BDNF transcription, and translation 
into BDNF protein. 
8.3.1.2. GABAB-mediated inhibition of BDNF mRNA after acute 
antidepressant drug treatment 
Chapter 4 outlined a hypothetical mechanism for the 
regulation of BDNF mRNA after acute antidepressant 
treatment. This involved the activation of excitatory 5-HT 
receptors present on GABA-ergic interneurone architecture 
within the hippocampus. This would, in theory, result in 
increased GABA release and subsequent inhibitory control 
over hippocampal cells, thereby inhibiting BDNF mRNA. Acute 
administration of the GABAs agonist baclofen, but not the 
GABAA agonist THIP or the benzodiazepine flunitrazepam 
significantly inhibited BDNF mRNA in the CA3 and DG. 
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Furthermore, GABAB receptor antagonist pre-treatment prior 
to acute baclofen treatment appeared to attenuate the 
inhibitory response. This therefore appears to confirm a 
role for GABAB, but not GABAA mechanisms in the acute 
regulation of BDNF in the DG. However, the role of GABAB-
mediated mechanisms in acute antidepressant (paroxetine) 
inhibition of BDNF mRNA in the hippocampus was not fully 
established. Further research incorporating the acute 
administration of antidepressants with varying affinities 
to NA and/or 5-HT reuptake sites after GABAB receptor 
antagonist administration is required to confirm this 
effect. 
Several studies, including the present study, have 
demonstrated an up-regulatory effect on BDNF after chronic, 
but not acute antidepressant drug treatment (Nibuya et aI, 
1995; Zetterstr6m et al, 1998; Russo-Neustadt, 1999; 2000; 
Coppell et al, 2003). These findings have suggested a 
significant role for BDNF in the mechanism of action of 
antidepressant drugs, thereby implying an up-regulatory 
effect on BDNF gene transcription may be beneficial in the 
treatment of depression. It may be speculated that the 
initial inhibitory effect on BDNF mRNA found after acute 
antidepressant administration could be seen as a 
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detrimental phenomenon which may contribute to the apparent 
~therapeutic latency period" (See Section 1.4.3.1) of 
antidepressant drugs. Therefore, the elimination of such an 
effect may enhance the action of antidepressants on BDNF 
and possibly reduce the latency period. Possible GABAs 
receptor-mediated involvement in the acute down-regulatory 
response in BDNF after acute antidepressant treatment 
perhaps suggest that GABAs receptor blockade may be 
beneficial in the initial phase of antidepressant 
treatment. This could have important clinical implications 
for the shortening of the latency period of therapeutic 
onset of antidepressant drugs. 
B.3.1.3. Chronic and acute ECS up-regulate BDNF mRNA in the 
rat hippocampus 
Unlike antidepressant drug treatment where chronic, but not 
acute administration, resulted in the up-regulation in 
BDNF, ECS up-regulated BDNF mRNA in the DG, when given both 
acutely and chronically. BDNF mRNA has been shown to be up-
regulated acutely by enhanced neuronal activity and 
glutamatergic transmission (Zafra et aI, 1991; 1992). The 
up-regulatory effect on BDNF mRNA from acute ECS however is 
not consistent with the time-course for the therapeutic 
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action of ECS. Therefore it was suggested in Chapter 6, 
that up-regulation of BDNF mRNA alone is not sufficient to 
bring therapeutic response. Interestingly, Zetterstr6m et 
al (1998a) found that though acute ECS produced an up-
regulation in BDNF mRNA at 4h, the effect was transient and 
levels returned to normal after 24h. However, chronic ECS 
application produced far longer lasting increases in BDNF 
mRNA, perhaps suggesting chronic adaptation in components 
mediating BDNF signalling. Both ECS and antidepressant drug 
treatments potentiate the cAMP signalling cascade at 
several levels (Ozawa and Rasenick, 1991; Nibuya et aI, 
1996). An important target for this system is CREB, which 
has been shown to regulate BDNF transcription (Shieh et aI, 
1998; Tao et aI, 1998). Moreover, chronic administration of 
antidepressant drugs or ECS increases CREB in the rat 
hippocampus (Nibuya et aI, 1996). 
8.3.1.4. The implications of enhanced BDNF signalling 
BDNF has been identified as an important mediator in 
several vital functions within the brain. In addition to 
promoting the survival of both 5-HT and NA neurones (Altar 
et aI, 1994), direct BDNF infusion has also been shown to 
produce neurotrophic effects of 5-HT neurones in the 
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neocortex (Mamounas et al, 1995; 2000). This may represent 
a reciprocal process between monoamine function and BDNF 
production, whereby persistent increases in monoamine 
levels, such as from chronic antidepressant drug treatment, 
potentiate BDNF levels which in turn produce neurotrophic 
events, altering morphology and increasing neuronal system 
efficiency. Conversely, chronic stress, through enhanced 
CRF and/or glucocorticoid levels may promote morphological 
deficits in such neuronal systems associated with 
depression, chronic stress has been demonstrated to result 
in neuronal atrophy in CA3 neurones (Sapolsky et al, 1990; 
Watanabe et al, 1992; Magarinos et al, 1996), possibly 
through deleterious effects on BDNF turnover (Smith et al, 
1995). It is therefore tempting to suggest that elevations 
in BDNF protein may be predictive response for the 
mechanistic actions of antidepressant interventions. 
However, despite the apparent up-regulatory effect of 
chronic ECS, the effect antidepressant drug administration 
on BDNF protein remains somewhat inconclusive. It is 
therefore apparent that more studies are needed in this 
area in order to fully establish the role of BDNF in the 
mechanistic action of antidepressant drugs. 
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8.3.2. Future studies and areas of investigation 
8.3.2.1. Impact of stress on BDNF exon transcripts 
Chronic exposure to stress has long been implicated in the 
pathophysiology of depression. Additionally, chronic stress 
models in rats have been shown to lower BDNF mRNA in the 
hippocampus (Smith et aI, 1995; Ueyama et aI, 1997), as 
does elevation of exogenous corticosterone levels (Schaaf 
et aI, 1998), an effect that is blocked by subsequent 
antidepressant treatment (Nibuya et aI, 1995; See Section 
1.6.2.4). Using exon-specific oligonucleotide probes, the 
effect of stress paradigms upon variable BDNF transcripts 
could be assessed. In addition, the impact of subsequent 
antidepressant treatment after stress on BDNF exon 
transcripts could be examined. Such studies would help 
address which BDNF exons are affected by stress and allude 
to the mechanism by which chronic antidepressant treatment 
may reverse this effect. 
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8.3.2.2. Double-labelling strategies 
Double ISH and ICC labelling techniques may be employed to 
help assess the changes in total BDNF and individual BDNF 
exon transcript mRNA, in relation to the localisation 
subsets of neurones. For example, this series of 
experiments may be important in identifying the 
localisation of GABAergic interneurones in relation to 
changes in BDNF mRNA after acute antidepressant drug 
treatment (See Chapter 4). 
8.3.3.3. Transgenic animals 
Transgenic mice contain additional foreign DNA in every 
cell, allowing them to be used to study gene function or 
regulation and to model human diseases. Thus, targeted gene 
insertion techniques could be used to produce transgenic 
mice displaying knockout genes to further investigate the 
role of BDNF in antidepressant function. For instance, to 
further investigate the role of specific monoamine 
receptors in BDNF mRNA transcription, specific receptor 
protein knockout mice could be bred. The effect of 
antidepressant treatment on BDNF mRNA or individual BDNF 
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exon transcript mRNA in the receptor knockout mice could 
then be assessed. 
8.4. Concluding remarks 
BDNF is a versatile molecule, capable of variable responses 
to antidepressant challenge. The results presented in this 
thesis have outlined some novel findings with regard to the 
regulation of the BDNF gene after antidepressant treatment. 
Continued study in this area will hopefully facilitate the 
development of faster, more efficacious and specific 
treatments for those suffering this devastating affliction. 
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